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ABSTRACT  
  
Despite the importance of extracellular phosphate, the mechanisms and 
control of intestinal phosphate transport remain unclear. The present 
study used in vivo and in vitro methods to compare the extent of Na+-
dependent versus Na+-independent phosphate transport along the rat 
small intestine and colon at different luminal phosphate concentrations. 
Na+-dependent and Na+-independent phosphate transport and genomic 
expression of type II (NaPi-II) and type III (PiT) transporters in young (3-
week old) and adult (8- and 16-week old) animals fed a control or low 
phosphate diet have also been quantified. mRNA levels of Na+-
dependent phosphate transporters have been analysed in the 5/6 
nephrectomy model of chronic renal failure and following treatment with 
matrix extracellular phosphoglycoprotein (MEPE). The acute effects of 
altered luminal phosphate concentration on intestinal phosphate transport 
and renal phosphate transporter expression was also assessed.  
 
The findings confirm the jejunum to be the main site of Na+-dependent 
phosphate absorption under both normal and low dietary phosphate 
conditions.  Low phosphate diet upregulates Na+-dependent and Na+-
independent phosphate transport in both duodenum and jejunum, 
whereas age only affects Na+-dependent component in the duodenum 
and jejunum. When luminal phosphate concentrations are in the 
physiological (millimolar) range, absorption in the jejunum displays less 
Na+-dependency and is unlikely to be mediated exclusively by the Na+-
dependent NaPi-IIb cotransporter. In the ileum, again using millimolar 
luminal phosphate concentrations, significant Na+-dependent phosphate 
transport was detected, but the rate of phosphate absorption was lower 
than in the jejunum.  Since NaPi-IIb is not expressed at the rat ileal 
brush-border membrane (BBM), the presence of significant Na+-
dependent phosphate transport suggests an alternative phosphate 
uptake pathway in the ileum. At millimolar luminal phosphate 
concentrations in the distal colon, only Na+-independent phosphate 
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absorption was detected. Thus, at concentrations of phosphate normally 
present in the intestinal lumen, Na+-independent pathways of phosphate 
absorption are present in the proximal small intestine and distal colon, as 
well as a non-NaPi-IIb-mediated Na+-dependent pathway in the distal 
small intestine. 
 
PiT2 assumes a dominant role in phosphate transport in the jejunum of 
pre-weaned animals, and in the kidneys of animals fed a low phosphate 
diet. PiT1 transporter is not regulated by age or low phosphate diet at the 
genomic level. Chronic renal failure reduces intestinal and renal 
expression of the major transporter NaPi-II, and also PiT1 and PiT2. 
However, MEPE reduces intestinal expression of NaPi-IIb and PiT2 alone 
in chronic renal failure animals. Acute duodenal instillation of either 15 
mM or 1.3 M phosphate did not affect the renal BBM protein expression 
of NaPi-IIa and NaPi-IIc. Duodenal instillation of 1.3 M, but not 15 mM, 
phosphate increased phosphate uptake in the duodenum only; however, 
the small intestine is unlikely to encounter phosphate concentrations in 
the molar range.  
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1.1. Phosphate 
Inorganic phosphorus is vital for processes such as cell signalling, 
skeletal mineralisation, energy metabolism, membrane function and 
nucleic acid synthesis (Berndt & Kumar 2007; Tenenhouse, 2007). 
Phosphorus is the second most abundant mineral in all human tissues 
and it is critical that its homeostasis is maintained, since it can affect the 
system of almost any organ. Inorganic phosphorus exists predominantly 
as phosphate anion (PO43-) in the form of H2PO4- and HPO42-, with a 1:4 
ratio, respectively at a physiological pH of 7.5.  
 
1.2. Homeostasis of body phosphate 
Phosphate balance is maintained according to dietary phosphate intake 
and body need. The serum phosphate concentration is maintained within 
a narrow range through a complex interplay between intestinal 
absorption, exchange with intracellular and bone storage pools, and renal 
tubular reabsorption. Most of the phosphate within the body is in bone 
(85%) complexed with calcium, whilst the remainder is essentially 
distributed in soft tissue (Crook & Swaminathan, 1996; Hansen et al., 
1976).  
 
Serum phosphate concentrations are highest at the neonatal stage (1.9 – 
2.4 mM), and lower in childhood (1.5 – 1.8 mM) and lowest in adulthood 
(0.9 – 1.4 mM) (Chan et al., 1981; Crawford et al., 1950; McCrory et al., 
1952). The small intestine and kidney are the two main organs primarily 
involved in phosphate homeostasis. The small intestine absorbs, in a 
regulated manner, phosphate from the chyme passed from the stomach. 
The amount of phosphate absorbed across the small intestine in man is 
approx 0.9 g per day (Fig. 1.1). This represents almost 70% absorption of 
the dietary phosphate, which is more phosphate than is required by the 
body (Cramer, 1961). Plasma unbound phosphate is freely filtered by the 
kidney and then reabsorbed (~80%) in the proximal tubules (Cheng & 
Sacktor, 1981; Dousa & Kempson, 1982). The amount of excreted 
22 
(urinary) phosphate is equivalent to phosphate absorbed by the small 
intestine, and remainder of the phosphate is excreted in the faeces 
(Berner & Shike, 1988; Harrison HE & Harrison HC, 1941).  
 
The kidneys represent the major control site for whole body phosphate 
homeostasis and it can increase or decrease its phosphate reabsorptive 
capacity to accommodate the phosphate need (Crawford et al.,1950). In 
man, the diurnal fluctuation in rate of phosphate excretion is associated 
with a parallel change in plasma phosphate concentration (Fiske, 1921; 
Stanbury & Thomson, 1951; Mills & Stanbury, 1955). This response of 
the kidney to changes in plasma phosphate concentration is dependent 
on maximum tubular reabsorption (Tm) (Schiesse et al., 1948). 
23
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1.3. Phosphate absorption 
Phosphate absorption across the brush-border membrane (BBM) of the 
small intestine and kidney occurs against an electrochemical potential 
difference. This active process involves the transfer of the phosphate 
anion from lumen to interstitium and is inhibited by metabolic inhibitors 
(Berner et al., 1976; Gullans et al., 1982). Transport of phosphate is 
coupled to the flux of sodium ions; this process is secondary active, and 
driven by the Na+ gradient (Baumann et al., 1975; Harrison HE & 
Harrison HC, 1963). The Na+ concentration in luminal fluid is greater than 
that in the cytosol, thus providing a concentration gradient to drive Na+-
dependent phosphate transport. The Na+ gradient is the rate-limiting step 
for intestinal and renal Na+-dependent phosphate transport.  Protons or 
univalent cations such as K+, Li+ and Cs+ cannot substitute for Na+ in the 
active transport of phosphate (Sacktor & Cheng, 1981; Berner et al., 
1976). 
 
Phosphate transport across intestinal enterocytes and proximal tubule 
cells of the kidney involves two further steps: phosphate transfer to the 
serosal side of the cell, followed by phosphate moving across the 
basolateral membrane (BLM) and entering the extracellular space 
(Matsumoto et al., 1980). BBM vesicles represent a suitable experimental 
tool for the in vitro analysis of the first stage of epithelial phosphate 
transport, without the complications of cell metabolism. This is the reason 
why many previous studies have used BBM vesicles. Using BBM 
vesicles, phosphate transport in the small intestine and kidney of rodents 
was shown to be largely Na+-dependent with an affinity constant (Kt) of 
~0.1 mM (Berner et al., 1976; Lee et al., 1986b; Loghman-Adham et al., 
1993). Phosphate absorption in other species such as chicks, rainbow 
trout and ruminants has also been studied. However, their phosphate 
transport characteristics differ from that observed in rodents and humans.  
 
Na+-dependent phosphate transport in the small intestine and kidney 
saturates at Na+ concentrations of 100 mM, demonstrated using BBM 
vesicles, oocytes and Ussing apparatus (Berner et al., 1976; Hartmann et 
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al., 1995; Lee et al., 1986b; Quamme, 1985). Therefore, the majority of 
renal and intestinal phosphate uptake studies have used 0.1 mM 
phosphate and 100 mM Na+ concentrations. Phosphate absorption 
across the small intestine occurs via both passive and active routes, in 
contrast to kidney where phosphate absorption is thought to be mediated 
solely via the Na+-dependent transcellular pathway (Kempson et al., 
1985; Szczepanska-Konkel et al., 1986; Ullrich & Murer, 1982).  
 
1.4. Paracellular phosphate absorption 
The evidence behind the contribution of Na+-independent paracellular 
transport to total phosphate absorption by the small intestine is 
contradictory. Some studies imply that Na+-independent component is 
responsible for 40-50% of total phosphate absorption (Cross et al., 1990; 
Murer et al., 1976; Katai et al., 1999). Debiec & Lorenc (1985) showed, 
using intestinal BBM vesicles, that in younger rats Na+-dependent 
phosphate transport is predominant whereas in adults paracellular 
transport is the major pathway for phosphate transport. More recent 
studies confirmed this in adult rats, both in vitro and in vivo (Douard et al., 
2010; Williams & DeLuca, 2007). The study of Debiec & Lorenc (1985) 
proposed that the contribution of Na+-dependent and Na+-independent 
component in rats is age-dependent. 
 
Other studies proposed that paracellular transport of phosphate is 
dependent on dietary phosphate intake and paracellular phosphate 
transport may play a larger role under normal dietary conditions (Danisi et 
al., 1980; Walton & Gray, 1979; Williams & DeLuca, 2007). Following 
ingestion of a phosphate-containing meal, postprandial increases in 
phosphate concentration would likely favour the paracellular pathway. 
This corresponds with the majority of the in vivo findings that 
demonstrated total phosphate absorption is Na+-independent under 
normal dietary conditions (Williams & DeLuca, 2007; McHardy, 1956; 
Davis et al., 1983; Aloia & Yeh, 1985). In vivo studies in man indicate that 
phosphate absorption is mediated by active Na+-dependent transport at 
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luminal concentrations below 2 mM and by passive diffusion when over 2 
mM phosphate (Davis et al., 1983). Intracellular phosphate concentration 
is difficult to determine due to the rapid turnover of various organic 
phosphate species (Dennis, 1996). The phosphate concentrations in rat 
and human intestinal luminal fluid are thought to vary between 2 to 12 
mM (Davis et al., 1983; Kirchner et al., 2008). Some studies showed 
linear, non-saturated phosphate absorption with increasing luminal 
phosphate (Berner et al., 1976; Davis et al., 1983; Lee et al., 1986b; 
McHardy, 1956; Walton & Gray, 1979). However, the small intestine is 
also claimed to have a low permeability to the phosphate anion (Cross et 
al., 1990). Therefore, the role of the passive pathway in intestinal 
phosphate absorption is unclear. 
 
1.5. Transcellular phosphate absorption  
Transcellular phosphate uptake in the small intestine and kidney is 
initiated by Na+-dependent phosphate transporters present at the BBM 
(Figs. 1.2 and 1.3). These transporters utilise the Na+ gradient 
established by the Na+/K+-ATPase at the BLM (Forster et al., 2006). So 
far, three different Na+-dependent phosphate transporter families have 
been identified. These transporters differ in their amino acid sequence, 
affinity for phosphate and mechanisms controlling their activity and tissue 
expression. It is the type II transporters that are thought to play a key role 
in phosphate transport across the small intestine and kidney.  
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Figure 1.2. Intestinal phosphate absorption. At the BBM of enterocytes three 
different Na+-dependent phosphate transporters, designated as NaPi-IIb, PiT1 
and PiT2, mediate uptake of phosphate from the lumen. Phosphate may also be 
absorbed via the passive route (represented by a blue dotted line). The 
phosphate efflux pathway is so far uncharacterised. 
 
1.6. Na+-dependent phosphate transporters 
 
1.6.1. Type I 
Type I transporters belong to the solute carrier family 17 (SLC17) and are 
expressed in the kidney, liver and brain (Fernandes et al., 1999). In 
kidney, type I transporter (NaPi-I) is expressed at the proximal tubules 
and to a lesser extent in distal tubules (Chong et al., 1995; Murer & Biber, 
1997). When type I transporters were expressed in oocytes and Madin-
Darby Canine Kidney cell line, they mediated Na+-dependent phosphate 
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transport (Werner et al., 1991; Werner et al., 1990; Quabius et al., 1995). 
However, Na+-dependency was found to be weak in the 
electrophysiological studies and type I transporters such as NaPi-I and 
BNP1 were linked to increased permeability of chloride and other anions 
(Busch et al., 1996; Uchino et al., 2000). None of the type I transporters 
characterised to date are critical for phosphate absorption in any organ. 
Thus, the identified type I transporters are not involved in Na+-dependent 
phosphate transport, and their role and importance in phosphate 
homeostasis is unclear (Virkki et al., 2007). Type I transporters share 
20% amino acid sequence homology to type II transporters (Custer et al., 
1993 & 1994). 
 
1.6.2. Type II 
Type II family of Na+-dependent phosphate transporters belong to the 
SLC34 family and comprise both electrogenic and electroneutral NaPi-II 
isoforms, expressed in epithelial cells. So far isoforms NaPi-IIa 
(SLC34A1), NaPi-IIb (SLC34A2) and NaPi-IIc (SLC34A3) have been 
identified. In addition to the small intestine and kidney, these transporters 
are also expressed in other organs such as lungs, colon, salivary and 
mammary glands, liver and testes (Hilfiker et al., 1998; Virkki et al., 
2007). Amino acid sequences of type II isoforms are similar except in the 
main extracellular loop and N- and C-terminal regions (Virkki et al., 2007). 
NaPi-II structure consists of several transmembrane-spanning domains 
with N and C terminus positioned intracellularly (Virkki et al., 2007). NaPi-
II transporters have a Kt for phosphate of ~0.1 mM and are Na+-
dependent, with a Kt for Na+ of 50 mM (Busch et al., 1995; Forster et al., 
1998). The activity of type II transporters is higher at neutral or alkaline 
pH and they preferentially transport the divalent phosphate species 
(Forster et al., 1999; Virkki et al., 2005; Xu et al., 2002b). Physiological 
regulation of phosphate is mediated by changes in the expression of 
phosphate transporter proteins, and this is related to changes in the 
maximum velocity (Vmax) of phosphate cotransport activity. 
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1.6.2.1. NaPi-IIa 
This was the first family member of SLC34 to be identified and cloned 
(Magagnin et al., 1993). Multimeric NaPi-IIa cotransporter consists of 
eight transmembrane domains and several potential phosphorylation 
sites for protein kinase C (Murer et al., 2000). Mouse and rat NaPi-IIa 
have a sequence homology of 90.9 and 91.2%, respectively to the human 
NaPi-IIa isoform (Berndt & Kumar, 2007). Earlier immunohistochemical 
evidence showed that NaPi-IIa was expressed mainly along the apical 
membrane of rat proximal tubules, in S1-S3 segments, with highest 
protein expression in S1 segment (Collins & Ghishan, 1994; Custer et al., 
1994; Murer et al., 2000). Approximately 60-70% of total phosphate 
reabsorption occurs in the proximal convoluted tubule, whilst 15-20% in 
proximal straight tubule and the remaining 5-10% in the distal convoluted 
tubule (Knox & Haramati, 1981). Although NaPi-IIa is widely expressed in 
other tissues such as brain (Mulroney et al., 2004), osteoclasts (Khadeer 
et al., 2003) and chondrocytes (Mansfield et al., 2001), the protein is 
present at lower levels compared with kidney. NaPi-IIa is not expressed 
in the small intestine (Hilfiker et al., 1998).  
 
NaPi-IIa-mediated transport is electrogenic, since it transports phosphate 
with a 3:1 Na+:HPO42- stoichiometry. NaPi-IIa protein possesses a 
hydrophilic loop which contains two N-linked glycosylation sites at Asn-
298 and Asn-328. These sites are thought to be critical for BBM 
expression of NaPi-IIa (Hayes et al., 1994). The loss of NaPi-IIa gene 
function in mice impaired renal phosphate reabsorption by about 70% 
compared with wild type (Beck et al., 1998; Tenenhouse & Murer, 2003; 
Tomoe et al., 2010), implying that NaPi-IIa mediates 70% of total 
phosphate reabsorption in the kidney. NaPi-IIa is a major regulator of 
phosphate homeostasis and, therefore, crucial for normal skeletal 
development. 
 
NaPi-IIa is a highly regulated protein and expression of NaPi-IIa at the 
BBM can be reduced within minutes, as seen in response to parathyroid 
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hormone (PTH) (Bacic et al., 2006). Tertiary structure of NaPi-IIa consists 
of KR (Lys-Arg) motif, which is a signal recognised by PTH (Virkki et al., 
2007). NaPi-IIa also responds rapidly to changes in dietary phosphate 
load within 2 hours (Capuano et al., 2005; Villa-Bellosta et al., 2009b). 
This adaptation of NaPi-IIa is facilitated by modifying protein-protein 
interactions that stabilise NaPi-IIa protein at the BBM and by the 
activation of molecular motifs within the NaPi-IIa protein that mediates its 
endocytotic retrieval or exocytosis (reviewed in detail in Biber et al., 2009; 
Murer et al., 2000; Murer et al., 2003).  
 
Renal phosphate reabsorption is an age-regulated process; Na+-
dependent phosphate transport is much higher in younger animals and it 
progressively declines as animals get older (Sorribas et al., 1996; 
Silverstein et al., 1997). This is reflected in the age-dependent decline in 
expression of NaPi-IIa proteins (Arar et al., 1999; Sorribas et al., 1996). 
NaPi-IIa is a very important phosphate transporter in phosphate 
homeostasis as it cannot be compensated by other Na+-dependent 
phosphate transporters in the kidney such as NaPi-IIc (Beck et al., 1998; 
Tenenhouse & Murer, 2003; Tomoe et al., 2010). Changes in BBM 
expression of NaPi-IIa proteins parallel altered renal phosphate handling, 
highlighting its physiological importance (reviewed in detail in Biber et al., 
2009; Murer et al., 2000; Murer et al., 2003). NaPi-IIa is regulated by 
many physiological factors which are discussed in detail in the following 
sections of this chapter. 
 
1.6.2.2. NaPi-IIc 
The expression of NaPi-IIc occurs exclusively in the kidney and NaPi-IIc 
has been suggested to be a growth-related factor. Unlike NaPi-IIa, NaPi-
IIc protein (75 kDa) is expressed exclusively in S1 (convoluted) segment 
of the proximal tubules (Nowik et al., 2008; Segawa et al., 2002). NaPi-IIc 
is thought to be responsible for about 30% of the total renal phosphate 
reabsorption (Beck et al., 1998). Although NaPi-IIc protein level was 
increased to compensate for NaPi-IIa loss in NaPi-IIa knockout mice 
studies, NaPi-IIc did not successfully substitute for NaPi-IIa-mediated 
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transport (Beck et al., 1998). NaPi-IIc-mediated transport is an 
electroneutral process, since it transports phosphate with a 2:1 
Na+:HPO42- stoichiometry (Bacconi et al., 2005; Segawa et al., 2002). 
Similar to NaPi-IIa, NaPi-IIc preferentially transports the divalent 
phosphate species, but with a lower Kt of ~ 0.33 mM (Ghezzi et al., 2009; 
Villa-Bellosta & Sorribas, 2010b). However, NaPi-IIc functions efficiently 
owing to its electroneutrality (Bacconi et al., 2005; Segawa et al., 2002). 
As NaPi-IIc transports only two Na+ ions, compared with NaPi-IIa and 
NaPi-IIb that transport three Na+ ions, the energetic cost of transporting 
phosphate across the cell is smaller. Thus, fewer Na+ ions are loaded into 
the cell during NaPi-IIc-mediated transport, and therefore less energy is 
needed to maintain the negative membrane potential of the cell. The 
electroneutrality of NaPi-IIc is mediated by the replacement of an aspartic 
acid residue (found in NaPi-IIa and NaPi-IIb) with a glycine residue in a 
sodium-binding site within a conserved amino acid cluster in NaPi-IIc 
(Bacconi et al., 2005). The amino acids WLHSL in the cytoplasmic C 
terminus are thought to be important for the apical expression of NaPi-IIc 
(Ito et al., 2010). 
 
The studies on rodents have shown that expression of NaPi-IIc is age-
dependent; the highest NaPi-IIc level is found in weaning animals and 
expression decreases with age (Segawa et al., 2002; Silverstein et al., 
1997). Regulation of NaPi-IIc is not as well studied as NaPi-IIa, but it has 
been shown to be regulated by dietary phosphate levels (Segawa et al., 
2005; Ohkido et al., 2003; Segawa et al., 2002).  However, regulation of 
NaPi-IIc by phosphate diet occurs over a longer time course of >24 
hours, compared with <1-2 hours applicable for NaPi-IIa (Villa-Bellosta et 
al., 2009b; Segawa et al., 2005; Moe, 2009). Recently emerging evidence 
demonstrate that NaPi-IIc is also regulated by metabolic acidosis, dietary 
magnesium, the phosphatonin Fibroblast growth factor-23 (FGF-23) and 
possibly PTH, although the evidence is so far contradictory (Miyamoto et 
al., 2007; Nowik et al., 2008; Segawa et al., 2003; Segawa et al., 2007; 
Thumfart et al., 2008). Studies using NaPi-IIc knockout mice suggest that 
NaPi-IIc is involved in the calcium/vitamin D axis (Segawa et al., 2009b). 
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The same study demonstrated hypercalcaemia, hypercalciuria, and 
augmented levels of plasma 1,25-dihydroxyvitamin D3 in NaPi-IIc 
knockout mice. However, NaPi-IIc knockout mice do not develop 
hypophosphataemia, hyperphosphaturia, renal calcification or rickets, in 
contrast to NaPi-IIa knockout mice (Breusegem et al., 2009; Segawa et 
al., 2009b; Tomoe et al., 2010). Renal phosphate transport in NaPi-IIc 
knockout mice was not different from normal mice (Segawa et al., 2009b; 
Tomoe et al., 2010). Thus, NaPi-IIc is not considered to have a major role 
in phosphate reabsorption in rodents. Additional studies on the differential 
regulation of renal NaPi-IIa and NaPi-IIc provides further evidence that, in 
contrast to the complete internalisation of NaPi-IIa following a high 
phosphate diet, NaPi-IIc is only partially internalised to the subapical 
compartment (Segawa et al., 2005).  
 
Although NaPi-IIc only plays a minor role in phosphate homeostasis in 
rodents (Segawa et al., 2009b), the transporter is proposed to be much 
more important in man where it has a more widespread tissue distribution 
(Virkki et al., 2007). Mutations in the NaPi-IIc gene in humans cause 
hereditary hypophosphataemic rickets with hypercalciuria which is 
characterised by renal phosphate wasting leading to hypophosphataemia 
and secondary rickets or osteomalacia (Ichikawa et al., 2006; Bergwitz et 
al., 2006). Studies based on this genetic condition suggest that NaPi-IIc 
plays a more significant role in humans, in the control of renal phosphate 
reabsorption, bone mineralisation and plasma phosphate concentrations 
(Segawa et al., 2009a; Segawa et al., 2009b). 
 
1.6.2.3. NaPi-IIb 
The NaPi-IIb transporter electrogenically transports phosphate with a 3:1 
Na+:HPO42- stoichiometry. NaPi-IIb was characterised in Xenopus 
oocytes as Na+-dependent with a Kt of 10-50 µM for phosphate (Hilfiker 
et al., 1998; Forster et al., 2006). This high affinity Kt suggests that NaPi-
IIb-mediated transport would be saturated under normal dietary 
conditions and NaPi-IIb probably serves a bigger role in the small 
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intestine under phosphate-restricted conditions and during 
hypophosphataemia (Douard et al., 2010; Hilfiker et al., 1998; Marks et 
al., 2010; Williams & DeLuca, 2007). NaPi-IIb is also highly expressed in 
the lungs where it plays a role in the synthesis of surfactant in the alveoli 
(Huqun et al., 2007; Corut et al., 2006; Hashimoto et al., 2000). NaPi-IIb 
is also found in the colon (Capuano et al., 2009), testis (Xu et al., 2003a), 
liver (Frei et al., 2005), and mammary and salivary glands (Homann et 
al., 2005; Huber et al., 2007), but it plays a more significant role in the 
small intestine. NaPi-IIb is not expressed in the kidney (Hilfiker et al., 
1998). NaPi-IIb is regulated by several physiological factors, including 
1,25-dihydroxyvitamin D3 levels and chronic and acute changes in the 
level of dietary phosphate. The regulation by these factors is both 
species- and region-specific in the small intestine, since different regions 
of the small intestine (duodenum, jejunum and ileum) express distinct 
levels of NaPi-IIb across species (Borowitz & Granrud, 1992; Huber et al., 
2002; Huber et al., 2006; Marks et al., 2006; Radanovic et al., 2005; 
Schroder et al., 1998).  
 
NaPi-IIb expression is also essential for phosphate absorption during 
early embryonic development, since deletion of the NaPi-IIb gene in mice 
causes an embryonic lethal phenotype due to abnormalities in phosphate 
transfer from the maternal circulation (Shibasaki et al., 2009). Intestinal 
expression of NaPi-IIb is age-dependent with higher mRNA transcripts 
and proteins present in sucklings, corresponding with the maximal 
intestinal Na+-dependent phosphate absorption seen in these animals 
(Arima et al., 2002; Xu et al., 2002a). In mice, NaPi-IIb is a key player in 
total phosphate absorption, since NaPi-IIb knockout mice fed a low 
phosphate diet followed by an acute phosphate load showed 
approximately 50% less phosphate absorption than wild type controls, 
and in these experiments NaPi-IIb accounted for >90% of intestinal Na+-
dependent phosphate transport (Sabbagh et al., 2009). 
 
The NaPi-IIb cotransporter is an N-linked glycoprotein that is glycosylated 
during the suckling/weaning transition, a process thought to be important 
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for its plasma membrane expression (Arima et al., 2002; Hayes et al., 
1994). The fully glycosylated NaPi-IIb, containing complex 
oligosaccharidesis, has a molecular mass of approximately 108 kDa and 
is found at the BBM of enterocytes and at the apical pole of alveolar type 
II cells (Hilfiker et al., 1998; Traebert et al., 1999). There is no evidence of 
the presence of non-glycosylated NaPi-IIa transporters at any age, 
highlighting the differential structure-specific regulation of transporters 
within the SLC34 (type II) family. 
 
Type II transporters have been extensively characterised, in contrast to 
type III transporters. 
 
1.6.3. Type III 
Type III transporters PiT1 and PiT2 were initially isolated as cell surface 
receptors for gibbon ape leukemia virus (GALV) in mouse and humans 
and amphotrophic murine retrovirus (A_MuLV) in rats, respectively (Miller 
et al., 1994; Tatsumi et al., 1998; Bai et al., 2000).  They are members of 
the SLC20 family and are expressed ubiquitously (Kavanaugh et al., 
1994). PiT transporters only share about 60% amino acid sequence 
homology to mammalian type I and type II transporters (Zhao et al., 2006; 
Tatsumi et al., 1998). PiT1 and PiT2 phosphate transporters were 
originally thought to play a housekeeping role in phosphate absorption at 
the BLM by absorbing phosphate from interstitial fluid for normal cellular 
functions (Bottger & Pedersen, 2002; Collins et al., 2004; Ravera et al., 
2007). PiT-mediated phosphate transport in prokaryotes and plants is 
coupled to the H+-gradient (Harris et al., 2001; Daram et al., 1999), in 
contrast to the Na+-dependency seen in animals.  
 
In vitro studies have demonstrated PiT1 and PiT2 to be active Na+-
dependent phosphate transporters that are expressed in several tissues. 
Phosphate uptake studies in Xenopus laevis oocytes displayed Na+-
dependent phosphate uptake when PiT1 was expressed, with a Kt for 
phosphate of 89 µM when expressed in the rat and 333 µM when 
expressed in man (Bottger et al., 2006; Tatsumi et al., 1998).  Similarly, 
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PiT2-mediated transport was also Na+-dependent with a Kt of ~25 µM 
when expressed in oocytes and 200 µM when expressed in mammalian 
cells (Bai et al., 2000; Kavanaugh et al., 1994; Bottger et al., 2006). PiT 
transporters are also capable of transporting the phosphate analogue 
arsenate, but with a much lower affinity (Kt of 1-5 mM) (Villa-Bellosta & 
Sorribas, 2008b; Villa-Bellosta & Sorribas, 2010a). However, it is 
important to realise that uptake studies using oocytes is not necessarily 
specific or accurate in reflecting the behaviour in mammalian cells 
expressing the same gene.  
 
PiT1 and PiT2 transporters are widely expressed; including the small 
intestine, heart, kidney, parathyroid, distal colon, bone and vascular 
smooth muscles  (Bai et al., 2000; Capuano et al., 2009; Giral et al., 
2009; Kavanaugh & Kabat, 1996; Villa-Bellosta et al., 2009a; Villa-
Bellosta et al., 2009b; Tatsumi et al., 1998). PiT1 is thought to play an 
important role in bone remodelling, as it is expressed in osteoclasts and 
osteoblasts (Khadeer et al., 2003; Tatsumi et al., 1998). PiT transporters 
are also imperative for phosphate absorption in vascular smooth muscle 
cells (VSMC) (Virkki et al., 2007; Villa-Bellosta et al., 2007; Gonzalez et 
al., 2009).  Indeed, there is a strong interest in the role of PiT 
transporters, especially PiT1, in vascular calcification, since they are 
thought to be more highly expressed in VSMCs under this condition (Li et 
al., 2006). In contrast, minimal levels of NaPi-II transporters are present 
in VSMCs (Villa-Bellosta et al., 2007). The implication of PiT transporters 
in vascular calcification is discussed later in this chapter. Similar to NaPi-
II transporters, inter-organ PiT expression also varies between species; in 
mice highest expression of PiT2 was found in the jejunal region of the 
small intestine (Bai et al., 2000) whereas in rats minimal PiT2 levels were 
reported along the small intestine (Giral et al., 2009). Regarding the 
kidney, PiT2 is exclusively localised in the S1 segment of the rat proximal 
convoluted tubules under normal dietary conditions (Villa-Bellosta et al., 
2009b; Villa-Bellosta & Sorribas, 2010b).  
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PiT transporters preferentially transport monobasic phosphate species 
with a 2:1 Na+:H2PO4- stoichiometry. Thus, PiT-mediated transport is 
electrogenic and transport activity decreases when the pH is increased, 
in contrast to type II transporters (Bai et al., 2000; Villa-Bellosta et al., 
2007; Zhao et al., 2006). Earlier studies reported that monovalent 
phosphate species is preferentially transported across the intestinal BBM, 
whereas divalent phosphate (the NaPi-II substrate) is the predominantly 
transported phosphate species across the renal BBM (Hammerman, 
1986; Berner et al., 1976). Additionally, phosphate uptake studies using 
intestinal BBM vesicles displayed 4-fold higher transport activity when pH 
was decreased from 7.4 to 6, proposing a more important role for PiT 
transporters in intestinal epithelium (Berner et al., 1976).  In renal BBM 
vesicles PiT2-mediated uptake also varied with pH, contributing from 
approximately 3 to 40% of total phosphate transport at pH values of 7.5 
and 6.0, respectively (Villa-Bellosta & Sorribas, 2010b). However, the pH 
in the proximal tubular fluid does not fall below 6.6, even during metabolic 
acidosis, thus raising uncertainties in the contribution of PiT2 towards 
overall renal phosphate reabsorption (Gottschalk et al., 1960; DuBose et 
al., 1979).  
 
The relative abundance of PiT1 and PiT2 mRNA in the mouse kidney is 
very low, about 2% of that for NaPi-IIa (Tenenhouse et al., 1998). In wild 
type mice, the genomic expression of PiT1 and PiT2 is not regulated by 
dietary phosphate restriction and PiT transporters also do not 
compensate for NaPi-IIa in NaPi-IIa knockout mice fed a chronic low 
phosphate diet (Hoag et al., 1999; Tenenhouse et al., 1998).  However, in 
double knockout mice for NaPi-IIa and NaPi-IIc, there remains residual 
renal phosphate reabsorption, which is proposed to be PiT-mediated 
(Segawa et al., 2009a). Further evidence of the role of PiT transporters in 
renal phosphate reabsorption is supported by the finding that PiT1, but 
not PiT2, mRNA level is specifically increased by growth hormone and 
IGF-1, both important stimulators of Na+-dependent phosphate transport 
(Hammerman et al., 1980; Caverzasio et al., 1981; Tenenhouse et al., 
1998; Zoidis et al., 2004). Growth hormone also stimulates the production 
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of IGF-1. PiT1 is also important for normal liver growth as disruption of 
the PiT1 gene in mice leads to mid-gestation lethality due to severe 
defects in liver development (Beck et al., 2010). In these mice, PiT2 
cannot compensate for the loss of PiT1.  
 
In NaPi-IIb knockout mice, residual Na+-dependent phosphate transport 
was not evident in the small intestine, indicating that PiT1 and PiT2 
transporters are not likely to play an important role in intestinal phosphate 
absorption in mice (Sabbagh et al., 2009). In rats, PiT transporters are 
implicated to play an important role in phosphate absorption across both 
the small intestine and kidney. PiT expression in rats is regulated by 
factors that classically affect renal phosphate reabsorption; so far 
upregulation of renal PiT1 and PiT2 has been demonstrated during 
phosphate deprivation and metabolic acidosis, and PiT2 only during 
dietary potassium deficiency (Villa-Bellosta et al., 2009b; Villa-Bellosta & 
Sorribas, 2010b; Nowik et al., 2008; Breusegem et al., 2009). In contrast 
to NaPi-IIc, renal PiT2 expression is not age-dependent (Leung et al., 
2005). In rat small intestine, PiT1 and PiT2 are not regulated by changes 
in dietary phosphate (Giral et al., 2009), although PiT2 was shown to be 
regulated by 1,25-dihydroxyvitamin D3 in vitro (Katai et al., 1999). The 
exact physiological role of PiT transporters in intestinal phosphate 
absorption remains uncharacterised. 
 
1.7. Inhibitors of Na+-dependent phosphate transport 
Arsenate is a toxic anion structurally analogous to phosphate anion and 
has been shown to be a competitive inhibitor of Na+-dependent 
phosphate transport in the small intestine (Villa-Bellosta & Sorribas, 
2008b; Villa-Bellosta & Sorribas, 2009c; Villa-Bellosta & Sorribas, 2010a). 
Arsenate specifically inhibits NaPi-IIb-mediated transport whereas renal 
proteins NaPi-IIa, NaPi-IIc, PiT1 and PiT2 show low affinity for arsenate 
(Villa-Bellosta & Sorribas 2008b; Villa-Bellosta & Sorribas, 2010a). Thus, 
arsenate is not a suitable agent for inhibiting Na+-dependent phosphate 
transport in the kidney. Although arsenate can be used to inhibit Na+-
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dependent phosphate transport in isolated small intestine, it is also a 
potent metabolic inhibitor, deeming it unsuitable for in vivo studies. 
Phosphonoformic acid (PFA) is equally as effective as arsenate and 
inhibits Na+-dependent phosphate transport in both small intestine and 
kidney (Villa-Bellosta & Sorribas, 2009a; Loghman-Adham et al., 1987; 
Loghman-Adham, 1996; Forster et al., 1998). PFA is an inhibitor of NaPi-
II, but not PiT, mediated transport (Villa-Bellosta et al., 2007; Ravera et 
al., 2007). PFA and arsenate have no effect on BBM alkaline 
phosphatase activity or the transport of solutes across the BBM, 
demonstrating the specificity of these agents for phosphate transport 
(Yusufi et al., 1986). PFA acts at a site located on the luminal surface of 
the BBM and its binding to NaPi-II transporters is mainly dependent on 
sodium concentration, in contrast to arsenate that acts as a solute 
analogue of PO43- (Szczepanska-Konkel et al., 1987; Villa-Bellosta & 
Sorribas, 2009a; Loghman-Adham et al., 1987). 
 
Nicotinamide is another compound that dose-dependently inhibits NaPi-
IIa- and NaPi-IIb-mediated transport across the BBM (Wu et al., 1988). In 
rats with renal failure, administration of nicotinamide inhibits intestinal 
phosphate transport and NaPi-IIb expression across the jejunal BBM, 
thus preventing the progressive increase in serum phosphate levels (Eto 
et al., 2005). Similarly, clinical studies in haemodialysis patients showed 
that nicotinamide was able to reduce and keep serum phosphorus under 
a similar control level that is seen with current phosphate binders 
(Takahashi et al., 2004). However, nicotinamide is thought to have some 
serious side-effects, making it unsuitable for use in man (Takahashi et al., 
2004).  
1.8. Phosphate efflux across the basolateral membrane 
Phosphate efflux across the BLM of absorptive cells in the small intestine 
and kidney has yet to be characterised, although a number of theories 
have been proposed such as: an anion exchange mechanism, a type 3 
transporter and an "unspecific" phosphate leak pathway (Tenenhouse & 
Murer, 2003; Tenenhouse, 2007). Basolateral phosphate transport is 
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bidirectional and has two important functions; when luminal phosphate 
entry exceeds cellular phosphate requirements phosphate is transported 
across the BLM; if BBM phosphate uptake is insufficient then basolateral 
phosphate influx from the extracellular fluid occurs to meet cellular 
phosphate needs (Murer et al., 2000). 
 
1.9. Kidney 
 
1.9.1. Phosphate absorption in the kidney 
Phosphate homeostasis is largely dependent on the process involving the 
renal reabsorption of phosphate against an electrochemical gradient. This 
is mediated by the Na+-dependent phosphate transporter NaPi-IIa and 
NaPi-IIc, and potentially PiT1 and PiT2, expressed at the BBM, which act 
as the rate-limiting step for phosphate entry (Fig. 1.3). Phosphate 
excretion in the kidney is the balance between free glomerular filtration 
and renal tubular reabsorption. The kidney specifically expresses NaPi-
IIa at the apical membrane of proximal tubular cells, which is largely 
responsible for the maintenance of phosphate homeostasis and to a 
lesser importance NaPi-IIc and NaPi-I transporters (Murer et al., 2000; 
Murer et al., 2004; Tenenhouse & Murer, 2003). This corresponds to high 
Na+-dependent phosphate transport in the proximal tubules, especially in 
the early segments S1 and S2 (Greger et al., 1977; Kayne et al., 1993; 
Baumann et al., 1975). The experimental techniques of micropuncture, in 
situ microperfusion and primary cell cultures revealed that Na+-dependent 
phosphate transport is higher in the proximal convoluted tubules, 
compared with proximal straight tubules and distal regions of the kidney, 
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Figure 1.3. Renal phosphate reabsorption. At the BBM of proximal tubule cells, 
four different Na+-dependent phosphate transporters, designated as NaPi-IIa, 
NaPi-IIc, PiT1 and PiT2, mediate phosphate uptake from the lumen. The 
phosphate efflux pathway at the BLM is so far uncharacterised. 
 
and this was ascribed to a higher Vmax of the Na+-dependent phosphate 
transport system (Berndt & Knox, 1992). Inter- and intra-nephron 
expression of NaPi-IIa relies on the phosphate status of the body. Short-
term regulation of renal phosphate reabsorption is mediated by shuttling 
mechanisms involving the movement of NaPi-IIa and NaPi-IIc protein-
containing vesicles between the cytoplasm and the BBM (Segawa et al., 
2005; Picard et al., 2010; Levi et al., 1994; Kempson et al., 1995). 
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Phosphate reabsorption by the kidney is predominantly regulated by 
PTH, dietary phosphate intake, serum phosphate levels and 
phosphatonins, and their effects are mediated through changes in the 
abundance of NaPi-IIa and NaPi-IIc proteins at the BBM. Thus, 
physiological and pathophysiological regulation of renal phosphate 
reabsorption is associated with changes in the expression of NaPi-IIa, 
and sometimes NaPi-IIc, at the BBM.  
 
Proximal tubular phosphate reabsorption is increased at higher pH (>7), 
due to the preferential transport of the HPO42- phosphate species by 
NaPi-II transporters (Amstutz et al., 1985; Magagnin et al., 1993). Type I 
and type III transporters are not thought to play an important role in renal 
phosphate reabsorption, since their expressions are not increased to 
compensate for NaPi-IIa loss in NaPi-IIa knockout mice (Hoag et al., 
1999). A recent report has shown immunohistochemical evidence of 
localisation of PiT2 protein at the BBM of the rat kidney (Villa-Bellosta et 
al., 2009b). The abundance of PiT2 proteins at the renal BBM is 
regulated by dietary phosphate; Villa-Bellosta et al (2009b) showed the 
induction of PiT2 protein expression in all segments of the proximal 
tubules upon dietary phosphate restriction. The time course of regulation 
of renal PiT2 transporter in response to changes in diet is about 8 hours, 
which is different from the time taken for NaPi-IIa and NaPi-IIc, 
suggesting that the regulatory pathway involved in PiT regulation is 
different to that involved in NaPi-II transporters (Villa-Bellosta et al., 
2009b). PiT transporters are physically associated with the actin 
cytoskeleton network and forms high molecular weight complexes 
(Salaun et al., 2001; Salaun et al., 2004; Rodrigues & Heard, 1999). 
Acute post-translational changes in PiT transporter expression at the 
BBM can occur, e.g. in response to extracellular phosphate 
concentrations (Rodrigues & Heard, 1999).  However, the processes 
involved are unknown. 
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In contrast to the slow adaptations seen in small intestine, the kidney is 
capable of changes in Na+-dependent phosphate transport within minutes 
or hours under altered physiological conditions. 
 
1.9.2 Regulation of renal phosphate reabsorption  
 
1.9.2.1. Dietary phosphate level 
A low phosphate diet increases renal phosphate absorption to the 
maximal rate (Trohler et al., 1976). Thus, in mice a low phosphate diet 
enhances Na+-dependent phosphate transport in the proximal tubules. 
This adaptation involves changes in NaPi-IIa at protein, but not mRNA, 
level (Madjdpour et al., 2004). In contrast, both protein and mRNA 
expression of NaPi-IIc at the BBM is increased (Madjdpour et al., 2004). 
In rats however, NaPi-IIa protein and mRNA expression are both 
upregulated (Villa-Bellosta et al., 2009b; Marks et al., 2007; Giral et al., 
2009), highlighting again the importance of species differences in the 
control of phosphate absorption. Dietary phosphate levels control the 
recruitment of NaPi-IIa and NaPi-IIc proteins to the BBM acutely, within a 
few hours, in a microtubular-dependent mechanism (Madjdpour et al., 
2004; Bacic et al., 2006; Keusch et al., 1998). High phosphate levels 
stimulate secretion and gene transcription of PTH indirectly (by 
decreasing 1,25-dihydroxyvitamin D3 production), and directly 
(independent of 1,25-dihydroxyvitamin D3 and calcium levels) (Almaden 
et al., 1998; Tallon et al., 1996; Hernandez et al., 1996; Keusch et al., 
1998). Conversely, dietary phosphate restriction causes a type of 
“resistance” to the phosphaturic effect of PTH, therefore stimulating renal  
phosphate reabsorption (Harris & Seely, 1979).  
 
An in vitro study showed rapid upregulation of phosphate transport in 
cultured proximal tubule cells exposed to low phosphate concentrations, 
indicating an intrinsic ability of these cells to sense and adapt to 
phosphate levels without the involvement of PTH (Markovich et al., 
1995). Furthermore, this ‘phosphate sensing’ effect at the BBM of 
proximal convoluted tubule may be linked to a calcium sensor and/or 
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cytosolic calcium concentrations, since changes in phosphate and 
calcium concentrations are interdependent (Murer et al., 2000).  
 
1.9.2.2. Parathyroid hormone 
Regulation of PTH levels is dependent upon two processes: the release 
of PTH already stored in secretory granules within the parathyroid gland 
and the other involves the synthesis of new PTH (Fox & Heath, 1981; 
Habener et al., 1984). Rapid changes in serum PTH concentrations occur 
through alterations in the release of PTH from secretory granules, which 
are controlled by the binding of calcium to the calcium-sensing receptor 
(CaSR) in the parathyroid gland (Pollak et al., 1994; Pollak et al., 1993; 
Muff et al., 1988). More long-term changes in PTH release rely on the 
synthesis of new PTH. 
 
1,25-dihydroxyvitamin D3 inhibits  PTH gene transcription and secretion 
in the parathyroid glands and suppresses parathyroid cell growth (Silver 
et al., 1986; Cantley et al., 1985; Russell et al., 1984; Silver et al., 1985; 
Kremer et al., 1989; Szabo et al., 1989). 1,25-dihydroxyvitamin D3 is 
thought to act on the PTH gene by increasing Vitamin D receptor (VDR) 
mRNA in the parathyroid gland (Okazaki et al., 1988). VDR 
heterodimerises with retinol X receptor (RXR) and binds to vitamin D-
response elements within the PTH gene, thus repressing its transcription. 
VDR mRNA levels in the parathyroid glands is equivalent to the VDR 
levels present in the duodenum, a main tissue targeted by 1,25-
dihydroxyvitamin D3 (Dupret et al., 1987; Liel et al., 1999).  
 
PTH causes phosphaturia by inhibiting Na+-dependent phosphate 
transport at the renal BBM (Murer et al., 2000). Plasma PTH levels are 
rapidly regulated, in some cases within minutes. Such regulation was 
demonstrated in vivo during duodenal gavage of a low and high 
phosphate diet, which caused changes in plasma PTH levels within 10-15 
minutes (Martin et al., 2005). This effect is hypothesised to be mediated 
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through an unidentified ‘intestinal phosphatonin’, which efficiently links 
changes in intestinal phosphate levels to altered secretion PTH.  
 
PTH inhibits NaPi-IIa-mediated transport by inducing endocytic retrieval 
of NaPi-IIa from the renal BBM into the late endosomal/lysosomal 
compartment, signaling via type I PTH receptor (PTHR1) (Zhao & 
Tenenhouse, 2000; Bacic et al., 2006). PTH stimulates several signal 
transduction pathways including extracellular signal-regulated kinases 
(ERK), which inhibits renal phosphate reabsorption independent of 
changes in NaPi-IIa expression (Lederer et al., 2000). PTH stimulates 
ERK, one of the mitogen-activated protein kinase (MAPK) cascades, 
through two signal transduction pathways: one involving the tyrosine 
kinase and phosphoinositide kinase-3 (PI3K) and the other pathway 
dependent on protein kinase C. Thus, PTH inhibits Na+-dependent 
phosphate reabsorption via two distinct mechanisms, one involving the 
internalisation of NaPi-IIa from the BBM and the other relating to the ERK 
pathway. PTH bound PTH receptor 1 activates Gα(S)/adenylyl 
cyclase/cAMP/PKA (cAMP/PKA) and Gα(q/11)/phospholipase 
C/phosphatidylinositol 1,4,5-trisphosphate (IP3/PKC) signaling pathways 
to mediate its inhibitory action on NaPi-IIa (Nagai et al., 2011). The direct 
phosphorylation of NaPi-IIa has not yet been demonstrated (Murer et al., 
2003). Further events following the activation of the cAMP/PKA and 
IP3/PKC pathways are not yet known. PTH also decreases activity of the 
Na+/K+-ATPase at the BLM and this may indirectly reduce phosphate 
transport across the BBM via a reduced sodium electrochemical gradient 
(Ribeiro & Mandel, 1992). 
 
1.9.2.3. Vitamin D3 
The active form of vitamin D, 1,25-dihydroxyvitamin D3, is produced in the 
proximal tubule cells and it stimulates phosphate absorption in the 
proximal tubule (Berndt & Knox, 1984, 1992). In vitamin D-deficient rats, 
the genomic and protein expression of NaPi-IIa is significantly decreased 
in the juxtamedullary kidney cortex, and following 1,25-dihydroxyvitamin 
D3 administration, renal Na+-dependent phosphate transport is increased 
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in parallel with elevated NaPi-IIa mRNA and protein levels (Taketani et 
al., 1998).  
 
1,25-dihydroxyvitamin D3 is converted from the precursor 25-
hydroxyvitamin D3 through the activity of 25-hydroxyvitamin D3-1α-
hydroxylase (1α-hydroxylase) enzyme, which adds a hydroxyl group to 
circulating 25-hydroxycholecalciferol. This enzyme is stimulated by PTH, 
an effect involving the recruitment of the protein kinase A/protein kinase 
C signalling pathways (Ro et al., 1992; Janulis et al., 1993). Thus, an 
endocrine feedback loop regulates the synthesis of PTH and 1,25-
dihydroxyvitamin D3.  
 
Surprisingly, Mühlbauer et al (1981) showed that 1,25-dihydroxyvitamin 
D3 inhibits renal phosphate reabsorption in thyroparathyroidectomised 
(TPTX) rats. Later work showed that this effect of 1,25-dihydroxyvitamin 
D3 was mediated via an effect on serum levels of a phosphatonin called 
Fibroblast Growth Factor-23 (FGF-23) (Sommer et al., 2007; Shimada et 
al., 2004a). Administration of FGF-23 decreases serum phosphate and 
1,25-dihydroxyvitamin D3 levels in both normal and TPTX rats (Shimada 
et al., 2004a). FGF-23 inhibits 1,25-dihydroxyvitamin D3 production by 
regulating renal expressions of main enzymes involved in the vitamin D 
metabolism, independently of PTH (Sommer et al., 2007; Shimada et al., 
2004a; Shimada et al., 2004b). Evidently, serum levels of 1,25-
dihydroxyvitamin D3 is higher in FGF-23 knockout mice (Sommer et al., 
2007). Further details are discussed in section 1.12.1. 
 
1.9.2.4. Metabolic acidosis  
Phosphate plays a role in the compensation of metabolic acidosis, acting 
as a buffer in extracellular fluid and more importantly in urine (Stauber et 
al., 2005). Increases in the release of phosphate from bone, together with 
renal excretion of protons and absorption of bicarbonate are the major 
mechanisms involved in restoring acid-base balance during metabolic 
acidosis (Hamm & Simon, 1987; DuBose & Alpern, 2001).  
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During metabolic acidosis, renal excretion of phosphate and ammonia is 
increased to preserve bicarbonate and to excrete excess protons 
(Tanner, 1984; Guntupalli et al., 1982; Nowik et al., 2008). The increase 
in phosphate excretion is moderate (from 1.8 to 2.8 millimoles), 
compared with ammonia excretion (from 1.4 to 5.7 millimoles) (Nowik et 
al., 2008). Increased urinary phosphate excretion is mediated by 
inhibition of renal phosphate reabsorption, as supported by the evidence 
that Na+-dependent phosphate transport in renal BBM vesicles is 
decreased during metabolic acidosis, in parallel with reduced levels of 
NaPi-IIa mRNA and protein in rats (Ambuhl et al., 1998). This effect is 
independent of PTH, extracellular fluid volume, natriuresis, plasma 
phosphate or changes to the phosphate balance (Guntupalli et al., 1982; 
Ambuhl et al., 1998). Similarly, in mice, metabolic acidosis increases 
urinary phosphate excretion. However, neither Na+-dependent phosphate 
uptake nor NaPi-IIa and NaPi-IIc protein expression is decreased during 
metabolic acidosis in mice (Nowik et al., 2008), demonstrating the 
differential regulation of renal phosphate reabsorption between species. 
Interestingly, metabolic acidosis increases NaPi-IIc and PiT2 levels in 
both rat and mice (Nowik et al., 2008; Villa-Bellosta & Sorribas, 2010b) 
(Fig. 1.4). 
 
1.9.2.5. Other factors influencing renal phosphate transport 
In addition to PTH and the vitamin D-endocrine system, bone-derived 
phosphaturic factors called phosphatonins also play an important role in 
the regulation of phosphate reabsorption in the kidney (Berndt et al., 
2005; Marks et al., 2008; Rowe et al., 2000; Shaikh et al., 2008). These 
phosphatonins, which are discussed later in this chapter (section 1.12), 
were identified from studies on a number of diseases associated with 
hypophosphataemia.  
 
Renal phosphate reabsorption and NaPi-IIa expression are also 
regulated by other factors, including epidermal growth factor (EGF), 
glucocorticoids, growth-related hormone and thyroid (Alcalde et al., 1999; 
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Taketani et al., 1998; Sorribas et al., 1995; Guner et al., 1999; Arar et al., 
1999; Arar et al., 1995).  
 
EGF is an important regulator of renal phosphate reabsorption in addition 
to its importance in DNA synthesis, tissue proliferation and nutrient 
absorption (Xu et al., 2001). EGF is a polypeptide secreted predominantly 
by salivary glands and to a lesser extent by the kidney. Inhibition of renal 
phosphate reabsorption by EGF in vitro and in vivo is mediated by 
regulation of NaPi-IIa expression at the protein and genomic level (Xu et 
al., 2001; Han et al., 2003; Arar et al., 1999).  
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Figure 1.4. Main factors controlling type II and type III phosphate (Pi) 
transporters in the proximal tubule. Type II and type III transporters are 
differentially regulated.  
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The signalling pathway used by EGF in regulating phosphate transport is 
unknown; it is independent of cyclic adenosine monophosphate (cAMP) 
but may involve tyrosine kinases (Han et al., 2003).  
 
Insulin-like growth factor 1 (IGF-1) stimulates proximal tubular Na+-
dependent phosphate reabsorption, an effect mediated through the 
binding of IGF-1 to growth hormone receptors present at the BLM of 
proximal tubules and subsequent activation of phospholipase C and/or 
tyrosine kinase pathway (Mulroney et al., 1989; Caverzasio et al., 1990; 
Hammerman et al., 1980).  
 
Thyroid hormone is another regulator of renal phosphate transport. 
Thyroid hormone stimulates phosphate reabsorption in the proximal 
tubules by increasing the genomic and protein expression of NaPi-IIa 
(Alcalde et al., 1999). The increase in renal phosphate reabsorption is 
significant enough to increase serum phosphate concentration. Unlike 
PTH and dietary phosphate, the regulation of phosphate transport by 
thyroid hormone is more long-term (Alcalde et al., 1999). Thyroid 
hormone also influences Na+-dependent phosphate transport in the 
kidneys of weaning animals, an effect that involves changes in the Kt and 
Vmax (Euzet et al., 1995; Euzet et al., 1996; Alcalde et al., 1999). In rats, 
the stimulatory effect of thyroid hormone is reduced in older rats (Alcalde 
et al., 1999), which is likely to be related to altered expression of NaPi-IIa. 
 
Glucocorticoids are regulators of a number of responses including 
immunologic and inflammatory responses, and these hormones also play 
a role in the regulation of renal phosphate reabsorption. Glucocorticoids 
act on the proximal tubules and their effect is independent of PTH (Levi et 
al., 1995). Administration of glucocorticoids increases urinary phosphate 
excretion whilst decreasing serum phosphate levels (Komiya et al., 
1992). This effect involves a reduction in the Vmax of Na+-dependent 
phosphate transport in adults only, complemented by a decrease in the 
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protein and genomic expression of NaPi-IIa (Guner et al., 1999; Levi et 
al., 1995). 
 
The CaSR is also thought to play a role in regulating renal phosphate 
reabsorption although the mechanism is unknown. Expression of CaSR 
occurs in the kidney, and interestingly its BBM expression in the proximal 
convoluted tubule was altered in parallel with NaPi-IIa expression 
following changes in dietary phosphate (Riccardi et al., 2000; Brown et 
al., 1995). Thus, it was proposed that expression of NaPi-IIa and CaSR 
may be co-regulated during renal phosphate handling. The potential 
importance of CaSR in phosphate homeostasis was further highlighted by 
the findings that 1,25-dihydroxyvitamin D3 alters renal expression of 
CaSR and activation of CaSR in turn prevents inhibition of PTH-sensitive 
renal phosphate reabsorption (Ba et al., 2003; Brown et al., 1996). 
 
Renal phosphate reabsorption is also regulated by other hormonal factors 
such as: 1) PTH-related peptide (PTH analog), which is produced by 
tumours and causes phosphaturia identical to the PTH pathway (Berndt, 
1992), 2) glucagon, which directly, through glucagon receptors expressed 
in the kidney, and indirectly causes phosphaturia by increasing cAMP 
concentrations in the plasma  (Brubaker & Drucker, 2002; Ahloulay et al., 
1996), and 3) prostaglandins, which is produced in the kidney and 
antagonises the phosphaturia caused by different physiological 
conditions such as increased PTH levels (Berndt, 1992). Other effects 
include those by nerve transmitters, since acute renal denervation 
increases renal phosphate excretion independent of PTH levels (Bello-
Reuss et al., 1975; Mann et al., 1992). 
 
1.9.3. Mechanisms involved in cellular redistribution of NaPi-IIa  
The internalization of NaPi-IIa protein at the BBM in response to 
phosphaturic signals occurs by highly specific pathways. As mentioned 
previously, increases in PTH levels or the feeding of high phosphate diets 
causes rapid internalisation of NaPi-IIa from the BBM and subsequent 
degradation in the lysosomes (Murer et al., 2000). For PTH, the hormone 
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initially binds to its receptor (PTHR), at both BBM and BLM, activating 
protein kinase A, protein kinase C  and cAMP-dependent signalling 
pathways (Tenenhouse & Murer, 2003). Internalisation occurs at 
intermicrovillar clefts involving clathrin and adapter protein (AP-2) 
(Traebert et al., 2000).  MAPK and ERK1/2 are also thought to take part 
in this pathway, since NaPi-IIa internalisation is prevented by ERK1/2 
inhibition (Hernando et al., 2005; Tenenhouse & Murer, 2003).  FGF-23 
inhibits NaPi-IIa-mediated phosphate transport via activation of MAPK 
(Yamashita et al., 2002). The downstream targets for ERK/MAPK-
mediated phosphorylation are unknown. 
 
The last three amino acids (TRL) in the C terminus tail of NaPi-IIa are 
important for its expression at the BBM (Hernando et al., 2002; Gisler et 
al., 2001; Gisler et al., 2003). Single PDZ (post synaptic density protein) 
domains of the Na/H exchange regulatory factors (NHERF1, NHERF2, 
NHERF3 and NHERF4) interact with TRL residues and play a critical role 
in ensuring the trafficking of NaPi-IIa transporter to the BBM. Additionally, 
NHERF1/2 interact with MERM (merlin–ezrin–radixin–moesin) in order to 
provide a link to the cytoskeleton (Hernando et al., 2010). Further 
mechanistic details behind the involvement of these proteins have not yet 
been established. 
 
Besides NHERF proteins, PDZ domains of Shank2E (splice form of 
Shank2) and GABAA-receptor associated protein (Gabarap) are also 
thought to play a role in the apical expression of NaPi-IIa (Reining et al., 
2007; McWilliams et al., 2005). Shank2E is found at the BBM of proximal 
tubules (McWilliams et al., 2005). In Gabarap-null mice, NaPi-IIa, but not 
NaPi-IIc, expression is increased, in parallel with increased Na+-
dependent phosphate transport (Reining et al., 2007; McWilliams et al., 
2005). Despite the pronounced effect seen in these animal models, the 
mechanisms behind Gabarap involvement in apical expression of NaPi-
IIa are not yet known. 
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Deletion studies and other work on the involvement of proteins at 
intermicrovillar clefts such as the microtubular network and clathrin, have 
shown two amino acids in intracellular loop 3 domain of NaPi-IIa to be 
important for BBM retrieval (Tenenhouse & Murer, 2003). The 
microtubular network does not partake in the initial internalization step, 
but it is pivotal for the transfer of NaPi-IIa containing vesicles to the 
lysosomes for degradation (Pfister et al., 1998; Lotscher et al., 1999; 
Keusch et al., 1998). On the contrary, insertion of NaPi-IIa transporter 
requires an intact microtubular network (Lotscher et al., 1999). NaPi-IIa is 
not thought to be recycled, but this process cannot be ruled out as a 
“fine-tuning system” for rapid adaptations to minor fluctuations in PTH 
and FGF-23 levels (Tenenhouse & Murer, 2003). 
 
The signalling cascade of events leading to insertion or retrieval of NaPi-
IIa transporters from the BBM is not completely understood. Interacting 
proteins involved in the ubiquitination of NaPi-IIa proteins following their 
retrieval may also play a role in the membrane redistribution of NaPi-IIa. 
It is not known whether internalisation of NaPi-IIa is preceded by 
transporter inhibition, as seen with PTH-dependent inhibition of the NHE3 
(Tenenhouse 2003). In contrast, mechanisms and proteins involved in 
BBM expression of NaPi-IIc and PiT2 are not known. One study 
proposed the interaction of NaPi-IIc with NHERF1 and NHERF3 (Villa-
Bellosta et al., 2008a); however the link between this interaction with 
apical expression of NaPi-IIc was not established. 
 
1.10. Small intestine 
 
1.10.1. Intestinal phosphate absorption 
Despite the plethora of knowledge on the mechanisms and regulation of 
renal phosphate transport, less is known about intestinal phosphate 
absorption.  This is because, in contrast to the kidney, hormonal 
regulation of intestinal phosphate transport was thought to play only a 
minor role in phosphate homeostasis. 
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Enterocytes undergo a process of maturation during transit from the crypt 
of Lieberkühn to villus tip. Only those enterocytes located in the mid to 
upper region of the villi are responsible for phosphate uptake (Marks et 
al., 2007). These cells express NaPi-IIb transporters at the BBM and this 
process is thought to be the rate-limiting step for phosphate absorption 
(Berndt et al., 2007; Marks et al., 2006 & 2007). A recent report has 
shown immunohistochemical evidence of localisation of PiT1 protein at 
the rat small intestinal BBM (Giral et al., 2009). However, the role of PiT 
transporters in BBM phosphate absorption remains unclear. 
 
Na+-dependent phosphate absorption across the intestinal BBM has been 
reported to decrease with age in several mammalian species, and NaPi-
IIb gene and protein expression also decreases proportionally with age 
(Xu et al., 2002a; Arima et al., 2002). Na+-dependent phosphate transport 
across the intestinal BBM is higher in suckling animals compared with 
weanlings and adults (Borowitz et al., 1985; Arima et al., 2002). In 
contrast, renal BBM Na+-dependent phosphate transport is lowest in 
suckling rats, highest in weanling rats, and lower in adults (Taufiq et al., 
1997). This might be attributed to the rapid maturation of the intestinal 
mucosa during the suckling/weaning transition (Henning et al., 1994), in 
combination with the change of diet from milk to solid food. 
 
Phosphate absorption across the rat small intestine shows similar 
regional features to that in the human small intestine in that the highest 
rate of phosphate transport is seen in the duodenum and jejunum and 
least in the ileal region (Walton & Gray 1979; Borowitz & Ghishan 1989; 
Marks et al., 2006). In contrast, in mice maximal phosphate absorption 
occurs in the ileum with small amounts absorbed in the jejunum and 
duodenum (Marks et al., 2006; Radanovic et al., 2005). This makes the 
rat a potentially suitable model for the study of intestinal phosphate 
transport in man. However, it is important to note that results from in vitro 
and ex vivo based studies may be biased, since the natural movement of 
food contents along the intestinal tract does not occur under these 
conditions. A compartmental mathematical analysis based on an in vivo 
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technique showed that although phosphate absorption in rats is generally 
greater in the duodenum, the ileum is responsible for the largest 
proportion of phosphate absorption, about 40% of total absorption, 
compared with other regions of the small intestine due the increased 
segment length and thus longer transit time (Kayne et al., 1993). The ileal 
membrane contains Na+/H+ exchangers that permit net Na+ entry, thus 
contributing to the serosa positive potential difference (Kikuchi et al., 
1988). However, no known phosphate transporter proteins are present in 
the rat ileum to mediate favoured entry of the negatively charged 
phosphate.The study of Kayne et al (1993) defined distal jejunal segment 
as ileum in their analysis, thus making their prediction slightly inaccurate. 
These studies together present a slightly confused understanding of 
region-specific regulation of intestinal phosphate transport. Despite this, it 
is now generally accepted that the majority of phosphate is absorbed in 
the proximal small intestine of rats (Giral et al., 2009; Marks et al., 2006, 
2007 &, 2008). 
 
Intestinal phosphate transport is controlled by genomic and protein 
changes in the Na+-dependent phosphate transporters expressed at the 
BBM. NaPi-IIb plays a main role in phosphate absorption across the 
small intestine; in mice NaPi-IIb is responsible for over 90% of total active 
phosphate absorption (Sabbagh et al., 2009). The absence of NaPi-IIb 
gene in NaPi-IIb knockout mice triggers compensatory mechanisms 
whereby renal NaPi-IIa expression is significantly upregulated (Sabbagh 
et al., 2009). Inhibition of NaPi-IIb in hyperphosphataemic late stage 
chronic renal failure successfully reduces serum phosphate levels, thus 
proving intestinal NaPi-IIb as a promising target for interventions in 
phosphate conditions associated with loss of kidney function (Eto et al., 
2005). NaPi-IIb is regulated predominantly by phosphate diet and 1,25-
dihydroxyvitamin D3 (Marks et al., 2006; Tenenhouse, 2007; Katai et al., 
1999). Although PTH is a major regulator of NaPi-IIa expression in the 
kidney, there is no evidence of any direct effect of PTH on intestinal 
expression of NaPi-IIb (Murer et al., 2001). Thus, PTH affects intestinal 
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phosphate absorption indirectly via its stimulatory effect on renal 1,25-
dihydroxyvitamin D3 synthesis. 
 
1.10.2. Regulation of intestinal phosphate absorption 
 
1.10.2.1. Phosphate diet  
Low dietary phosphate intake increases the synthesis of 1,25-
dihydroxyvitamin D3 via stimulation of the renal 1α-hydroxylase enzyme 
(Brown et al., 1999; Capuano et al., 2005). Increased 1,25-
dihydroxyvitamin D3  levels in turn stimulate Na+-dependent phosphate 
absorption across the small intestine by increasing expression of NaPi-
IIb. In mice, a low phosphate diet increases the protein and gene 
expression of NaPi-IIb transporter, whereas in rats only NaPi-IIb protein 
expression is increased (Brown et al., 1999; Capuano et al., 2005) 
implying control of the transporter at post-transcriptional level.  
 
Studies indicate that a low phosphate diet can upregulate Na+-dependent 
phosphate transport across the small intestine independently of 1,25-
dihydroxyvitamin D3 levels, since vitamin D receptor knockout mice, 1α-
hydroxylase knockout mice and 1α-hydroxylase-deficient mice all showed 
increased intestinal phosphate uptake in response to a low phosphate 
diet  (Capuano et al., 2005; Segawa et al., 2004).  
 
1.10.2.2. Vitamin D3 
Several studies have shown that 1,25-dihydroxyvitamin D3 increases Na+-
dependent phosphate absorption across the small intestine (Danisi et al., 
1980; Fuchs & Peterlik, 1980; Lee et al., 1986b; Matsumoto et al., 1980; 
Xu et al., 2002a). However, vitamin D deficiency does not cause a large 
effect on total intestinal phosphate absorption in adult rats, suggesting 
that 1,25-dihydroxyvitamin D3 plays a minor role in regulating intestinal 
phosphate handling (Walling, 1977; Lee et al., 1986a; Katai et al., 1999). 
 
In contrast to the genomic effect of 1,25-dihydroxyvitamin D3 on renal 
NaPi-IIa expression, the effect on the small intestine of adult rats involves 
56 
post-transcriptional increases in NaPi-IIb proteins (Hattenhauer et al., 
1999; Katai et al., 1999). Interestingly, PiT2 mRNA levels were increased 
by 1,25-dihydroxyvitamin D3 in vitro (Katai et al., 1999); the significance 
of this effect is unknown. In suckling rats however, 1,25-dihydroxyvitamin 
D3 treatment increases NaPi-IIb mRNA expression, indicating that the 
genomic effect of 1,25-dihydroxyvitamin D3 is age-dependent (Xu et al., 
2002a). The responsive region in the promoter and the factors involved in 
1,25-dihydroxyvitamin D3 regulation of the NaPi-IIb gene are so far 
unidentified.  
 
1.10.2.3. Metabolic acidosis  
Compared to the well characterised response of renal phosphate 
reabsorption during metabolic acidosis, intestinal phosphate absorption 
has received much less consideration. The study of Gafter et al (1986) 
showed that metabolic acidosis in rats increased intestinal Na+-
dependent phosphate uptake, an effect mediated by a concomitant 
increase in the abundance of NaPi-IIb protein at the BBM. They claimed 
that metabolic acidosis caused this effect by enhancing the stimulatory 
effect of 1,25-dihydroxyvitamin D3 on intestinal phosphate absorption.  In 
mice, the increase in Na+-dependent phosphate transport and NaPi-IIb 
protein expression during metabolic acidosis is seen in the ileum, the 
region responsible for maximal phosphate absorption in this species 
(Marks et al., 2006; Stauber et al., 2005). However, in both the rat and 
mouse, the adaptation to metabolic acidosis does not extend to changes 
in genomic expression of NaPi-IIb. The importance of intestinal 
phosphate absorption during metabolic acidosis is not clearly established 
but increased phosphate transport would help buffer the excess protons 
and compensate for the loss of phosphate from bone during acidosis.  
 
1.10.2.4. Other physiological factors 
In addition to dietary phosphate and 1,25-dihydroxyvitamin D3, intestinal 
phosphate absorption is also regulated by other factors such as 
phosphatonins (see section 1.12), EGF and glucocorticoids, factors that 
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also regulate renal phosphate reabsorption.  EGF is proposed to be an 
important part of a system involved in gut morphogenesis and 
maintenance (Chailler & Menard, 1999). High affinity EGF receptors are 
expressed along the gastrointestinal tract and EGF treatment in rats 
decreases NaPi-IIb mRNA levels by approximately 50% (Xu et al., 2001; 
Chailler & Menard, 1999). This transcriptional regulation involves a 
reduction in the NaPi-IIb gene promoter activity. In some conditions, such 
as intestinal ischemia or injury-induced hyperphosphataemia, EGF levels 
are significantly increased as is the tissue utilization of endogenous EGF 
(Thompson, 1999), implying an important role in the regulation of 
intestinal phosphate absorption. 
 
Glucocorticoids are also important physiological regulators of intestinal 
maturation, and plasma levels of glucocorticoids are age-dependent 
(Henning, 1978). The inhibitory effect of glucocorticoids on intestinal 
phosphate transport is also age-dependent with higher inhibition of Na+-
dependent phosphate transport in sucklings. This is in contrast to the 
effect of glucocorticoids on renal phosphate reabsorption that occurs in 
adult rats only (Arima et al., 2002). The inhibitory effect of glucocorticoids 
on intestinal phosphate uptake is mediated through changes in genomic 
and protein expression of NaPi-IIb.  
 
NaPi-IIb expression is stimulated by glucocorticoid-inducible kinase 1 
(SGK1), an effect partly mediated by phosphorylation and therefore 
inhibition of Nedd4-2 (Neural precursor cell expressed, developmentally 
down-regulated 4) (Palmada et al., 2004).  SGK1 is highly expressed in 
enterocytes and is activated by IGF-1 and insulin (Kobayashi et al., 1999; 
Kobayashi & Cohen, 1999). The significance of SGK1 in intestinal 
phosphate regulation is unclear. 
 
Oestrogen is important in the maintenance of calcium homeostasis. It 
plays a role in regulating calcium absorption, bone density and 1,25-
dihydroxyvitamin D3 synthesis (Xu et al., 2003b). Oestrogen stimulates 
intestinal Na+-dependent phosphate transport, an effect mediated through 
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changes in genomic and protein expression of NaPi-IIb (Xu et al., 2003b). 
Studies have established the presence of oestrogen receptors in the 
intestinal epithelium, implying the ability of the hormone to regulate gene 
transcription of proteins involved in Na+-dependent enterocyte phosphate 
absorption (Thomas et al., 1993). 
 
CaSR is expressed along the rat and human small intestine but its role in 
intestinal phosphate absorption is not yet known (Gama et al., 1997; 
Chattopadhyay et al., 1998).  
 
1.11. Disturbances of phosphate homeostasis 
 
1.11.1. Phosphate deficiency 
Abnormal phosphate homeostasis occurs in many characterised clinical 
disorders. Hypophosphataemia is an important consequence of 
malnutrition or malabsorption of phosphate, or inherited disorders 
affecting renal phosphate reabsorption such as X-linked 
hypophosphataemia and tumour-induced osteomalacia (Bielesz et al., 
2004; Amanzadeh & Reilly, 2006). Tumour-induced osteomalacia is an 
acquired rare syndrome characterised by excessive urinary phosphate 
excretion, hypophosphataemia, reduced 1,25-dihydroxyvitamin D3 levels, 
and osteomalacia (Kumar, 2000). Children with the Tumour-induced 
osteomalacia condition exhibit defective bone and cartilage 
mineralisation, whereas in adults only bone mineralisation defect is 
obvious (Drezner, 2001). X-linked hypophosphataemia  syndrome has a 
similar biochemical phenotype to tumour-induced osteomalacia (Kumar, 
2000). These disorders are linked in the long term to further clinical 
features such as bone demineralisation, nephrolithiasis, haemolysis, and 
reduced myocardial contractility (Amanzadeh & Reilly, 2006; Page et al., 
2008; Prie et al., 2002). 
 
A common cause of moderate hypophosphataemia is 
hyperparathyroidism (excessive PTH secretion), whereas PTH-
independent renal phosphate wasting is usually associated with more 
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severe hypophosphataemic conditions and is either a result of intrinsic 
proximal tubular defects (Fanconi syndrome) or due to abnormal levels of 
phosphatonins (Bando et al., 2009; Gore et al., 2009; Amanzadeh & 
Reilly, 2006; Pande et al., 2006; Higgins et al., 1990).  
 
1.11.2. Phosphate overload 
Chronic renal failure results in a progressive loss of renal function; 
glomerular filtration rate (GFR) gradually decreases as time progresses. 
Renal phosphate handling is altered by the progressive decline in the 
fraction of filtered phosphate that is reabsorbed, normally ~70%. In 
patients with chronic renal failure, PTH secretion is increased to enhance 
calcium release from bone.  The increase in PTH secretion is triggered by 
the decrease in ionised serum calcium concentrations, detected by the 
CaSR, due to high phosphate levels complexing with serum calcium 
(Brown & MacLeod, 2001). High PTH levels in turn increase urinary 
phosphate excretion to remove the excess phosphate.  
 
Chronic renal failure suppresses renal 1α-hydroxylase enzyme, thus 
decreasing 1,25-dihydroxyvitamin D3 levels in chronic renal failure 
patients (LaClair et al., 2005). The following mechanisms are responsible 
for the downregulation of this enzyme in chronic renal failure:  
- decreasing functional renal mass, which means lower levels of 1α-
hydroxylase is available, 
- declining GFR, which may limit the distribution of the substrate 25-
hydroxyvitamin D3 to 1α-hydroxylase (Nykjaer et al., 2001; Willnow 
& Nykjaer, 2002; Hilpert et al., 2002), 
- phosphate retention/hyperphosphataemia (Dusso et al., 2005) 
- increasing FGF-23 levels seen in chronic renal failure patients 
(see section 1.12.1), since FGF-23 directly inhibits transcription of 
1α-hydroxylase (Perwad et al., 2007; Shimada et al., 2004a). 
Additionally, PTH fragments (N-terminally truncated or C-terminal) are 
also thought to decrease 1α-hydroxylase enzyme activity (Usatii et al., 
2007). Inhibition of 1,25-dihydroxyvitamin D3 in turn decreases intestinal 
absorption of calcium and renal reabsorption of calcium and phosphate, 
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thus impairing bone mineralisation. Since 1,25-dihydroxyvitamin D3 
normally inhibits PTH, the loss of 1,25-dihydroxyvitamin D3 in chronic 
renal failure contributes towards the overproduction of PTH. 
 
As renal failure reaches end-stage, where GFR falls below 25 to 40 
ml/min and the number of functioning nephrons is very low, renal 
phosphate reabsorption rate drops to as low as 15% and the failure to 
excrete the required amount of absorbed/ingested phosphate leads to 
hyperphosphataemia, hypocalcaemia and vascular calcification (see 
section 1.11.3 for details on vascular calcification). As 
hyperphosphataemia stimulates PTH release, over-secretion of PTH 
eventually leads to hyperparathyroidism as a secondary consequence 
(Fig. 1.5) (Slatopolsky et al., 1984; Yalcindag et al., 1999; Stanbury, 
1981).  
 
Additionally, decrease in CaSR expression in parathyroid glands of 
chronic renal failure patients is thought to contribute towards secondary 
hyperparathyroidism (Block et al., 2004; Gogusev et al., 1997). 
Secondary hyperparathyroidism also now contributes towards 
hyperphosphataemia by continuing to stimulate the release of calcium 
phosphate from bone (Levin et al., 2007). Although PTH increases renal 
phosphate excretion, as renal failure progresses the kidney’s ability to 
excrete phosphate continues to worsen. 
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Figure 1.5. A model for progression of events in chronic renal failure: a pre FGF-
23 paradigm. Arrows ↑ and ↓ indicate increase and decrease. Adapted from 
Kopple & Massry (2004). 
 
Current treatments for hyperphosphataemia to prevent mortality include 
dietary phosphate restriction and oral phosphate binders, which helps to 
reduce plasma levels of PTH and phosphate, and this delays the 
progression of this condition (Miyamoto et al., 2003; Locatelli et al., 2002; 
Loghman-Adham, 1999; Loghman-Adham, 2003; Qunibi et al., 2004). 
However, these treatments are not without side-effects and may even 
contribute to accelerated vascular calcification, which leads to 
cardiovascular morbidity (Albaaj & Hutchison, 2003; Loghman-Adham, 
1999; Locatelli et al., 2002). For example, intake of aluminium-containing 
phosphate binders leads to accumulation of aluminium following its 
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absorption across the small intestine, and causes toxic side effects such 
as osteomalacia and microcytic anaemia (Cannata-Andia & Rodriguez-
Garcia, 2002; Loghman-Adham, 1999). Calcium-containing binders can 
lead to vascular calcification due to the excessive calcium absorbed 
(Bushinsky, 2006). Dietary phosphate restriction in uraemic patients, 
although successful at reducing phosphate retention, may induce protein 
malnutrition. 
 
Unlike the kidney, chronic renal failure does not affect the intestinal 
handling of phosphate (Douard et al., 2010; Marks et al., 2007). When 
dietary phosphate intake was restricted in chronic renal failure rats, 
circulating PTH levels were lowered and consequently renal NaPi-IIa 
expression was increased. In contrast, there was no change in intestinal 
phosphate absorption or NaPi-IIb mRNA level (Douard et al., 2010; 
Marks et al., 2007). Thus, the small intestine is a promising target in the 
prevention and treatment of hyperphosphataemia (Marks et al., 2007), 
making the search for an effective blocker of intestinal phosphate 
transport important for treating chronic renal failure. However, this search 
is restricted by our limited knowledge of the processes involved in 
phosphate absorption across the intestinal tract. 
 
1.11.3. Vascular Calcification  
Vascular calcification is one of the common complications of chronic 
renal failure. It involves ossification (deposition of calcium phosphate 
products), primarily within the arterial vessel wall, causing them to 
harden.  Vascular calcification contributes towards accelerated 
cardiovascular disease, which is known to be responsible for the largest 
cause of death in end-stage renal disease patients.  Calcification of 
VSMCs is stimulated by elevated extracellular levels of phosphate, 
calcium and PTH, commonly seen in chronic kidney disease (Hayden et 
al., 2005). The process of calcification during hyperphosphataemia 
involves osteogenic differentiation of VSMCs into osteoblast-like cells, 
promoted by the transcription factor Runx2/Cbfa1 (runt-related 
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transcription factor 2/core binding factor alpha1), which promotes 
expression of a broad range of genes related to the osteoblast phenotype 
such as bone Gla protein (BGP) and alkaline phosphatase (Moe & Chen, 
2004; Shanahan et al., 1999). An elevated level of phosphate in blood is 
responsible for driving this phenotypic change (Lau et al., 2010). 
 
Phosphate uptake by VSMCs encompasses both Na+-dependent and, to 
a lesser extent, Na+-independent components (Villa-Bellosta et al., 2007). 
The saturable Na+-dependent phosphate transport is mediated via the 
type III transporters PiT1 and PiT2 (Villa-Bellosta et al., 2007; Villa-
Bellosta et al., 2009a; Li et al., 2006). In contrast to the small intestine 
and kidney, genomic expression of type II transporters in VSMCs is 
minimal (Villa-Bellosta et al., 2007).. In these VSMCs, levels of PiT1 
mRNA were slightly higher than those of PiT2, in agreement with 
previous results (Lau et al., 2010). Increased expression of PiT1 and 
PiT2 transporters is thought to mediate vascular calcification during 
chronic renal failure, by permitting the increased entry of phosphate into 
VSMCs and causing subsequent VSMC osteochondrogenic phenotype 
change and calcification (Fig. 1.6) (Lau et al., 2010).  
 
Vascular calcification is a dynamic regulated pathological event where 
many factors are implicated. For example, inflammatory cytokine 
interleukin-6 and tumour necrosis factor alpha (TNF-α) are of particular 
importance in vascular calcification because they promote osteogenic 
differentiation and calcification of vascular cells (Bostrom, 2005). FGF-23 
phosphatonin and Klotho are thought to play an important role in 
promoting vascular calcification in hyperphosphataemic model, since 
FGF-23 or Klotho gene disruption is associated with accelerated vascular 
calcification (Memon et al., 2008). However, it is not yet known whether 
the effect of FGF-23/Klotho is direct or indirect.  
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Figure 1.6. The effects of high phosphate concentration on VSMCs. Na+-
dependent phosphate transporters PiT1 and PiT2 present at the plasma 
membrane of VSMCs allow cellular phosphate uptake and play a key role in 
vascular calcification. The potential inhibitory effects of FGF-23/Klotho are 
indicated. 
 
1.12. Phosphatonins 
PTH was considered the most important physiological regulator of renal 
phosphate excretion until the discovery of phosphatonins in 
mesenchymal tumours from patients with tumour-induced osteomalacia 
(Econs & Drezner, 1994; Cai et al., 1994). Phosphatonins, produced 
primarily by osteoblasts (cells responsible for bone formation), are now 
known to act as humoral regulators of phosphate metabolism (Berndt & 
Kumar, 2007; Berndt et al., 2005; Bowe et al., 2001; Kumar, 2002; Yuan 
et al., 2008). They help circumvent the complications of phosphate 
overload. Based on a large number of clinical studies, phosphatonins 
may be crucial for the prevention or reversal of the complications 
associated with chronic renal failure and hyperphosphataemia. 
 
Phosphatonins are phosphaturic factors that cause increased renal 
excretion of phosphate, and are linked to phosphate wasting diseases 
such as tumour-induced osteomalacia, X-linked hypophosphataemia and 
autosomal dominant hypophosphataemic rickets. These phosphatonin-
↑ PiT1 and PiT2 (VSMCs) High Phosphate Levels 
Osteochondroblastic  
Differentiation 
Vascular calcification 
Runx2/Cbfa1 expression 
Loss of mineralisation = PiT1 / PiT2 
FGF-23/Klotho 
? 
? 
? 
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related disorders may be genetic (X-linked hypophosphataemia and 
autosomal dominant hypophosphataemic rickets) or acquired (tumour-
induced osteomalacia). In these disorders, phosphatonins such as FGF-
23, FGF-7, secreted frizzled-related protein-4 (sFRP-4) and matrix 
extracellular phosphoglycoprotein (MEPE) are found to be aberrantly 
expressed and resistant to inactivation by a number of proteases. These 
four phosphatonins inhibit proximal tubular phosphate reabsorption in 
vitro and in vivo, partly mediated by a decrease in the abundance of 
NaPi-IIa proteins at the BBM (Berndt & Kumar, 2007; Berndt et al., 2005; 
Marks et al., 2008). However, only FGF-23 and MEPE have been shown 
to inhibit phosphate absorption across the small intestine (Marks et al., 
2008 & 2010; Miyamoto et al., 2005).  
 
The following sections in this chapter will focus on the linkage of 
phosphatonins to the well-studied bone diseases X-linked 
hypophosphataemia, tumour-induced osteomalacia, autosomal dominant 
hypophosphataemic rickets, hereditary hypophosphataemic rickets with 
hypercalciuria and oncogenic hypophosphataemic osteomalacia (OHO), 
which are all associated with renal phosphate wasting (Tenenhouse & 
Murer, 2003).  
 
1.12.1. Fibroblast growth factor-23 
FGF-23 is a naturally occurring peptide produced in several tissues, 
including the small intestine, parathyroid, heart, liver and bone (White et 
al., 2006). In mice, the highest genomic expression of FGF-23 is found in 
bone (Mirams et al, 2004; Liu et al, 2006). FGF-23 is thought to be 
important in the regulation of normal renal phosphate handling, since 
serum levels of FGF-23 are rapidly altered in response to dietary 
phosphate loading in both rodents and humans (Burnett et al., 2006; 
Ferrari et al., 2005; Perwad et al., 2005). 
 
Clinical studies showed that in early stage of chronic renal failure, the 
higher levels of circulating FGF-23 levels prevented the development of 
hyperphosphataemia by inducing phosphaturia (Juppner et al., 2010). 
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However, FGF-23 also reduced plasma levels of 1,25-dihydroxyvitamin 
D3 (discussed later in this chapter), thus contributing to the development 
of secondary hyperparathyroidism. Furthermore, in patients with end-
stage renal disease FGF-23 levels increased with increasing plasma 
phosphate, and the elevated levels of FGF-23 were linked to bone 
mineralisation, vascular calcification, left ventricular hypertrophy and 
mortality (Juppner et al., 2010). An abnormally elevated FGF-23 level is 
associated with several inherited and acquired hypophosphataemic 
disorders such as autosomal dominant hypophosphataemic rickets, X-
linked hypophosphataemia and tumour-induced osteomalacia, 
respectively. 
 
Autosomal dominant hypophosphataemic rickets is a rare inherited 
disorder characterised by renal phosphate wasting, hypophosphataemia, 
abnormally low or normal Vitamin D3 levels, and rickets or osteomalacia 
(Imel et al., 2007). Autosomal dominant hypophosphataemic rickets is 
caused by heterozygous FGF-23 missense mutations in the amino acid 
residues 176 or 179 (Imel et al., 2007). These residues form part of a 
protease cleavage site for subtilisin-like proprotein convertase, thus 
mutations cause resistance of FGF-23 to intracellular cleavage 
processing. The gain-of-function mutations in FGF-23 gene consequently 
cause severe hypophosphataemia in autosomal dominant 
hypophosphataemic rickets patients due to its phosphaturic actions.  
 
X-linked hypophosphataemia is another inherited disorder characterised 
by impaired renal phosphate handling caused by inactivating mutations in 
PHEX (phosphate-regulating gene with homologies to endopeptidases on 
the X chromosome), which encodes for a protein with homology to M13 
zinc metallopeptidases (Dixon et al., 1998; Juppner et al., 2010). The 
physiological substrate of the PHEX gene product is unknown. FGF-23 is 
one of the main phosphatonins responsible for mediating renal phosphate 
wasting in X-linked hypophosphataemia. The loss-of-function mutation in 
PHEX indirectly causes a reduction in the proteolytic degradation of full-
length FGF-23; full-length non-processed FGF-23 inhibits renal 
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phosphate reabsorption (Benet-Pages et al., 2004). Furthermore, 
inactivating mutations in PHEX have also been linked to elevated 
proteolytic release of a carboxy-terminal peptide called ASARM (acidic 
serine-aspartate-rich MEPE-associated motif) from MEPE, and ASARM 
inhibits bone mineralization (David et al., 2009). 
 
Tumour-induced osteomalacia is an acquired disorder caused by small 
tumours that express augmented levels of FGF-23 protein and mRNA. 
Hence patients display severe hypophosphataemia due to the 
phosphaturic actions of FGF-23 (Jüppner et al., 2010). 
 
In addition to PHEX, DMP1 (dentin matrix protein 1), and ENPP1 
(ectonucleotide pyrophosphatase phosphodiesterase 1) are also thought 
to be upstream regulators of FGF-23 synthesis (Juppner et al., 2010). 
FGF-23 exerts its inhibitory effect on renal phosphate absorption by 
binding to FGF receptors (FGFR) that are associated with its co-receptor 
Klotho (see section 1.12.2), leading to increased phosphate excretion 
due to decreased expression of NaPi-IIa and NaPi-IIc (Juppner et al., 
2010; Shimada et al., 2004c; Larsson et al., 2004). FGF receptors have a 
widespread distribution, and, therefore, their activation is controlled by 
the tissue-specific expression of Klotho. FGFR1, and to a lesser extent 
FGFR4, are the main receptors that mediate the phosphaturic effect of 
FGF-23 (Gattineni et al., 2009). FGF-23 injection stimulates rapid 
phosphorylation of MAPK and the expression of the early growth-
response gene 1 (Egr-1) in the distal tubules, where Klotho is mainly 
expressed. These changes are associated, via an unknown pathway, 
with decreased NaPi-IIa expression in neighbouring proximal tubules 
(Kuro-o et al., 1997; Farrow et al., 2009).  
 
FGF-23 decreases 1,25-dihydroxyvitamin D3 levels by  increasing renal 
24-hydroxylase (enzyme responsible for clearance of 1,25-
dihydroxyvitamin D3 by converting it into 24,25-dihydroxyvitamin D3) 
whilst decreasing 1α-hydroxylase (Saito et al., 2003; Kolek et al., 2005; 
Barthel et al., 2007). In patients with X-linked hypophosphataemia, 
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abnormally low circulatory levels of 1,25-dihydroxyvitamin D3 are present 
evident due to elevated FGF-23. The low plasma levels of 1,25-
dihydroxyvitamin D3 contributes further towards  hypophosphataemia, 
since 1,25-dihydroxyvitamin D3 is a stimulator of both renal and intestinal 
phosphate absorption (Palmada et al., 2004; Berndt et al., 2003; Berndt & 
Kumar, 2007; Bowe et al., 2001; Dobbie et al., 2008; Kumar, 2002; Marks 
et al., 2008). FGF-23 treatment of wild type mice reduced plasma levels 
of 1,25-dihydroxyvitamin D3 and inhibited intestinal phosphate transport 
and NaPi-IIb protein expression (Miyamoto et al., 2005). This action by 
FGF-23 is dependent on the VDR, since the same response is not 
elicited in VDR-null mice (Miyamoto et al., 2005). Interestingly, 
administration of 1,25-dihydroxyvitamin D3 in mice is directly linked to 
increases in serum FGF-23 levels (Kolek et al., 2005). High dietary 
phosphate and 1,25-dihydroxyvitamin D3 are, therefore, the two most 
important stimulators of FGF-23 synthesis (Juppner et al., 2010). Chronic 
changes in intestinal phosphate transport can also influence circulating 
FGF-23 levels (Sabbagh et al., 2009). Thus, this feedback loop between 
FGF-23 and 1,25-dihydroxyvitamin D3 not only links phosphate 
absorption across the small intestine and kidney together (gut-renal axis), 
but also proposes that FGF-23 is the main hormone affected by long-term 
changes in intestinal phosphate transport. However, the processes 
underlying the intestinal control of circulating FGF-23 are not yet known. 
 
FGF-23 is also an important promising biomarker in uraemic patients, 
since levels are an accurate diagnostic tool for analysing phosphate 
homeostasis in normal and pathophysiological conditions. FGF-23 may 
form an important part of therapeutic interventions in the different stages 
of chronic renal failure. 
 
1.12.2. Klotho 
FGF-23 mediates its effects through FGFR-Klotho complex. At normal 
physiological concentrations, FGF-23 has very low affinity to FGFR and 
the FGF-23/FGFR receptor interaction requires the presence of co-
receptor Klotho (Yu et al., 2005). Thus, Klotho is essential for facilitating 
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the phosphaturic effect of FGF-23.  The link between FGF-23 and Klotho 
provide strong evidence for a bone-kidney endocrine axis in the 
maintenance of phosphate homeostasis (Kuro-o, 2008; Kuro-o et al., 
1997). The loss of klotho gene causes resistance to FGF-23, since 
klotho-deficient mice were resistant to FGF-23 although they expressed 
augmented serum FGF-23 levels (Tsujikawa et al., 2003; Yoshida et al., 
2002).  
 
Only recently the importance of Klotho protein in phosphate metabolism 
was realised, aided by the revelation that the phenotypes of Klotho-
deficient mice were similar to mice deficient in FGF-23 (Kuro-o, 2010; 
Shimada et al., 2004b). Mice deficient in FGF-23 or Klotho exhibit 
hyperphosphataemia, soft tissue calcification and premature-aging 
syndrome (DeLuca et al., 2008; Tsujikawa et al., 2003; Yoshida et al., 
2002; Utsugi et al., 2000; Razzaque et al., 2006; Shimada et al., 2004b). 
These studies revealed an unanticipated link between phosphate 
homeostasis and the aging process.  
 
The klotho gene is also thought to function as an aging suppressor 
(Kurosu et al., 2005; Kuro-o, 2010). There are two forms of the Klotho 
protein; membrane-bound Klotho and secreted Klotho, and they have 
differential functions. The secreted Klotho acts as a humoral factor 
responsible for regulating the activity of multiple glycoproteins on the cell 
surface, such as ion channels and growth factor receptors (i.e. 
insulin/IGF-1 receptors), while membrane-bound Klotho acts as a co-
receptor for FGF-23 (Kuro-o, 2010).  
 
A summary of the linkage between 1,25-dihydroxyvitamin D3, FGF-23 
and Klotho is as follows: 
- 1,25-dihydroxyvitamin D3 binds to VDR forming a heterodimer with 
another nuclear receptor RXR (Fig. 1.7).  
- The VDR-RXR heterodimer then binds to the FGF-23 gene promoter 
and activates its expression.  
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- Secreted FGF-23 binds to the Klotho–FGF receptor complex in the 
kidney and conveys a signal to inhibit the synthesis of 1,25-
dihydroxyvitamin D3 and stimulate inactivation of 1,25-dihydroxyvitamin 
D3.  
- In the parathyroid gland, secreted FGF-23 inhibits PTH production and 
secretion. PTH stimulates 1,25-dihydroxyvitamin D3 levels in the kidney. 
Therefore, inhibition of PTH by FGF-23 is another route by which FGF-23 
reduces serum levels of 1,25-dihydroxyvitamin D3. 
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This regulation forms a negative feedback loop that is essential for 
vitamin D-regulated phosphate homeostasis, since abnormalities in either 
FGF-23 or Klotho can lead to augmented levels of 1,25-dihydroxyvitamin 
D3. 
 
Recent work by Hu et al (2010) showed that Klotho caused phosphaturia 
and inhibited NaPi-IIa in FGF-23 null mice. Hu et al (2010) also 
demonstrated direct dose-dependent inhibition of NaPi-IIa-mediated 
transport in vitro, in renal BBM vesicles and opossum kidney (OK) cells. 
Thus, Klotho has a direct, FGF-23-independent, phosphaturic effect on 
renal phosphate reabsorption, via a mechanism so far unknown. 
 
1.12.3 Matrix extracellular phosphoglycoprotein 
MEPE, a member of the SIBLING (Small Integrin Binding Ligand N-
Glycoprotein) family, is abundantly expressed in bone and its 
phosphaturic effect is mediated by the C-terminal peptide ASARM that is 
released following proteolysis by cathepsin (Rowe et al., 2004; Fisher & 
Fedarko, 2003).  
 
Zn-metalloendopeptidase PHEX protects MEPE from cleavage by 
preventing cathepsin B/protease cleavage (Rowe, 2004). Phex knockout 
mice displayed increased synthesis and serum levels of MEPE and FGF-
23 (Yuan et al., 2008). MEPE was initially cloned from a tumour resected 
from a tumour-induced osteomalacia patient (Rowe et al., 2000). MEPE 
is normally expressed in osteoblasts, osteocytes and odontoblasts, with 
increased expression in Hyp (murine X-linked hypophosphataemia 
homologue) osteoblasts (as PHEX is defective) and OHO tumours 
(Rowe, 2004). MEPE is thought to contribute towards pathogenesis of 
hypophosphataemia in patients with tumour-induced osteomalacia (Rowe 
et al., 2000 & 2004). MEPE is present in healthy humans and their levels 
decline with age, correlating positively with serum phosphate and 
negatively with PTH concentrations (Jain et al., 2004). Thus, MEPE 
protein is thought to be important for bone and tooth mineralisation in a 
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normal population. In mice, MEPE knockout causes age-dependent 
accelerated bone mineralisation and bone formation although serum 
phosphate and calcium levels are normal (Rowe et al., 2000; Jain et al., 
2004; Gowen et al., 2003), whereas MEPE overexpression causes 
defects in growth and mineralisation (David et al., 2009; Rowe et al., 
2000). Administration of human derived-MEPE in nomal mice causes 
dose-dependent hypophosphataemia and hyperphosphaturia (Rowe et 
al., 2004).  
 
MEPE was demonstrated to dose-dependently suppress renal phosphate 
reabsorption in vivo, and this correlated with increased phosphate 
excretion and reduced expression of NaPi-IIa in proximal convoluted 
tubules (Dobbie et al., 2008; Marks et al., 2008; Rowe et al., 2004).  
Overexpression of MEPE in mice increases serum phosphate levels by 
stimulating the expression of renal NaPi-IIa (David et al., 2009). Short-
term infusion of MEPE in rats inhibited in vivo phosphate absorption in 
the jejunum, but not duodenum (Marks et al., 2008). This effect was 
independent of changes in the blood levels of PTH, 1,25-
dihydroxyvitamin D3 and FGF-23. This study of Marks et al (2008) 
contradicts a previous report that demonstrated increased serum 1,25-
dihydroxyvitamin D3 levels in mice following treatment with human-
derived MEPE (Rowe et al., 2004). Thus, it was proposed that differences 
in MEPE exposure time causes differential effects (Marks et al., 2008). 
Additionally, MEPE mRNA was detected in the small intestine and 
kidney, with higher expression levels in the BBM of proximal convoluted 
tubules and duodenum (Marks et al., 2010; Ogbureke & Fisher, 2005; 
Rowe et al., 2000). Thus, MEPE may be secreted into the tubular and 
intestinal lumen, where it binds to its (so far unidentified) cell surface 
receptor and cause an autocrine or paracrine effect. A local effect in bone 
was demonstrated in a recent in vivo study where MEPE acted in an 
autocrine manner in osteoblasts to inhibit bone resorption following its 
secretion (David et al., 2009).  
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Findings from studies using rodents suggest that MEPE may be involved 
in a complex interplay with FGF-23 and 1,25-dihydroxyvitamin D3. 
Changes in serum MEPE levels was reported in healthy subjects who 
consumed high phosphate diets (Allen et al., 2003). This might be related 
to 1,25-dihydroxyvitamin D3 levels, since studies in rodents showed that 
1,25-dihydroxyvitamin D3, which is decreased by a high phosphate diet, 
inhibits MEPE expression (Argiro et al., 2001). Furthermore, VDR null-
mice express augmented levels of MEPE mRNA (Okana T et al., 2003). 
MEPE expression by osteoblasts is also suppressed by 1,25-
dihydroxyvitamin D3 (Rowe et al., 2004). MEPE also increases FGF-23 
production in bone marrow stromal cells (Liu et al., 2007; Argiro et al., 
2001; Rowe et al., 2005).  
 
1.12.4. Secreted frizzled-related protein-4 
sFRP-4 is a phosphatonin found highly expressed in tumours associated 
with renal phosphate wasting and osteomalacia (De Beur et al., 2002). 
sFRP-4 protein causes phosphaturia and hypophosphataemia by 
decreasing renal phosphate reabsorption and by suppressing the 
compensatory increases in 1α-hydroxylase enzyme (Berndt et al., 2003). 
This effect on renal phosphate handling is directly related to a decrease 
in Na+-dependent phosphate transport at the renal BBM as well a 
decrease in NaPi-IIa protein expression (Berndt et al., 2006). sFRP-4 is 
expressed in many tissues, including the kidney (Berndt et al., 2003). 
Augmented levels of sFRP-4 is found in bone and serum of Hyp mice and 
Phex knockout mice (Yuan et al., 2008). 
 
sFRP-4 is thought to play a role in the long-term regulation of renal 
phosphate reabsorption following a high dietary phosphate intake, since 
sFRP-4 protein levels were upregulated in the kidneys of rats fed a 
chronic high phosphate diet (Sommer et al., 2007). In contrast, levels of 
sFRP-4 were not altered in animals fed a chronic low phosphate diet.  
 
sFRPs are antagonists for the Wnt proteins, which play a role in the 
activation of cellular events upon binding to frizzled receptors and 
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changing the levels of the intracellular messenger β-catenin (Berndt et 
al., 2003). Based on two studies by Berndt et al (2003 & 2006), sFRP-4 is 
proposed to function by altering Wnt signalling pathways in proximal 
tubule cells.  
 
1.12.5 Fibroblast growth factor-7 
FGF-7, also called keratinocyte growth factor (KGF), was identified in 
tumours from tumour-induced osteomalacia patients where it was found 
to be overly expressed (Carpenter et al., 2005). FGF-7 stimulates wound 
healing and is thought to be a potential tumour marker (Carpenter et al., 
2005). FGF-7 is highly expressed in keratinocytes and is also found in the 
gastrointestinal epithelium, transitional urothelial cells, and type II 
pneumocytes (Danilenko, 1999; Beer et al., 2000). FGF-7 inhibits Na+-
dependent phosphate transport in opossum kidney cells, and causes 
phosphaturia in vivo (Carpenter et al., 2005). However, details behind the 
mechanism of FGF-7 action are unknown.  
 
1.13. Choice of animal 
Sprague Dawley rats (SD) were chosen to study intestinal phosphate 
absorption for several reasons.  SD rats are a good model to study 
developmental changes, since young rats are of manageable size and 
the small intestine is more easily manipulated compared with mice, where 
the intestine is very fragile for manipulation of the tissue for uptake 
studies. The quantity of mucosa that can be retrieved from small intestine 
of mice for western blotting and other studies is also much less in mice 
compared with rats. 
 
1.14. Aims 
 
- To employ suitable in vitro and in vivo techniques for measuring Na+-
dependent and Na+-independent phosphate transport across the BBM of 
the rat small intestine. 
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- To determine the normal luminal unbound phosphate concentrations 
along the intestinal tract of rats.  
 
- To measure Na+-dependent and Na+-independent transport in the 
duodenum, jejunum and ileum under normal luminal phosphate 
concentrations found in rats, with the use of the validated in vitro and in 
vivo techniques.  
 
- To measure Na+-dependent and Na+-independent transport in the 
proximal and distal colon under normal luminal phosphate 
concentrations. 
 
- To determine the effect of a chronic low phosphate diet, aging, chronic 
renal failure and MEPE treatment on mRNA expression of PiT 
transporters in the small intestine and kidney. 
 
- To investigate whether the release of a proposed duodenal 
‘phosphaturic factor’, following exposure to a high luminal phosphate 
concentration, causes local effects on intestinal phosphate absorption 
and to determine whether increased phosphate excretion, as observed by 
Berndt et al (2007), is mediated through changes in BBM abundance of 
renal NaPi-II transporters.  
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2.0. Measurement of intestinal phosphate transport 
using in vitro and in vivo techniques 
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2.1. Introduction 
 
There are conflicting views concerning mechanisms involved in intestinal 
phosphate uptake and these are likely in part to reflect the wide variety of 
techniques and experimental conditions used. Another confounding factor 
arises from important species differences in the primary location of 
phosphate absorption along the intestinal tract. In the rat, phosphate 
transport occurs maximally in the proximal small intestine, which is similar 
to the profile in human small intestine (Armbrecht, 1986; Davis et al., 
1983; McHardy, 1956; Marks et al., 2006). In contrast, in mice the ileum 
displays the highest rate of phosphate absorption; only small amounts 
are absorbed in the jejunum and duodenum (Marks et al., 2006; 
Radanovic et al., 2005).  
 
Intestinal phosphate absorption occurs via two distinct pathways: 
paracellular transport involving tight junctions, and transcellular transport. 
Early studies using brush-border membrane (BBM) vesicles revealed a 
phosphate transport system that was critically dependent on sodium, with 
a Kt for phosphate of around 0.1 mM (Berner et al., 1976; Lee et al., 
1986b; Loghman-Adham et al., 1987). The type II sodium phosphate 
cotransporter, NaPi-IIb, was later cloned and characterised, and 
proposed to be responsible for active, saturable phosphate transport 
across the intestinal BBM (Hilfiker et al., 1998). However, in vivo studies 
found no evidence of this Na+-dependent process  (McHardy, 1956; 
Williams & DeLuca, 2007). Similarly, using the everted sac technique, 
Douard et al (2010) showed no Na+-dependency for phosphate uptake. 
Furthermore, reports, based mainly on studies using BBM vesicles, 
indicate that the Na+-dependent transport process is regulated by dietary 
phosphate level and by aging (Danisi et al., 1980; Giral et al., 2009; 
Kirchner et al., 2008; Xu et al., 2002a). Figure 2.1 summarises the overall 
changes induced by a low or high phosphate diet for maintenance of 
serum phosphate levels within the normal range. The detailed regional-
specific adaptation induced under both of these conditions is, however, 
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not well established in the small intestine, including the regulation of Na+-
independent transport. 
 
The aim of this study was to determine the extent of Na+-dependency for 
phosphate transport in the three regions of the small intestine: 
duodenum, jejunum and ileum.  To achieve this, in vitro and in vivo 
techniques were employed to measure Na+-dependent phosphate 
transport at 0.1 mM phosphate. These two techniques were validated by 
using chronic low phosphate diet and aging, two physiological conditions 
classically known to regulate intestinal phosphate absorption. Uptake 
data are of great importance, since there are currently no reliable 
available antibodies for the detection of NaPi-IIb protein in rats. 
Therefore, a number of potential antibodies were tested, using tissues 
from young and adult rats. 
80
 
                    Fi
gu
re
 2
.1
. 
D
ia
gr
am
 d
em
on
st
ra
tin
g 
m
ec
ha
ni
sm
s 
fo
r 
m
ai
nt
en
an
ce
 o
f 
se
ru
m
 p
ho
sp
ha
te
 (
P
i) 
le
ve
ls
 in
 c
on
di
tio
ns
 o
f 
hi
gh
 o
r 
lo
w
 p
ho
sp
ha
te
 d
ie
t. 
A
da
pt
ed
 fr
om
 B
er
nd
t &
 K
um
ar
 (
20
07
).
 
81 
2.2. Materials and Methods  
Experiments were performed in accordance with national and local 
ethical guidelines.  
During experimentation, animals under anaesthesia were constantly 
checked for pedal withdrawl to a pinch and/or eye-blink reflex, and 45 
mg/kg of the orginal anaesthetic dose of pentobarbitone sodium was 
given intraperitoneally to maintain the animal under a deep level of 
anaesthesia. Rats were killed at end of experiment by using an overdose 
of anaesthetic (60 mg/kg of pentobarbitone sodium).  
 
 
2.2.1. Animals and diet 
Male Sprague Dawley (SD) rats aged 21 days, 8 weeks, and 16 weeks 
were obtained from Charles River Laboratories (UK) and used in 
accordance with the Animals (Scientific Procedures) Act 1986. Control 
rats were allowed ad libitum access to a standard rodent chow containing 
0.52% phosphate (Diet RM1, SDS Ltd, Witham, Essex, UK), and water. 
 
Rats on normal diet were switched to a low phosphate diet containing 
0.02% phosphate (Harlan Tekland, Indianapolis, USA) for 7 days prior to 
experimentation. 
 
2.2.2. Phosphate uptake 
 
2.2.2.1. Phosphate uptake by everted intestinal sleeves 
The everted sleeve technique exposes the mucosal surface to the 
incubation buffer containing radiolabelled phosphate, therefore allowing 
direct measurement of phosphate uptake across the intestinal BBM.  In 
comparison with in vivo techniques, there is a great reduction of unstirred 
water layer thickness, owing to vigorous stirring rates of mucosal 
solutions. The validation of this preparation and optimal conditions for in 
vitro measurement of solute uptake has been described in detail by 
Karasov & Diamond (1983).  Rats were anaesthetised with an 
intraperitoneal (i.p) injection of pentobarbitone sodium (45 mg/kg) 
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Regions of intestine (2-4 cm) representing duodenum (1 cm from 
stomach), jejunum (beginning at the ligament of Treitz), ileum (5 cm 
proximal to the caecum), proximal colon (4 cm distal to the caecum) and 
distal colon (2 cm distal to the caecum) were then removed from the 
animal. The lumen was flushed through with saline (154 mM NaCl) at 
room temperature to remove contents, everted on a glass rod and the 
everted tissue secured to the rod with ligature thread before pre-
incubation for 5 min pre-incubation buffer (pH 7.4) containing, in mM: 16 
HEPES, 3.5 KCl, 10 MgSO4, 1 CaCl2 and 125 NaCl, which was 
oxygenated with 100% O2 and stirred continually at room temperature. 
The tissue was then incubated at room temperature for 2 min in 2 ml of 
oxygenated and stirred uptake buffer (Fig. 2.2) containing pre-incubation 
buffer, with the addition of 10 mM glucose, 0.1 mM KH2PO4 and 0.74 
MBq 32P (PerkinElmer, Bucks, UK).  A period of 2 min was chosen for 
phosphate uptake, since this time was on the constant phase of uptake 
(Fig. 2.3) and long enough to allow for adequate uptake across the BBM 
and equilibration of the adherent fluid, as well as to minimise the efflux of 
32P to the serosa. Both buffers were rapidly stirred to minimise the effects 
of static water layers at the mucosal surface. Choline chloride (ChCl) was 
used as an iso-osmotic substitute for NaCl for sodium-free phosphate 
uptake solutions (pre-incubation buffer, incubation buffer and wash 
solutions) and intestinal tissues were flushed with 150 mM ChCl before 
mounting on glass rods.  For some experiments 1 or 10 mM 
phosphonoformic acid (PFA) was added to the pre-incubation buffer and 
uptake solution to inhibit NaPi-IIb-mediated phosphate cotransport (Bai et 
al., 2000; Collins et al., 2004; Ravera et al., 2007; Virkki et al., 2007). 
Uptake was then terminated by washing the tissue with 10-fold (when 
phosphate concentration in the uptake solution was less than 1 mM) or 
20-fold cold excess phosphate (when phosphate concentration was 
greater than 1 mM) in 150 mM NaCl or ChCl for 10 min, followed by PBS 
(phosphate-buffered saline) for 5 min at room temperature. These two 
washes were sufficient to displace most bound 32P on the mucosal 
surface and at the same time retain absorbed radiolabelled 32P in the 
cells (Karasov & Diamond, 1983; Marks et al., 2007). Incubated tissue 
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(~100 mg) was weighed and digested overnight in Solvable (Perkin 
Elmer, MA, USA) and counted in Ultima-Gold using a scintillation counter 
(Beckman LS2000, Beckman-Coulter Research, Buckinghamshire, UK). 
32P activity in digested samples and in the initial uptake solution was used 
to calculate tissue phosphate retention in nmoles/100 mg mucosa. For 
each rat, two sleeves were used from the same region of small intestine 
for measuring uptake rates in the presence and absence of sodium at 0.1 
mM phosphate concentration. 
 
During experimentation, animals were constantly checked for pedal 
withdrawl and/or eye-blink reflex to a pinch, and 1:4 diluted 45 mg/kg of 
the orginal anaesthetic dose of pentobarbitone sodium was given 
intraperitoneally to maintain the animal under a deep level of 
anaesthesia. Rats were killed at end of experiment by using an overdose 
of anaesthetic (60 mg/kg) of pentobarbitone sodium.  
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Figure 2.2. Diagram showing in vitro preparation for measurement of 
intestinal phosphate uptake. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Time-dependence of intestinal phosphate uptake using the 
everted sleeve technique. 0.1 mM phosphate was used in the uptake 
buffer. 
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2.2.2.2. Transepithelial phosphate absorption 
The in situ loop method was used to measure transepithelial phosphate 
absorption, since it has been previously shown to be suitable for 
measurement of  transepithelial absorption of phosphate (Aloia & Yeh, 
1985; Marks et al., 2006, 2007, 2008).  Marks et al (2007) have 
demonstrated that a 30 min incubation period is suitable for 
measurement of duodenal and jejunal phosphate absorption. Rats were 
anaesthetised with an i.p injection of pentobarbitone sodium (45 mg/kg) 
and their body temperature maintained at 37°C using a thermostatically 
controlled heating blanket. A 5 cm long segment of duodenum, jejunum, 
ileum, proximal colon or distal colon was selected (location was as 
described above for the everted sleeve technique) and cannulated and 
flushed with 150 mM NaCl or ChCl (at 37˚C) to remove contents, followed 
by air.  500 µl of uptake buffer containing, in mM: 16 Na-HEPES or Na-
free HEPES, 140 NaCl or ChCl, 3.5 KCl, 0.1 KH2PO4 and 0.37 MBq 32P, 
was instilled into the lumen without causing distension and both ends of 
the segment were tied off, to achieve a closed loop (Fig. 2.4) and 
returned to the abdominal cavity. In some experiments 1 or 10 mM PFA 
was added to the buffer to inhibit NaPi-IIb-mediated transport. Blood was 
collected after 30 min by cardiac puncture and centrifuged at 1,500 g for 
10 minto obtain plasma. The intestinal segment was removed from the 
animal and mucosal bound 32P was displaced by flushing through quickly 
with 40 ml of 10-fold (when phosphate concentration in the uptake 
solution was less than 1 mM) and 20-fold excess phosphate (when 
phosphate concentration was over 1 mM) and 40 ml saline at room 
temperature, using a 20 ml syringe. The mucosa was removed by 
scraping with a microscopic slide and weighed and digested with Protosol 
(Perkin Elmer, MA, USA). The radioactivities of both mucosa and plasma 
were counted using Ultima Gold scintillation fluid. The rates of mucosal 
phosphate retention and transepithelial transport (32P appearance in 
plasma) were calculated taking into account the initial 32P activity in the 
uptake buffer. All uptake experiments were repeated a minimum six 
times. 
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Figure 2.4. A picture showing the in vivo in situ closed loop technique performed 
using rat jejunum. 
 
 
2.2.3. Phosphate assay 
Blood samples, collected from animals fed a normal and low phosphate 
diet for 7 days, were centrifuged at 1,500 g for 10 min. Plasma phosphate 
levels were determined using a Quanichrom phosphate assay kit 
(BioAssay Systems, Hayward, CA) and used according to the 
manufacturer’s instructions. 
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2.2.4. Membrane vesicles 
 
2.2.4.1. Intestinal brush-border membrane (BBM) vesicles  
Rats were terminally anaesthetised and three regions of small intestine 
were removed as follows: 5 cm duodenum (1 cm from the pylorus), 10 cm 
upper jejunum (3 cm from the ligament of Treitz) and 10 cm ileum (last 10 
cm proximal to caecum). All subsequent steps were carried out at 4°C 
and the methods used for the preparation of vesicles followed those 
described previously by (Kessler et al., 1978). This technique allows the 
removal of subcellular contaminants for the separation of intact BBM. The 
intestinal regions were flushed through with ice-cold saline to remove 
contents and then opened longitudinally on an ice-cold glass surface, and 
the mucosa was scraped away using glass microscope slides. The 
mucosa was added to homogenising buffer (pH 7.1), 28 ml/g mucosa, 
containing, in mM: 50 mannitol, 2 HEPES (4- [2-hydroxyethyl]-1-
piperazine ethanesulfonic acid), and 0.25 PMSF (phenylmethane 
sulphonylfluoride), and homogenised (Ultra Turrax homogeniser, Janke & 
Kunkel, FRG) at setting 5 for three times at 20 s with a 5 s interval in 
between. MgCl2 was added to a final concentration of 10 mM, and stirred 
on ice for 20 min. The suspension was centrifuged at 3,000 g for 20 min 
and the resulting supernatant further centrifuged for 30 min at 27,000 g. 
The pellet was resuspended using a 21-gauge needle in resuspension 
buffer (pH 7.2) containing, in mM: 300 mannitol, 20 HEPES, 0.1 MgSO4 
and 0.25 PMSF. The suspension was centrifuged at 6,000 g for 15 min 
and the supernatant further centrifuged at 27,000 g for 30 min. The final 
pellet represented purified BBM vesicles and was resuspended with the 
same resuspension buffer (50-150 µl) by 6 passes using a 21-gauge 
needle and syringe to obtain a final protein concentration of 5-9 mg/ml. 
When weaning animals were used less mucosal scrapes were available, 
so samples were pooled. Aliquots of BBM vesicles were immediately 
frozen in liquid nitrogen and stored at -70°C. 
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2.2.4.2. Lung membrane vesicles 
Lung tissue sections were harvested from normal rats and were used for 
extraction of a crude membrane fraction, as described by Traebert et al., 
(1999). All steps were carried out at 4°C.  Tissue was homogenized with 
an Ultra Turrax homogeniser at setting 5 for 1 min in 15 ml of buffer A 
(pH 7.1) containing, in mM: 300 mannitol, 5 EGTA, and 12 Tris/HCl and 
0.5 PMSF.  The suspension was centrifuged at 1,000 g for 10 min and 
the resulting supernatant was diluted with 10 ml of deionised water and 
further centrifuged at 27,000 g for 30 min. The pellet obtained was 
resuspended in 20 ml of the same buffer and centrifuged at 27,000 g for 
30 min. The final pellet was resuspended in about 2 ml of buffer A by 6 
passages through a 21-gauge needle fitted to a syringe to obtain a 
protein concentration of ~7-9 mg/ml.  
 
2.2.4.3. Determination of protein concentration 
Protein concentration was measured using the Bradford assay (Bradford, 
1976), designed to assess binding of proteins to Coomassie Brilliant Blue 
G-250 dye. A calibration curve was obtained by measuring known 
concentrations of bovine serum albumin (BSA), ranging from 15-90 
mg/ml, in 0.1 M sodium hydroxide (NaOH). Protein binding causes the 
absorption maximum of the dye to shift from 465 to 595 nm, measured 
using a spectrophotometer (Beckman 650, Beckman-Coulter Research, 
Buckinghamshire, UK), and the increase is proportional to the protein 
concentration. Samples were initially diluted 1:10 in 0.1 M NaOH before 
adding the Bradford reagent. 
 
2.2.4.4. Determination of intestinal purity 
Alkaline phosphatase assay was used to calculate an enrichment value 
for the enzyme in the final BBM vesicles suspension, relative to the initial 
homogenate, as a measure of purity. It was important to establish that 
vesicles were highly purified and largely free of basolateral membrane 
and subcellular components. Alkaline phosphatase activity was 
measured in the initial homogenate (1:5 dilution) and the final purified 
BBM vesicles (1:50 dilution) extracted, using the method described by 
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Forstner et al (1968). The assay is based on the rate of formation of the 
yellow product p-nitrophenol (p-NP), which is produced by hydrolysis of 
p-nitrophenylphosphate (p-NPP) in alkaline solution. 
 
As a standard 4-nitrophenol was used, ranging from 50-300 nM 
concentration; following the necessary dilution of samples and standard 
with distilled water, 100 µl was aliquoted into fresh tubes to which 500 µl 
of alkaline buffer (pH 9.4) was added  that contained, in mM: 0.05 
glycine, 5 MgCl2 and 1 Zn(O2CCH3)2. After preincubation for 30 min at 
37°C, the reaction was terminated by adding 2.5 ml of 1 M NaOH. The 
change in absorbance resulting from the production of p-NP was read 
spectrophotometrically at 405 nm. Enzyme activity was expressed as 
units/mg protein and calculated as shown below: 
 
Intestinal BBM vesicles typically showed an alkaline phosphatase 
enrichment of: Duodenum 10.3 ± 2.1, Jejunum 11.1 ± 2.9, and Ileum 9.9 
± 1.9. There were no segmental differences in the enrichment values 
(P=0.78, using one-way ANOVA). 
 
2.2.5. Detection of NaPi-IIb protein 
 
2.2.5.1. Western Blotting 
BBM vesicle samples (15-100 µg protein) were solubilised in 2 x Laemmli 
sample buffer (Bio-Rad, CA, USA) containing 5% sodium dodecyl 
sulphate (SDS – Sigma, Dorset, UK) and/or 5% mercaptoethanol, 
depending on the degree of denaturation needed. Loaded samples and 
Kaleidoscope pre-stained molecular weight marker (Bio-Rad, Hemel 
Hempstead, UK) were electrophoresed on a 10% SDS polyacrylamide 
gel in running buffer containing, in mM: 25 Tris, 192 glycine and 0.1 % 
(w/v) SDS-running buffer, at 20 mA for about 1 h. Separated proteins 
were transferred to Sequi-blot PVDF nitrocellulose membrane (Bio-Rad) 
X           
BBM alkaline phosphatase 
BBM [protein] 
= 
 
BBM alkaline phosphatase activity (nmol) 
Homogenate 
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by semi-dry electrophoretic blotting for 1 h at a fixed current of 110-130 
mA for 1-1½ h. The membrane was then blocked in 6% skimmed milk in 
0.1% PBS-Tween for 1 h at room temperature to remove non-specific 
protein binding. Following two quick washes with PBS-Tween, 
membranes were incubated with a number of potential NaPi-IIb primary 
antibodies overnight on a shaker at 4°C, as listed in Table 2.1. Primary 
antibody β-Actin only needed 1 h incubation at room temperature. 
 
The membrane blots were washed in PBS-Tween once for 5 min and 
then twice for 10 min, and incubated with secondary antibody IgG 
conjugated to horseradish peroxidase for 1 h at room temperature. After 
washing with PBS-Tween as above, bound antibodies were detected 
using an enhanced chemiluminescence kit (Amersham Pharmacia 
Biotech UK Ltd, Bucks, UK) and visualised using a Fluor-S MultiImager 
System (Biorad, Hertfordshire, UK).  
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The membrane was stripped of antibodies bound to the protein, using 
stripping buffer (Fisher Scientific, Leicestershire, UK) for 5-8 min and 
washed twice with PBS for 5 min. The membrane was treated as before, 
starting with the milk blocking step and probed for β-actin.  
 
2.2.5.2. Dot blot 
The dot blot technique is based on the same principles as western 
blotting, but differs in that protein samples are not separated 
electrophoretically and are spotted directly onto the nitrocellulose 
membrane. Therefore, it is an easier and less time consuming way of 
testing antibodies. Two filter papers were initially soaked in PBS and the 
nitrocellulose membrane in methanol for a few minutes, followed by PBS. 
Wet membrane was placed directly above the filter papers. Protein 
samples (50-100 µg), prepared using the same conditions as those 
described for western blotting (without the coloured loading dye), were 
applied directly onto the membrane and left to dry overnight. The rest of 
the procedure followed was the same as that used for western blotting, 
starting at blocking with milk. NaPi-IIb antibodies were tested using this 
method. 
 
2.2.6. Statistical analysis 
Data are presented as means ± SEM. Unpaired t-test or a one-way 
ANOVA, as appropriate, was used and group differences were 
considered statistically significant if P <0.05; n represents the number of 
samples per group. Post hoc analysis was carried out within groups by 
using the Bonferroni correction, 
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2.3. Results  
 
2.3.1. Sodium-dependency of intestinal phosphate transport  
Na+-dependent phosphate transport in the three regions of small intestine 
was measured by two techniques; in vitro using the everted sleeve 
method and in vivo via blood appearance of radiolabelled phosphate 
using the in situ closed loop technique. For both approaches, 
experiments were carried out with or without sodium in the uptake buffer. 
Initially, a concentration of 0.1 mM phosphate was chosen for uptake 
solutions, in keeping with the known kinetic parameters for NaPi-IIb-
mediated phosphate transport. The increase in phosphate uptake using 
everted sleeves showed a constant relation with time for the initial 2 
minutes (Fig. 2.3).  Therefore, 2 minutes was chosen as the incubation 
period for in vitro uptake of phosphate. The optimal instillation period for 
measurement of in vivo transepithelial phosphate absorption was 
previously established as 30 minutes (Marks et al., 2008). 
 
As previously reported, phosphate absorption occured predominantly in 
the jejunum (Figs. 2.5 and 2.6); minimal phosphate transport was seen in 
the ileum, which was not Na+-dependent. In the jejunum, Na+-dependent 
transport accounted for 84% of total transport measured in vitro (Fig. 2.5) 
and 67% in vivo (Fig. 2.6). In the duodenum, 61% of transport in vitro was 
Na+-dependent, but surprisingly Na+-dependent phosphate transport was 
not evident when measured in vivo. This is the first in vivo observation of 
Na+-dependency of intestinal phosphate absorption. Under Na+-free 
conditions in vivo, there is a possibility of back-leak of Na+ into the lumen, 
therefore driving Na+-dependent phosphate transport under ‘nominally’ 
Na+-free conditions. For this reason, in Chapter 3 the Na+ concentration 
in the lumen under Na+-free conditions following the 30 minute instillation 
period was measured.  
 
2.3.2. Inhibiton of phosphate transport by PFA  
PFA is an established competitive inhibitor of NaPi-IIb-mediated 
transport. Na+-dependent phosphate transport in the jejunum was 84% of 
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total transport and 10 mM PFA inhibited 66% of the total transport in vitro 
(Fig. 2.7), in broad agreement with that previously reported (Loghman-
Adham et al., 1987). This means that the remaining 18% of Na+-
dependent transport was PFA-insensitive.  
 
 
Figure 2.5. Transport of 0.1 mM 32P measured in vitro using duodenal, 
jejunal and ileal regions of small intestine. Na+-dependent (shaded bars) 
and –independent (open bars) transport was measured. Data are means 
± SEM. ***P <0.005 compared with absorption in the same region in the 
presence of sodium using unpaired t-test. n = 6-9.  
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Figure 2.6. Transepithelial phosphate absorption measured in vivo by the 
A: plasma appearance of 32P and B: mucosal retention of 32P following 30 
min instillation of buffer containing 0.1 mM 32P into cannulated loops of 
duodenum, jejunum and ileum. Na+-dependent (shaded bars) and Na+-
independent (open bars) transport were measured. Data are means ± 
SEM. ***P <0.005 compared with absorption in the same region in the 
presence of sodium using unpaired t-test. n = 6-9.  
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Figure 2.7. Inhibition of Na+-dependent phosphate uptake by PFA, 
measured in vitro using uptake buffers containing 0.1 mM 32P. Na+-
dependent (shaded bars) and Na+-independent (open bars) transport 
were measured in the jejunum. Phosphate uptake was also measured in 
the presence of 1 and 10 mM PFA (hatched bars), which was added to 
the pre-incubation and incubation buffers. Data are means ± SEM. ***P 
<0.005 compared with absorption in the absence of PFA and ###P <0.005 
compared with absorption in the absence of sodium using unpaired t-test. 
n = 6-9.  
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Using the in situ loop technique, 67% of the total transepithelial 
phosphate absorption in the jejunum was Na+-dependent and 1 and 10 
mM PFA completely inhibited this component (Fig. 2.8). There was no 
PFA-insensitive component of phosphate uptake evident in vivo. Past 
studies have generally used 10 mM PFA to inhibit NaPi-II mediated 
transport (Eto et al., 2006; Loghman-Adham et al., 1987). The apparent 
Ki for PFA, established from jejunal BBM vesicles, is 1.3 mM (Loghman-
Adham et al., 1987). In the study of Loghman-Adham et al (1987), 
although there was a progressive decrease in Na+-dependent transport, 
maximal reduction in intestinal Na+-dependent phosphate transport was 
achieved using 10 mM PFA. Similarly, a recent study used increasing 
concentrations of PFA to inhibit Na+-dependent phosphate transport in 
renal BBM vesicles, again measured using 0.1 mM phosphate (Picard et 
al., 2010). They demonstrated the EC50 for PFA to be in the low millimolar 
range (~3 mM). However, the present study results show that 1 mM PFA 
caused the same percentage of inhibition as 10 mM PFA both in vitro and 
in vivo.  
 
2.3.3. Response to chronic low phosphate diet  
A low phosphate diet increases Na+-dependent phosphate absorption 
across the small intestine via increased NaPi-IIb protein expression (Giral 
et al., 2009; Hattenhauer et al., 1999). To assess whether the everted 
sleeve technique was suitable for evaluating the adaptation of intestinal 
phosphate uptake, experiments were carried out using 0.1 mM 
phosphate in the uptake buffer with or without sodium, using intestine 
from rats fed a normal or low phosphate diet for 7 days. A low phosphate 
diet upregulated Na+-dependent phosphate transport in the duodenum 
and jejunum (Fig. 2.9). Na+-dependent phosphate transport adaptations 
were proportionally greater in the jejunum than duodenum. Interestingly, 
a low phosphate diet also promoted Na+-independent phosphate 
transport in the duodenum and jejunum by 2 and 3-fold, respectively. 
Plasma phosphate levels, measured from blood collected from rats fed a 
normal or chronic low phosphate diet, were similar in the two groups 
(Table 2.3).  
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Figure 2.8. Inhibition of Na+-dependent phosphate absorption by PFA, 
measured in vivo using instillation buffer containing 0.1 mM 32P. Na+-
dependent (shaded bars) and Na+-independent (open bars) absorption 
were measured in the jejunum. A: plasma appearance of 32P and B: 
mucosal retention of 32P were determined following 30 min instillation 
period. Phosphate absorption was also measured in the presence of 1 
and 10 mM PFA (hatched), which was added to the instillation buffers. 
Data are means ± SEM. ***P <0.005 compared with absorption in the 
presence of Na+ and PFA using unpaired t-test. n = 6.  
 
A 
 
 
 
 
 
 
B 
Mucosal retention of 32P
0
2
4
6
8
10
12
+ Na  + 1 mM PFA  + 10 mM PFA - Na
nm
ol
es
 / 
10
0m
g 
m
uc
os
a
*** ***
 10
0 
F
ig
ur
e 
2.
9.
  
In
 v
itr
o 
ph
os
ph
at
e 
up
ta
ke
 b
y 
du
od
en
um
 a
nd
 je
ju
nu
m
 u
si
ng
 b
uf
fe
r 
co
nt
ai
ni
ng
 0
.1
 m
M
 3
2 P
 w
ith
 (
+)
 o
r 
w
ith
ou
t 
(-
) 
so
di
um
. 
 T
is
su
e 
w
as
 t
ak
en
 f
ro
m
 r
at
s 
m
ai
nt
ai
ne
d 
on
 a
 n
or
m
al
 (
op
en
 b
ar
s)
 o
r 
lo
w
 p
ho
sp
ha
te
 d
ie
t 
(s
ha
de
d 
ba
rs
) 
fo
r 
7 
da
ys
. 
R
es
ul
ts
 a
re
 m
ea
n 
± 
S
E
M
. 
**
*P
 <
0.
00
5 
co
m
pa
re
d 
w
ith
 n
or
m
al
 d
ie
t 
an
d 
##
# P
 <
0.
00
5 
co
m
pa
re
d 
w
ith
 u
pt
ak
e 
in
 t
he
 p
re
se
nc
e 
of
 
so
di
um
 u
nd
er
 lo
w
 p
ho
sp
ha
te
 d
ie
t. 
n 
= 
6.
 
  
 101 
 
 
Table 2.3. Plasma phosphate levels in animals fed a normal or low 
phosphate diet for 7 days. Results are mean ± SEM. n = 5-6. 
 Plasma phosphate (mM) 
Normal diet   1.09 ± 1.33 
Low phosphate diet   0.98 ± 1.39 
 
Therefore, changes in intestinal phosphate handling in rats fed a chronic 
low phosphate diet were independent of plasma phosphate levels. Body 
weight was also similar in both group of animals (normal 255 ± 15 g and 
low phosphate diet 260 ± 18 g). 
 
2.3.4. Response to aging 
Na+-dependent phosphate transport and NaPi-IIb expression dramatically 
decreases with age (Xu et al., 2002a; Kirchner et al., 2008; Arima et al., 
2002), whereas the Na+-independent component has been reported to 
increase (Debiec & Lorenc, 1985), or remain unchanged (Armbrecht et 
al., 1980). The everted sleeve technique was further assessed for its 
suitability in detecting age-dependent adaptation of phosphate transport.  
Animals of three age groups were used for the study: 3-week (suckling), 
8-week, and 16-week old rats. Na+-dependent phosphate transport in 
duodenum and jejunum were maximal during suckling (Fig. 2.10A and 
2.10B), which is consistent with a previous observation of Kirchner et al 
(2008), in which they reported Na+-dependent phosphate transport in 
weaning rats with a Kt of 2 mM. Na+-dependent phosphate transport in 
both duodenum and jejunum declined significantly during development to 
the adult stage, but once animals reached adulthood, no further decline 
was apparent. In contrast, ileal transport was minimal and transport rates 
were similar in all three age groups (Fig. 2.10C), demonstrating that this 
region is not regulated by age. There was no Na+-dependent component 
in the ileum (P=0.6 at 3 weeks, P=0.3 at 8 weeks and P=0.9 at 16 
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weeks). In addition, age had no significant effect on Na+-independent 
phosphate transport in any of the three intestinal regions.   
 
Figure 2.10. Na+-dependent (+) and Na+-independent (-) phosphate 
uptake across A: duodenum, B: jejunum and C: ileum of young (3 week), 
adult (8 week) and aged (16 week) rats. Experiments were carried out in 
vitro using 0.1 mM 32P in the uptake buffer. Results are mean ± SEM.  
**P <0.01 and ***P <0.005 compared with Na+-dependent absorption in 
weaned animals, using unpaired t-test. n = 6. 
 A 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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2.3.5. Detection of NaPi-IIb protein 
BBM vesicles represent microvillus membrane prepared free of 
subcellular contaminants and fibrillar material (Forstner et al., 1968). 
Intestinal BBM vesicles were prepared for the detection of NaPi-IIb, since 
the protein is known to be expressed at the apical membrane (Giral et al., 
2009). BBM preparations need to be of high purity; alkaline phosphatase 
(a brush-border marker enzyme) assay was performed to monitor purity. 
The enrichment values for this enzyme in intestinal BBM preparations 
were 10 to 18-fold. 
 
A number of different rat antibodies were tested for the detection of NaPi-
IIb protein. Both antibodies from Acologix (Fig. 2.11A) were specifically 
designed against rat NaPi-IIb sequences, whereas all other antibodies 
were specific for mouse or human NaPi-IIb sequences and were highly 
homologous to rat, except for 1 or 2 differences in some residues (Table 
2.2). Three types of tissues were tested: adult lung membrane, since 
lungs highly express NaPi-IIb compared with other organs (Traebert et 
al., 1999), and small intestine from young (Fig. 2.11B) and adult rats. 
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Young animals express the highest level of age-dependent NaPi-IIb 
protein in the small intestine (Xu et al., 2002a). The only available 
commercial NaPi-IIb antibody reported to work in rats was obtained from 
US Biological. The remainder of the antibodies were gifts from institutes 
or organisations (Table 2.1) that have been successfully used to detect 
NaPi-IIb protein in mice. 
 
Denaturing is a common approach used for western blot detection of 
proteins. The extent of denaturing conditions used can, in some cases, 
improve the detection of the protein of interest.  The different denaturing 
conditions that protein samples were subjected to prior to electrophoresis 
are: 5% SDS, 5% SDS and heating at 95°C (2 minutes), 5% 
Mercaptoethanol with 5% SDS or 5% Mercaptoethanol with 5% SDS and 
heating at 95°C (2 minutes). The latter method is the severest denaturing 
condition imposed on the native NaPi-IIb protein. Furthermore, BBM 
vesicles that have been stored for months at low temperatures and that 
have undergone repeated freeze-thawing cycles are likely to be 
degraded. Therefore, fresh BBM vesicles prepared on the day were also 
used for comparison with those stored at -200C (Fig. 2.11C). However, 
clear bands using both western blotting (Fig. 2.11) and dot blot 
techniques (data not shown) were undetectable with all of the above 
tissues, antibodies and conditions used. 
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75 
Figure 2.11. Western Blotting analysis of NaPi-IIb protein in membrane 
vesicles prepared from lungs and specific regions of the rat small 
intestine. A: Detection of NaPi-IIb protein in BBM vesicles prepared from 
intestinal mucosa of adult jejunum using two dilutions of the antibody 
from Acologix. Samples were heated in SDS and Mercaptoethanol prior 
to loading. B:  Detection of NaPi-IIb protein in lung (L) membrane 
vesicles, duodenal (3wd) and jejunal (3wj) BBM vesicles from 3 week old 
sucklings, using 1:1000 dilution of primary antibody obtained from US 
Biological. Samples were heated in SDS prior to loading. C: Detection of 
NaPi-IIb in jejunal (J), duodenal (D) and ileal (I) BBM vesicles prepared 
and stored at -200C for approximately a month (1) and in BBM vesicles 
freshly prepared on the day (2) using 1:2000 dilution factor of antibody 
supplied by J Biber (University of Zurich) directed against the C terminus. 
β-actin protein was used as loading control. Samples were loaded with 
SDS. 
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2.4. Discussion 
 
Hyperphosphataemia is a severe disturbance in phosphate balance, most 
commonly caused by chronic renal failure. In this disease setting, 
expression levels of NaPi-IIa in the kidney are significantly decreased, 
both at mRNA and protein level (Elhalel et al., 2004; Marks et al., 2007), 
and although a low phosphate diet is commonly used to reduce plasma 
phosphate levels, this approach to treating the disease is limited by the 
progressive loss in renal function. In contrast, intestinal phosphate 
absorption and NaPi-IIb  expression have been shown to be unaffected in 
chronic renal failure (Marks et al., 2007; Douard et al., 2010), making the 
small intestine a promising target for the treatment of 
hyperphosphataemia. However, the mechanisms involved in phosphate 
absorption are still not well understood, partly due to species differences 
and the limitations of the techniques used for assessing uptake. To date, 
information on the regulation of phosphate transport has employed 
mainly in vitro techniques to study changes in Na+-dependent phosphate 
transport. In vivo studies are needed to confirm that regulatory changes 
at the BBM correspond to overall changes in transepithelial phosphate 
absorption.  The aim of this study was to characterise further the relative 
contribution of Na+-dependent and Na+-independent phosphate transport 
in different regions of the rat small intestine using both in vitro and in vivo 
approaches. The results reveal that, in keeping with previous reports, the 
majority of phosphate transport occurs in the jejunum, both in vitro and in 
vivo, and compared with other regions of the small intestine the jejunum 
exhibits by far the greatest adaptation to a chronic low phosphate diet 
and to aging.   
 
Studies using intestinal BBM vesicles revealed a phosphate transport 
system critically dependent on sodium, with a Kt for phosphate of around 
0.1 mM (Danisi et al., 1980; Lee et al., 1986b; Loghman-Adham et al., 
1987; Harrison HE & Harrison HC, 1963). Therefore, most studies to date 
have used phosphate concentrations of around 0.1 mM to investigate 
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features of the transport process.  The present study also used this 
phosphate concentration in uptake buffer, so that the results can be 
compared with previous work. This has enabled conclusions to be made 
on the suitability of the in vitro everted sleeve and in vivo in situ closed 
loop technique for uptake studies. 
 
Phosphate absorption in rats occurs in the proximal small intestine, the 
duodenum and jejunum, as also observed in man (Walton & Gray, 1979; 
Marks et al., 2006; Davis et al., 1983). Data presented in this chapter 
show that both in vitro and in vivo the duodenum absorbs significant 
levels of phosphate, although maximal phosphate absorption does not 
occur in this region of the small intestine, in contrast to the in vivo 
observation by Marks et al (2006). The in vitro technique used in this 
chapter shows that duodenal phosphate transport is a combination of 
Na+-dependent and Na+-independent pathways, as established 
previously (Debiec & Lorenc, 1985; Giral et al., 2009; Loghman-Adham et 
al., 1987). Conversely, the in vivo technique illustrates that duodenal 
transepithelial phosphate absorption is completely Na+-independent.  The 
reason for this discrepancy is not clear. Unstirred water layer effects 
and/or sodium ion secretion in the duodenum may have influenced Na+-
dependent transport under nominally Na+-free conditions (Dugas et al., 
1975).  Previous results have consistently reported that the rat ileum has 
little or no capacity to absorb phosphate (Marks et al., 2006; Peters & 
Binswanger, 1988). In agreement, data presented in this chapter show 
minimal ileal phosphate transport, which importantly is not Na+-
dependent. In contrast, the jejunum is responsible for maximal phosphate 
absorption, which is Na+-dependent, as established previously in BBM 
vesicle systems (Loghman-Adham et al., 1987). This correlates with the 
detection of the highest level of NaPi-IIb mRNA in the jejunum (Giral 
2009). Thus, both in vitro and in vivo techniques give very similar results 
for phosphate uptake, except in the case of the duodenum.  
 
PFA is a competitive and specific inhibitor of NaPi-IIb-mediated 
phosphate transport (Bai et al., 2000; Loghman-Adham et al., 1987 & 
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1993; Ravera et al., 2007). This study used PFA to dissect the 
contribution of NaPi-IIb and PiT transporters, as some claim that the latter 
proteins are insensitive to PFA (Collins et al., 2004; Ravera et al., 2007; 
Villa-Bellosta & Sorribas, 2009b). 
 
A potential role of PiT transporters in phosphate handling by the small 
intestine has only just started to emerge. Expression of PiT1 mRNA in the 
small intestine and PiT1 protein at the intestinal BBM have been reported 
in rats (Giral et al., 2009). In contrast, expression of PiT2 mRNA is 
minimal along the rat small intestine (Giral et al., 2009), but a regional 
profile remains to be established.  The Kt for both PiT1 and PiT2 has 
been estimated to be between 25-89 µM (Bai et al., 2000; Kavanaugh et 
al., 1994; Tatsumi et al., 1998), but a functional role for these proteins in 
intestinal phosphate absorption has not been confirmed. The in vitro and 
in vivo experiments of the present study were designed to test two 
concentrations of PFA, 1 and 10 mM, that have been used in past work to 
inhibit Na+-dependent phosphate transport using 0.1 mM luminal 
phosphate in uptake buffer (Szczepanska-Konkel et al., 1986; Shillingford 
et al., 1996; Picard et al., 2010; Loghman-Adham et al., 1987; Loghman-
Adham et al., 1992). Data presented in the present study show that 1 and 
10 mM PFA reduced NaPi-IIb-mediated transport by the same amount in 
vitro and in vivo. This finding is in contrast to the progressive decline in 
Na+-dependent phosphate cotransport observed by Loghman-Adham et 
al (1987) using jejunal BBM vesicles. Past studies using PFA have 
consistently reported that 20-30% of total transport under in vitro 
condition is not inhibitable by PFA, regardless of the PFA concentration 
used (Szczepanska-Konkel et al., 1987; Picard et al., 2010; Loghman-
Adham et al., 1987). In agreement, the residual PFA-insensitive Na+-
dependent phosphate transport apparent in vitro in the present study was 
approximately 18%, which may represent PiT-mediated phosphate 
transport. However, in contrast, PFA completely inhibits the Na+-
dependent component of phosphate absorption measured in vivo. Thus, 
under in vivo conditions 1-10 mM PFA may completely inhibit NaPi-IIb-
mediated transport.  
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The effects of age and dietary phosphate restriction on phosphate 
absorption in different regions of the rat small intestine were studied to 
confirm the suitability of the everted sleeve technique for assessing 
changes in phosphate transport. Previous studies indicate that in man 
and rats, phosphate absorption occurs maximally in the jejunum and that 
regulation of intestinal phosphate absorption by 1,25-dihydroxyvitamin 
D3, MEPE and chronic dietary phosphate manipulation occurs exclusively 
in this region (Davis et al., 1983; Giral et al, 2009; Jungbluth & 
Binswanger 1989;  Marks et al., 2006, 2007 & 2008; Walling, 1977). Data 
presented in this chapter, using the everted sleeve technique, confirm 
and extend these previous findings. In keeping with previous reports, the 
highest rate of Na+-dependent phosphate absorption was seen in the 
jejunum, and adaptations to chronic dietary manipulation occur maximally 
in this region. It should also be noted that the slower transit time of 
contents in the jejunum compared with duodenum (Kayne et al., 1993) 
would accentuate this regional specificity.  Low phosphate diet stimulates 
Na+-dependent phosphate transport by increasing the recruitment of Na+-
dependent phosphate transporters at the BBM (Katai et al., 1999; 
Loghman-Adham et al., 1993). Thus, low phosphate diet increases the 
Vmax without affecting the Kt of Na+-dependent phosphate transporters 
involved (Kempson & Dousa, 1979;  Cheng et al., 1983; Katai et al., 
1999). Giral et al (2009) showed, using BBM vesicles, the duodenum to 
be capable of adaptation to acute, but not chronic, dietary phosphate 
manipulation. However, experiments reported in the present study 
detected adaptation in the duodenum in animals chronically fed a low 
phosphate diet. Plasma phosphate concentration in these animals was 
not different from those fed a normal phosphate diet, demonstrating that 
adaptation of the small intestine to dietary phosphate restriction is 
independent of changes in plasma phosphate levels, as established 
previously (Capuano et al., 2005; Katai et al., 1999; Loghman-Adham et 
al., 1993). 
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Past studies have demonstrated that the Na+-dependent phosphate 
transport system in the small intestine has similar characteristics, but is 
also distinct from, the cotransporter system in renal proximal tubules. 
Phosphate uptake in BBM vesicles independent of Na+ is much greater in 
the small intestine compared with that in the kidney (Loghman-Adham et 
al., 1987). Using BBM vesicles and other in vitro approaches, the Na+-
independent component of intestinal phosphate transport was until now 
thought to be unregulated (Douard et al., 2010; Fuchs & Peterlik, 1980; 
Katai et al., 1999; Lee et al., 1986b;  Walling, 1977). Interestingly, the in 
vitro approach used in our studies revealed that dietary phosphate 
deprivation increased the Na+-independent component of phosphate 
absorption. The precise identity of this component, which is usually 
designated in the literature as ‘paracellular’, is uncharacterised, partly 
due to the relatively minor role it plays in contributing towards phosphate 
absorption at low (0.1 mM) phosphate concentration (Berner et al., 1976; 
Loghman-Adham et al., 1987; Sabbagh et al., 2009).  It is therefore 
important to evaluate this component in detail. 
 
BBM vesicle studies have established that Na+-dependent phosphate 
transport is greatest in the small intestine of young animals and 
progressively declines during the development process (Xu et al., 2002a; 
Arima et al., 2002). This might reflect growth-related requirements for 
phosphate. Uptake data is paralleled in the increased expression of NaPi-
IIb (Arima et al., 2002; Kirchner et al., 2008; Xu et al., 2002a). Using BBM 
vesicles from rats of age 3, 4 and 7 weeks, Debiec & Lorenc (1985) 
demonstrated that Na+-dependent phosphate absorption predominated in 
younger rats, and as the animals got older the Na+-dependent component 
decreased in importance, whilst the Na+-independent component became 
more dominant. They observed in adult rats phosphate absorption was 
mediated solely via a process that was attributed to diffusion. In contrast, 
data presented in this chapter show that active Na+-dependent phosphate 
transport predominates at all age groups, from young to older rats, 
although Na+-dependent phosphate transport declined with age. Unlike 
the study of Debeic & Lorenc (1985), present results were derived from 
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intact tissue. Furthermore, in the present study aging did not influence the 
Na+-independent component, in keeping with the previous finding that the 
contribution of Na+-independent transport to overall intestinal phosphate 
absorption in young animals is low (Arima et al., 2002; Kirchner et al., 
2008). Importantly, data also show that although Na+-dependent 
phosphate transport was significantly higher in the duodenum and 
jejunum of younger rats, absorption does not decline further once the 
animals reach adulthood.  
 
The ileum is generally considered to play only a minor role in phosphate 
absorption in rats (Marks et al., 2006). Debiec & Lorenc (1985) claimed 
that ileal BBM vesicles do absorb phosphate and that the process is age-
regulated; uptake is predominantly Na+-dependent in younger rats, whilst 
in adults the rate of ileal phosphate transport is much lower and mediated 
by diffusion. Data presented in this chapter failed to find significant Na+-
dependent phosphate transport in the ileum of any of the age groups 
analysed. This contradictory finding to that of Debiec & Lorenc (1985) 
further highlights the limitations of the BBM vesicle uptake method that 
has been used almost exclusively to study phosphate transport.  
 
The transport data obtained using the everted sleeve technique in the 
present study accurately reflects past findings concerning the effects of 
dietary phosphate restriction and age on phosphate absorption across 
the small intestine, and extends that knowledge. The technique is a more 
suitable method for the study of phosphate transport since experimental 
conditions can be more easily manipulated, in contrast to the in vivo 
technique, where ion secretion and unstirred water layer effects may 
pose problems for the interpretation of uptake data (Dugas et al., 1975). 
However, in vivo studies are needed to obtain a picture of phosphate 
transport across epithelium under both physiological and pathological 
situations.  Also, since the blood supply is intact, the effect of circulating 
influences on phosphate uptake can be assessed.  
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Tha paracellular pathway may be responsible for Na+-independent 
phosphate absorption detected in the small intestine in vivo. The 
paracellular pathway consists of tight-junctions, which are paracellular 
‘pores’ that allow passage of certain molecules based on charge and 
size. The replacement of sodium with choline, under Na+-free conditions 
in the experiments presented in this thesis, would have changed the 
transepithelial electrical potential difference across the epithelium due to 
a positive serosal-to-mucosal Na+ gradient. As Na+ moves from serosa-
to-mucosa, the serosa becomes increasingly more negative and 
therefore there is less likelihood for paracellular movement of the 
negatively charged phosphate ion in the mucosal-to-serosal direction. 
Thus, the reduction in phosphate transport seen under Na+-free 
conditions may be a combination of both transcellular (because of 
reduced NaPi-IIb-mediated transport) and paracellular (because of 
change in epithelial polarity) transport of phosphate. The influence of 
transepithelial potential difference on the movement of ions has been 
observed in man (Gustke et al., 1981). 
 
A number of tight junction proteins are responsible for controlling the 
function of the tight epithelia, including claudin-1, claudin-3, claudin-4, 
claudin-5 and claudin-8 (Furuse et al., 2002; Van Itallie et al., 2001; 
Amasheh et al., 2005 & 2009). In addition, there are other members of 
the claudin family, such as claudin-2 and claudin-12, which form a 
paracellular channel and thus mediate paracellular transport of certain 
ions and molecules (Amasheh et al., 2002). Expression of claudins varies 
between species (Rahner et al., 2001). Claudin-2, claudin-7 and claudin-
12 mediate paracellular permeability (Amasheh et al., 2002; Fujita et al., 
2006). The rat colon strongly expresses claudin-1, claudin-3, claudin-4, 
claudin-5 and claudin-8, whereas ileum has a high expression of claudin-
2, claudin-7 and claudin-12, which control paracellular cation permeability 
(Markov et al., 2010). The jejunum expresses claudin-5 and claudin-12, 
permitting paracellular cation permeability, whereas duodenum highly 
express claudins associated with “tightening “of the junctions; claudin-1, 
claudin-3 claudin-4 and claudin-8. Thus, it is not surprising that the 
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duodenum has a high epithelial resistance compared with other regions 
of the small intestine. Expression of claudin-2, a paracellular channel that 
is highly cation-selective, increases distally along the small intestine   
(Amasheh et al., 2002; Markov et al., 2010). The cation-selective  
claudin-2 and claudin-12 act as paracellular Ca2+ channels in the small 
intestine and their expression is regulated by 1,25-dihydroxyvitamin D3 
(Fujita et al., 2008).  No anion-selective claudins have yet been analysed 
to see if they are capable of transporting the phosphate ion. 
 
It is important to establish that changes in gene expression and transport 
activity are supported by protein levels of corresponding transporters. 
Although there are several commercial antibodies available to detect 
NaPi-IIb expression in mice, none are available in rats. A number of 
potentially suitable NaPi-IIb antibodies were tested in rat BBM. 
Membrane vesicles were prepared from lungs, since this tissue is known 
to more highly express NaPi-IIb at the apical membrane than the small 
intestine (Feild et al., 1999; Hashimoto et al., 2000). Intestinal BBM 
vesicles from young animals were also used, since they have been 
reported to express a higher level of NaPi-IIb than adult rats. However, 
irrespective of the type of tissue used, none of the antibodies tested were 
effective at detecting NaPi-IIb protein in BBM vesicles using western 
blotting and dot blot techniques. Although some of these antibodies are 
known to successfully detect NaPi-IIb in mice (Antibody no 1 and 2 from 
Table 2.1) and man (Antibody no 3 from Table 2.1), they were unable to 
detect the same protein in rat BBM. The reasons behind this failure are 
unclear at the present time.  
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2.5. Conclusion 
 
The data obtained indicate that the everted sleeve technique is suitable 
for the study of phosphate transport across the BBM of intact intestine. 
The in situ closed loop technique is also sensitive enough to detect and 
distinguish between Na+-dependent and Na+-independent phosphate 
transport in vivo. The disparity in the overall contribution of Na+-
dependent transport with these in vitro and in vivo techniques highlight 
the necessity to use both approaches to study intestinal phosphate 
transport, and may also explain the discrepancies in the literature 
regarding the mechanisms of phosphate transport.  Results presented 
suggest that the everted sleeve technique is comparable to using BBM 
vesicles, in as much as Na+-dependent transport is readily measurable 
and quantifiable. Additional studies are needed to gain insight into the 
mechanisms and regulation of the Na+-independent component in the 
duodenum and jejunum that is upregulated by a chronic low phosphate 
diet. This may help develop novel therapeutic agents that could be used 
to target the different components of the overall transport process to 
control hyperphosphataemia.  
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3.0. Variations in Na+-dependent and Na+-
independent phosphate transport along the small 
intestine and colon. 
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3.1. Introduction 
 
Data presented in Chapter 2 showed that intestinal phosphate absorption 
involves both Na+-dependent and Na+-independent components and the 
latter may involve paracellular transport. Previous conflicting views on the 
mechanisms involved in phosphate transport are likely to reflect the 
variety of experimental techniques used for assessing uptake, as well as 
widely differing phosphate concentrations present in uptake buffers. 
Indeed, there is very little information concerning the normal postprandial 
phosphate level in the intestinal lumen. 
 
Although in vitro studies using BBM vesicles clearly demonstrated a 
saturable Na+-dependent process with a Kt of 0.1 mM, in vivo studies 
using very high luminal phosphate concentrations (up to 100 mM) 
revealed a linear relationship between phosphate concentration and its 
absorption, with no evidence for a saturable process (Aloia & Yeh, 1985; 
Davis et al., 1983; McHardy, 1956; Williams & DeLuca, 2007; Walton & 
Gray 1979). These and related studies concluded that paracellular 
transport was the dominant absorption pathway at phosphate 
concentrations in the high millimolar range. However, recent studies 
using NaPi-IIb knockout mice have reported that NaPi-IIb-mediated 
transport in the ileum, the region responsible for majority of intestinal 
phosphate transport in mice, accounts for 90% of total absorption 
(Sabbagh et al., 2009).  Interestingly, in rats oral administration of 
phosphonoformic acid (PFA), a competitive inhibitor of NaPi-IIb, had no 
effect on BBM phosphate transport using rats maintained on a normal 
phosphate diet, but it blunted the increased Na+-dependent phosphate 
transport induced by a low phosphate diet (Loghman-Adham et al., 
1993). Taken together, these studies raise the question of the identity of 
the transport pathway responsible for the non-NaPi-IIb component of 
phosphate absorption in rats. 
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The colon has hitherto not been considered to play a major role in 
phosphate absorption; however, paracellular phosphate transport has 
been reported in the distal colon (Lee et al., 1980; Hu et al., 1997). Hu et 
al (1997) demonstrated permeation of phosphate through the 
paracellular, mannitol permeable pathway using the in vitro Ussing 
technique. More recently, NaPi-IIb, PiT1 and PiT2 mRNA have been 
detected in rat distal colon, with expression levels regulated by dietary 
phosphate content (Capuano et al., 2009).  Interestingly, 1,25-
dihydroxyvitamin D3 stimulates active calcium absorption in the proximal 
colon of vitamin D-replete rats in vitro (Lee et al., 1980), implying the 
presence of the vitamin D receptor in colonocytes. The fact that in man 
high phosphate-containing enemas can induce hyperphosphataemia 
(Carl & Mitchell, 2007; Hu et al., 1997; Hunter et al., 1993) also indicates 
the existence of an absorptive route for rapid translocation of phosphate 
across the colonic mucosa. 
 
The aim of the present study was to address some of the discrepancies 
emerging from previous studies of intestinal phosphate absorption. Since 
very little is known about the postprandial concentration of phosphate in 
the intestinal lumen, unbound phosphate levels were measured in luminal 
contents collected from specific intestinal regions of rats maintained on a 
normal phosphate diet.  Based on these values, in vitro and in vivo 
methods were then used to determine the contribution of Na+-dependent 
and Na+-independent phosphate absorption in defined regions of rat 
small intestine. The contributions of the colon to phosphate uptake and 
the pathways involved have also been investigated. 
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3.2. Materials and Methods  
 
3.2.1. Animal models 
Male Sprague Dawley (SD) rats aged 3 weeks, 8 weeks and 16 weeks 
were obtained from Charles River Laboratories (UK) and used in 
accordance with the Animals (Scientific Procedures) Act 1986. Control 
rats were allowed ad libitum access to a standard rodent chow, 
containing 0.52% phosphate (Diet RM1, SDS Ltd, Witham, Essex, UK), 
and water. 
 
3.2.2. Phosphate uptake 
 
3.2.2.1. In vitro phosphate uptake using everted intestinal sleeves 
The protocol differed from that described in Chapter 2, section 2.2.2.1 in 
that the incubation buffer contained 0.1-10 mM phosphate. For each rat, 
adjacent sleeves of the particular segment of small or large intestine were 
used for measuring uptake in the presence or absence of Na+ at each 
luminal phosphate concentration. 1, 10 or 20 mM PFA in uptake buffer 
was used to inhibit NaPi-IIb mediated transport. 
 
3.2.2.2. In vivo transepithelial phosphate absorption 
The protocol differed in that described in Chapter 2, section 2.2.2.2 only 
in that the instillation buffer contained phosphate in the concentration 
range 0.1-5 mM. 1, 10 or 20 mM PFA in uptake buffer was used to inhibit 
NaPi-IIb-mediated absorption. 
 
3.2.3. Measurement of intestinal passive permeability 
Experiments were repeated as described in Chapter 2.2.2.1 and 2.2.2.2 
except that Na+ in the uptake buffer was substituted with choline chloride 
(ChCl) to determine Na+-independent phosphate uptake. In other 
experiments, buffer contained trace amounts of tritiated (3H) mannitol 
(0.74 MBq/1 ml buffer) and 2 mM KH2PO4 and 1 mM mannitol. The wash 
solution contained, in mM: 20 mannitol, 40 KH2PO4 and 150 ChCl. 
Mannitol was used as a passive permeability marker due to its low 
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molecular weight, non-toxicity, hydrophilic and lipophobic properties 
(Ukabam & Cooper, 1984; Krugliak et al., 1994).  
 
3.2.4. Measurement of sodium concentration in mucosal fluid 
This was carried out to assess the extent of Na+ secretion into initially 
Na+-free buffer. Uptake solutions made Na+-free by isosmotic 
replacement of Na+ with ChCl and containing 2 mM phosphate were 
instilled into cannulated sections of jejunum, ileum and colon, as 
described elsewhere (Chapter 2, section 2.2.2.2) and Na+ concentration 
in the luminal solution after 30 min incubation was measured using 
CoroNa™ Green dye (Invitrogen). A calibration curve was obtained using 
known concentrations of sodium up to 25 mM, and ChCl-HEPES buffer 
was used as a blank. 0.25 µM of dye was added to 100 µl of standard 
and sample solutions, and fluorescence was read at 492 nm using a 
spectrofluorimeter (SFM 25, Kontron Instruments, UK). 
 
For in vitro measurement of the extent of Na+ secretion, Na+-free uptake 
buffer containing 2 mM phosphate was incubated with everted jejunum, 
ileum and colon, as described elsewhere (section 2.2.2.1) and Na+ 
concentration in the uptake buffer after 2 min incubation was measured 
using CoroNa™ Green dye. 
 
3.2.5. Osmolarity measurements 
Osmolarity of uptake solutions were determined using freezing point 
depression osmometry using a micro-osmometer (Model 3M0, Advanced 
Instruments Inc, Massachusetts, US). All solutions used for studies of 
phosphate uptake were isotonic, within the range 290-310 mOsM. 
 
3.2.6. Phosphate level in the intestinal lumen. 
Intestinal contents were squeezed out of defined regions of the 
gastrointestinal tract of unfasted adult rats maintained on normal chow. 
The contents were diluted 1:1 with distilled water and vortexed 
vigorously. Solid contents from ileum and colon were diluted 1:1 and 
homogenised for 10 sec (Ultra Turrax homogeniser, Janke & Kunkel, 
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FRG). Samples were centrifuged at 6,000 rpm for 6 min and an aliquot of 
the supernatant was used to determine free (unbound) phosphate 
concentration using a Quantichrom phosphate assay kit (BioAssay 
Systems, Hayward, CA, USA), according to the manufacturer’s 
instructions. 
 
3.2.7. Statistical analysis.  
Data are presented as means ± SEM. Unpaired t-test or a one-way 
ANOVA, as appropriate, was used and group differences were 
considered statistically significant if P <0.05; n, represents the number of 
samples per group. Post hoc analysis was carried out within groups by 
using the Bonferroni correction, 
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3.3. Results 
 
3.3.1. Luminal phosphate concentration along the small and large 
intestine 
Most studies of intestinal phosphate handling have used phosphate 
concentrations of 0.1 mM.  However, other work have used low millimolar 
or even molar phosphate concentrations, making it difficult to compare 
the findings of these disparate reports (Williams & DeLuca, 2007; 
Kirchner et al., 2008; Douard et al., 2010; Berndt et al., 2007). Therefore, 
studies in this chapter measured the free (unbound) phosphate 
concentration in luminal contents collected from defined regions of the 
gastrointestinal tract in rats maintained on a normal phosphate diet. 
Interestingly, phosphate levels in all regions studied were in the millimolar 
range (Table 3.1). At these concentrations, NaPi-IIb-mediated transport 
will be highly saturated, since the Kt for the phosphate uptake process 
measured in vitro has been reported to be around 0.1 mM (Hilfiker et al., 
1998; Werner et al., 1998). The mean value for phosphate concentration 
in small intestinal luminal fluid was 6.3 mM; higher levels were found in 
the stomach, caecum and distal colon; regions that have not previously 
been considered to partake in phosphate transport (Berndt et al., 2007; 
Cramer, 1961; Kayne et al., 1993).  
 
Table 3.1. Unbound phosphate concentration in luminal contents 
removed from specific regions of the small and large intestine. Animals 
were allowed food the night before and contents were removed at midday 
the following day. Values are means ± SEM. n = 6-8. 
Tissue Free phosphate concentration (mM) 
Stomach 14.84 ± 3.43  
Duodenum   7.04 ± 1.50 
Jejunum   5.69 ± 0.37  
Ileum   6.27 ± 0.86  
Cecum 12.82 ± 1.18 
Distal Colon 11.49 ± 0.62  
 123 
3.3.2. Concentration dependence of phosphate uptake in duodenum 
and jejunum in vitro  
Based on the above luminal phosphate concentrations, the aim of work 
presented in this chapter was to examine the effect of increasing 
phosphate levels from 0.1 mM to a maximum of 10 mM in the uptake 
buffer on the rate of Na+-dependent and Na+-independent transport in 
vitro. In contrast to the expected saturable curve at millimolar 
concentrations, phosphate uptake continued to rise linearly with 
increasing phosphate concentrations in both the duodenum (Fig. 3.1) and 
jejunum (Fig. 3.2). The jejunum maintained its position as the region with 
the maximal transport activity in vitro using millimolar phosphate 
concentrations. Thus, at 5 and 10 mM luminal phosphate level, total 
phosphate transport in the jejunum was double that observed in the 
duodenum (P <0.005).  
 
In both the duodenum and jejunum, uptake was mediated by Na+-
dependent and -independent mechanisms. In duodenum, transport was 
dominated by Na+-independent uptake at phosphate concentrations 
above 0.5 mM. The Na+-dependent component on the other hand 
remained constant, indicating complete saturation at millimolar phosphate 
concentrations, with a mean Kt of 197 µM. In contrast, the Na+-dependent 
component in the jejunum increased linearly with increasing luminal 
phosphate levels, implying the presence of a Na+-dependent transporter 
other than NaPi-IIb in this region. The non-saturability meant that it was 
not possible to determine the Kt of this component in the jejunum. In 
contrast to the duodenum, activity of the Na+-independent transport 
increased in a similar fashion to Na+-dependent transport at phosphate 
levels over 2 mM. Na+-dependent transport at higher phosphate levels of 
2 and 10 mM corresponded to 65% and 50% respectively, of total 
phosphate transport in the jejunum compared with 84% at 0.1 mM 
phosphate.   
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3.3.3. Concentration dependence of phosphate absorption across 
the duodenum and jejunum in vivo  
Data representing appearance of 32P in the blood (Fig 3.3A and 3.4A), 
and mucosal retention (Figs. 3.3B and 3.4B), the amount of 32P retained 
by enterocytes, were analysed in vivo following instillation of phosphate 
buffer into defined intestinal regions for 30 minutes. Similar to the results 
in vitro, in the duodenum and jejunum transepithelial phosphate 
absorption followed a linear pattern with increasing phosphate 
concentrations (Figs 3.3 and 3.4, respectively). However, duodenal 
phosphate absorption in vivo appeared to be mediated by only a Na+-
independent pathway at all phosphate concentrations used.  In the 
jejunum, although total and Na+-independent transport rose linearly with 
phosphate concentration, Na+-dependent transport did not show the 
linear increase observed in vitro: Na+-dependent transport accounted for 
67% of uptake at 0.1 mM, but only 34% and 0% at 2 and 10 mM luminal 
phosphate, respectively. The Na+-dependent component of phosphate 
transport fits Michaelis-Menten kinetics (Fig 3.4B) with a Vmax of 4.84 
nmoles per 100 mg mucosa and an apparent Kt of 245 µM.   
 
Contrary to in vitro observations, total phosphate transport in the jejunum 
was only moderately higher than that in duodenum at 0.5-2 mM luminal 
phosphate concentrations, and at luminal phosphate levels above 5 mM 
transepithelial phosphate absorption was similar in the duodenum. 
However, transit time in the jejunum is longer than the duodenum (Kayne 
et al., 1993), and it would, therefore, be expected that the jejunum 
efficiently transports more phosphate from the diet. Thus, at luminal 
phosphate concentrations above 0.5 mM (since there is some Na+-
dependent transport evident in vitro at phosphate concentrations below 
0.5 mM), in vitro and in vivo results agree that phosphate transport in the 
duodenum is Na+-independent. 
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Figure 3.3. Phosphate absorption across the duodenum in vivo. A: Blood 
appearance of phosphate and B: mucosal retention of phosphate; Na+-
dependent (shaded bars) and Na+–independent (open bars). Results are 
mean ± SEM. ***P <0.005 compared with absorption at 0.1 mM and 2 
mM phosphate using an unpaired t-test. n = 6. Note that where SEM bars 
are not visible, they fall within the height of the symbol. 
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Figure 3.4. Phosphate absorption across the jejunum measured in vivo. 
A: Blood appearance of phosphate, B: Na+-dependent component from 
transepithelial data fitted Michaelis-Menten kinetics and C: mucosal 
retention of phosphate, Results are mean ± SEM. **P <0.01 and *P <0.05 
compared with absorption in the presence of Na+ at the same phosphate 
concentration, and ###P <0.005 and #P <0.05 compared with absorption at 
0.1 mM and 2 mM, respectively using an unpaired t-test n = 6. Note that 
where SEM bars are not visible, they fall within the height of the symbol. 
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The Kt of phosphate transport in everted sleeves of weaning rats was 
reported to be 2 mM using a 2 minutes uptake period (Kirchner et al., 
2008). In the present study, total phosphate transport in vitro and in vivo 
(Figs 3.1 - 3.4) in adult rats could not be separated into saturable and 
nonsaturable components, since in vitro and in vivo phosphate transport 
remain linear at the maximum luminal phosphate concentration studied. 
The Kt measured in vitro is therefore likely to be much higher than that 
reported previously (of 0.1 mM). Due to the unstirred layers associated 
with everted sleeve preparations (Karasov & Diamond, 1983), this Kt is 
likely to be higher than seen using BBM vesicles but is probably closer to 
the true Kt measured in vivo. Present results show that at the maximal 5 
mM luminal phosphate level, transepithelial phosphate absorption does 
not reach saturation.  
 
3.3.4. Inhibition of phosphate transport in vitro by PFA  
PFA is a well established inhibitor of NaPi-IIb-mediated phosphate 
transport (Loghman-Adham et al., 1987, 1992 & 1993; Picard et al., 
2010). At 0.1 mM phosphate, Na+-dependent phosphate transport 
measured in vitro in the jejunum was almost completely inhibited by 1 
and 10 mM PFA (Table 3.2 and Fig. 3.5A). Although 67 and 65% of total 
transport was Na+-dependent at 1 and 2 mM phosphate respectively, 
Mucosal retention of 32P
0
20
40
60
80
100
120
140
0.1 1 2 5
Pi concentration (mM)
nm
ol
es
 / 
10
0m
g
Total
Na-independent
**
*
*
###
#
 130 
when 1, 10 or 20 mM PFA was included in the uptake buffer BBM 
transport was inhibited by only 33-37%, suggesting the remaining PFA-
insensitive Na+-dependent phosphate transport in the jejunum may be 
PiT-mediated. These studies failed to observe the progressive increase in 
inhibition of Na+-dependent transport with increasing PFA concentrations, 
as reported in earlier studies (Loghman-Adham et al., 1987; Picard et al., 
2010; Szczepanska-Konkel et al., 1986).  
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Figure 3.5. Summary of data from Table 3.2 and Table 3.3A. Percentage 
of total transport that is Na+-dependent and Na+-independent are 
indicated in vitro (A) and in vivo (B). Na+-dependent transport (calculated 
as total transport minus Na+-independent transport) was differentiated 
into PFA-sensitive and –insensitive components. Values represent 
average inhibition of Na+-dependent phosphate transport by 1-20 mM 
PFA using 0.1 and 2 mM phosphate.  Note that there is no Na+-
dependent transport in figure B, and Na+-independent transport was 
assumed as PFA-insensitive based on no effect seen at 2 mM phosphate 
concentration under Na+-free conditions with and without PFA.  
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To elucidate whether the Na+-independent phosphate transport is driven 
by secretion of Na+ into the nominally Na+-free buffer, the Na+ 
concentration in the post-incubation in vitro uptake buffer was measured. 
Na+ was undetectable in the buffer after 2 minutes incubation (data not 
shown) and the increasingly dominant Na+-independent uptake in this 
preparation was, therefore, not due to Na+ secretion during the 2 minutes 
incubation period. 
 
3.3.5. Inhibition of phosphate absorption in vivo by PFA 
At 0.1 mM, 67% of the total phosphate absorption in the jejunum was 
Na+-dependent and 1 and 10 mM PFA completely inhibited this 
component (Table 3.3 and Fig 3.5B). At 2 mM, Na+-dependent transport 
accounted for only 34% of total transport, with PFA again completely 
inhibiting this component. Under Na+-free conditions and with buffer 
containing 2 mM luminal phosphate, 10 mM PFA was added to analyse if 
PFA inhibited Na+-independent absorption in the jejunum. Results 
indicated no such inhibition (Control 1.24 ± 0.20 vs 10 mM PFA 0.93 ± 
0.15 nmoles per 1 ml plasma/5cm, P=0.15). To determine whether the 
higher proportion of Na+-independent transport seen in vivo when 
compared with in vitro was driven by Na+ entering the luminal uptake 
buffer from mucosal secretions, the Na+ concentration of the buffer was 
measured 30 minutes after instillation of Na+-free uptake buffer into 
jejunal segments in vivo.  Results indicate that Na+ levels were too low to 
support significant Na+-dependent phosphate across the jejunal BBM 
(mean value 11.9 + 2.8 mM, n=6; reported Km for Na+ ~40 mM (Murer et 
al., 2004; Virkki et al., 2006). Normal luminal Na+ concentration is 
typically about 140 mM; the concentration at which the Vmax is achieved 
with Na+-dependent phosphate transport (Berner et al., 1976; Lee et al., 
1986b). However, this experiment measured the bulk luminal Na+ 
concentration, thus Na+ concentration in fluid bathing the BBM could be 
significantly higher. Since 10 mM PFA was equally effective as 1 and 20 
mM PFA for inhibition of Na+-dependent phosphate transport in vitro and 
in vivo, 10 mM PFA was used in subsequent experiments; this 
concentration was also used in previous studies of phosphate transport. 
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3.3.6. Ileal phosphate absorption.  
Previous transport studies have shown very low values for phosphate 
transport, and undetectable gene and protein expression for NaPi-IIb in 
the rat ileum (Giral et al., 2009; Marks et al., 2006).  The present study 
confirms that, using 0.1 mM luminal phosphate, minimal ileal phosphate 
transport occured in vitro (Fig. 3.6) and in vivo (Fig. 3.7), with or without 
Na+ in the uptake buffer. However, at 2 mM phosphate, some Na+-
dependent phosphate transport was noted, although it corresponded to 
only about 35-45% of the total transport observed in the jejunum; at this 
phosphate concentration, in vitro and in vivo phosphate transport was 
inhibited by ~60% with the addition of 10 mM PFA in the Na+-containing 
uptake buffer. Transport at 0.1 mM phosphate was not reduced under 
Na+-free conditions (Na+-dependent vs Na+-independent transport is 
0.094 ± 0.011 vs 0.069 ± 0.022 in vitro and 0.014 ± 0.002 vs 0.016 ± 
0.003 in vivo), unlike at 2 mM phosphate, suggesting the presence of a 
Na+-dependent phosphate transporter at higher (millimolar) phosphate 
concentrations but not at lower (micromolar) concentrations, Analysis of 
Na+ levels in Na+-free uptake buffer following 2 minutes uptake in vitro 
revealed that no Na+ was present (data not shown), whereas low levels of 
Na+ were present in the in vivo buffer after 30 minutes ileal exposure 
(mean value 12.89 + 5.27 mM, n=6). Therefore, under both conditions 
Na+ secretion does not reach a level for significant Na+-dependent 
transport to occur under nominally Na+-free conditions. However, Na+ 
concentration in fluid immediately adjacent to the ileal BBM could be 
significantly higher than the bulk value of 12.89 mM Na+ measured in the 
ileal lumen. 
 
3.3.7. Phosphate absorption in the colon 
Experiments were carried out in vitro and in vivo in order to determine 
whether the colonic epithelium is capable of transporting phosphate. 
Regardless of the phosphate concentrations used, a low rate of 
phosphate uptake was noted in the proximal colon in vitro (Fig. 3.8) and 
in vivo (Fig. 3.10). At 0.1 mM phosphate concentration, transport was 
minimal in the proximal and distal colon (Figs. 3.8 and 3.9). However, at 
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higher phosphate concentration (2 mM), absorption was consistently 
greater in distal compared with proximal colon measured in vitro (Figs. 
3.8 and 3.9) and in vivo (Fig. 3.10). Using 2 mM phosphate, transport in 
the distal colon was Na+-independent and was approximately 4- and 6-
fold higher, measured in vitro (Fig. 3.9) and in vivo (Fig. 3.10, A) 
respectively, than in proximal colon. Transport in the distal colon was also 
insensitive to PFA (Fig. 3.11), further demonstrating that the uptake 
process is unlikely to be mediated by NaPi-IIb.  
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Figure 3.6. Ileal phosphate uptake measured in vitro using 0.1 mM and 2 
mM phosphate in the presence (shaded bars) and absence (open bars) 
of Na+. Significant inhibition by 10 mM PFA (hatched bar) indicates Na+-
dependent phosphate transport at 2 mM phosphate. Results are mean ± 
SEM. ###P <0.005 compared with Na+-dependent uptake at 0.1 mM 
phosphate. **P <0.01 compared with uptake in the presence of Na+ and 
$P <0.05 compared with phosphate uptake in the absence of PFA at 2 
mM phosphate using one-way analysis of variance with post hoc 
comparisons performed using the Bonferroni multiple comparisons test. n 
= 6. 
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Figure 3.7. A: Transepithelial absorption and B: Mucosal retention of 
phosphate in the ileum, measured in vivo using 0.1 mM and 2 mM 
phosphate in uptake buffer. Experiments were carried out in the presence 
(shaded bars) and absence (open bars) of Na+. Significant inhibition by 
10 mM PFA (hatched) indicates Na+-dependent transport at 2 mM 
phosphate. Results are mean ± SEM. ###P <0.005 compared with Na+-
dependent absorption at 0.1 mM phosphate, ***P <0.005 compared with 
absorption in the presence of Na+,  $$P <0.01 and $$P <0.005  compared 
with transport in the absence of PFA at 2 mM phosphate using one-way 
analysis of variance with post hoc comparisons performed using the 
Bonferroni multiple comparisons test. n = 6. 
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Figure 3.8. Phosphate uptake in the proximal colon, measured in vitro 
using 0.1 mM, 0.5 mM and 2 mM phosphate in Na+-containing uptake 
buffer. Results are mean ± SEM. ***P <0.005 and ###P <0.005 compared 
with uptake at 0.1 and 0.5 mM phosphate, respectively using an unpaired 
t-test. n = 6. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Phosphate uptake in the distal colon, measured in vitro using 
0.1 mM, 0.5 mM and 2 mM phosphate with (shaded bars) or without 
(open bars) Na+ in uptake buffer. Results are mean ± SEM.  ***P <0.005 
and ###P <0.005 compared with values using 0.1 and 0.5 mM phosphate, 
respectively using an unpaired t-test. n = 6. 
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Figure 3.10. A: Transepithelial absorption and B: Mucosal retention of 
phosphate across the proximal and distal colon, measured in vivo using 
0.5 mM and 2 mM phosphate in the presence (shaded bars) and absence 
(open bars) of Na+ in uptake buffer. Results are mean ± SEM. ***P 
<0.005 compared with absorption at 0.5 mM phosphate and ###P <0.005 
compared with Na+-dependent absorption in the distal colon using an 
unpaired t-test.  n = 6. 
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Figure 3.11. Phosphate transport in the distal colon, measured in vitro 
using 2 mM phosphate with Na+-containing buffer alone (shaded bar) and 
the addition of 10 mM PFA (hatched bar) to uptake and pre-incubation 
buffers. Results are mean ± SEM. n = 6. 
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Analysis of Na+ levels in nominally Na+-free uptake buffer following 
uptake experiments revealed that Na+ was not present under in vitro 
conditions, whereas low Na+ levels were evident in the in vivo buffer 
(mean value 8.08 + 5.98 mM, n=6), indicating little likelihood of Na+ 
influencing phosphate transport under these conditions. 
 
3.3.8. Mannitol uptake in duodenum, jejunum and ileum in vitro 
The intestinal epithelium constitutes a barrier for the movement of ions in 
the mucosal to serosal direction. Mannitol is a marker commonly used for 
assessing intestinal permeability, facilitated by its small size and non-
absorbability under normal conditions (Krugliak et al., 1994). Permeability 
of mannitol through the intestinal epithelium occurs by passive diffusion 
through tight junctions (Ma et al., 1993). Mannitol was used in the present 
study as an independent measure of differences in non-specific 
permeability and paracellular transport across the small intestine and 
colon. The jejunum, ileum and distal colon expressed minimal 
permeability to mannitol in vitro (Fig. 3.12), making it unlikely that the high 
levels of Na+-independent phosphate uptake observed in jejunum and 
distal colon were due to passive diffusion. At 2 mM luminal phosphate, 
Na+-independent phosphate uptake was 8- and 12-fold higher than 
mannitol transport in the jejunum and colon, respectively. Interestingly, 
Na+-independent phosphate uptake in the ileum at 2 mM phosphate was 
the same as that for mannitol transport, suggesting that the minimal Na+-
independent ileal phosphate transport observed represents phosphate 
diffusion and/or mucosal bound 32P (but not transcellular transport). 
Although there were variations in the rate of mannitol uptake between 
animals, this was not statistically significant. 
 
 143 
Figure 3.12. Transport of 3H-mannitol and 32P measured in vitro. 
Transport was measured using uptake buffer containing 2 mM phosphate 
and 1 mM mannitol. Total and Na+-independent transport refer to 
phosphate transported in the presence (red bars) and absence (white 
bars) of Na+. Transport of mannitol (blue bars) was measured in the 
absence of Na+. ***P <0.005 and *P <0.05 compared with Na+-
independent phosphate absorption using an unpaired t-test. Results are 
mean ± SEM. n = 6. 
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3.3.9. Mannitol absorption in the duodenum, jejunum and ileum in 
vivo 
The in vivo permeability of mannitol is reported to be similar in the 
jejunum and ileum, but much higher in the colon (Krugliak et al., 1994). In 
agreement with this finding, present data shows that distal colon was 
significantly more permeable to mannitol than jejunum or ileum (Fig. 
3.13A). In addition, Hu et al (1997) reported a correlation between the 
permeabilities of phosphate and mannitol through the proposed 
intercellular pathway in distal colon in vitro. In keeping with this report, 
significant levels of radiolabelled mannitol were detected in the blood 
when (3H)-mannitol was instilled into the distal colon, demonstrating that 
mannitol was transferred from lumen to blood. The mucosal retention 
data (Fig. 3.13B) show minimal mannitol retention in the jejunum, ileum 
and distal colon. The low mucosal retention and high plasma appearance 
of mannitol imply absorption of mannitol between the colonic epithelial 
cells (through the tight junctions), rather than across the cells. Mucosal 
phosphate retention in the distal colon was Na+-independent and 
significantly higher than mannitol retention, implying different routes used 
by these substrates. Variability of mannitol absorption did not statistically 
differ between animals. 
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Figure 3.13. Absorption of 3H-mannitol and 32P measured in vivo. A: 
plasma appearance and B: mucosal retention of 32P and 3H measured 
using 2 mM phosphate and 1 mM mannitol in the instillation buffer. Total 
and Na+-independent transport refer to phosphate transported across that 
region in the presence and absence of Na+. Transport of mannitol was 
measured in the absence of Na+. Results are mean ± SEM. ***P <0.005 
compared with Na+-independent phosphate absorption and ###P <0.005 
compared with 3H-mannitol transport in  jejunum and ileum, using a one-
way analysis of variance with post hoc comparisons performed using the 
Bonferroni multiple comparisons test. n = 6. 
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3.4. Discussion 
 
The mechanisms and control of intestinal phosphate absorption remain 
ill-defined.  This is partly due to recognised species differences and the 
variety of techniques and experimental conditions that have been used to 
assess uptake, particularly the wide range, and often idiosyncratic choice, 
of phosphate concentration added to the uptake buffer. The work 
described here has established the concentration of phosphate normally 
available for absorption, and it has used in vivo and in vitro methods to 
characterise the relative contributions of Na+-dependent and Na+-
independent phosphate transport in different regions of the rat small and 
large intestine.  
 
Early studies aimed at defining the transport kinetics of phosphate 
transport across the rat jejunal BBM revealed a Na+-dependent process 
with a Kt of 0.1 mM; NaPi-IIb was later identified and held responsible for 
this transport process (Berner et al., 1976; Hilfiker et al., 1998; Lee et al., 
1986b; Loghman-Adham et al., 1992).  To date, subsequent studies have 
mostly used low phosphate concentrations (around 0.1 mM) to favour 
examination of the NaPi-IIb-mediated transport.  However, there is very 
little information regarding reliable values for the luminal ‘free’ phosphate 
concentration available for absorption.  In weaning rats, the phosphate 
level in upper small intestine has been reported to be approximately 5 
mM (Kirchner et al., 2008). Data obtained in the present work reveal 
similar values to that of Kirchner et al (2008) in duodenum and jejunum of 
adult animals.  Using phosphate levels of up to 10 mM to assess 
absorption, present data confirms the jejunum to be the primary region for 
phosphate absorption. However, a surprising finding was that significant 
phosphate uptake occurs in the ileum and distal colon at millimolar 
phosphate levels.  
 
The precise extracellular free phosphate concentration available for 
absorption along the intestine has not been clearly defined. There are 
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limited data on luminal phosphate concentrations in adult rats. In keeping 
with the finding by Kirchner et al (2008), data presented in this chapter 
found luminal free phosphate concentrations to be in the millimolar range 
in the stomach and along the small and large intestine of adult rats. This 
is the first ever report of the ‘free’ unbound concentration of phosphate 
available for absorption along the gastrointestinal tract. At these 
millimolar levels, it would be expected that Na+-dependent transport via 
NaPi-IIb will be saturated. The Kt of the phosphate transport system 
under in vivo conditions, however, was reported to be 2 mM or higher 
(Kirchner et al., 2008; McHardy, 1956; Williams & DeLuca, 2007). 
 
Low levels of phosphate are secreted into gastric juice, which might 
explain the higher luminal phosphate concentration seen in the stomach. 
The total microbiota population makes up about 35-50% of the colonic 
content volume, contributing towards the production of nutrients such as 
fatty acids (Tappenden & Deutsch, 2007; Munakata et al., 1995). These 
fatty acids are readily taken up by colonic mucosa and also may release 
free phosphate from bound proteins, thus increasing total available 
phosphate within the colon. This might be a reason why a higher luminal 
phosphate concentration was seen in the large intestine. 
 
Based on the finding that free phosphate concentrations in the intestinal 
lumen are in the millimolar range, the next step of this study was to 
determine the relative contribution of Na+-dependent and Na+-
independent transport in specific intestinal regions at normal phosphate 
levels in adult rats, both in vitro and in vivo. Increasing the phosphate 
concentration up to 10 mM caused a corresponding rise in total 
phosphate absorption, which did not reach saturation. This observation, 
together with recent reports of Na+-independent phosphate transport by 
Williams & Deluca (2007) and Douard et al (2010), imply that the Na+-
gradient is not the rate-limiting step in phosphate absorption across the 
proximal small intestine.  Interestingly, present in vitro data revealed that 
Na+-independent transport in the duodenum is linearly related to 
phosphate concentration, while the rate of Na+-dependent uptake is not 
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so dependent on luminal phosphate level. However, in the jejunum, both 
Na+-dependent and -independent transport are equally affected by 
increasing phosphate concentrations. In contrast, results in vivo show 
that Na+-dependent transport in both regions is unaffected by luminal 
phosphate concentration, and that the Na+-independent component is 
responsible for increased overall phosphate absorption at higher luminal 
phosphate levels. The unequivocal absence of a Na+ requirement for 
phosphate absorption at high phosphate levels in vivo is in keeping with 
previous in vivo and ex vivo studies (Aloia & Yeh, 1985; Douard et al., 
2010; McHardy, 1956; Williams & DeLuca, 2007).  At physiological 
phosphate concentrations, the fact that NaPi-IIb contributes little towards 
total phosphate absorption in adult rats is not surprising considering the 
decrease in NaPi-IIb expression with aging (Kirchner et al., 2008; Xu et 
al., 2002a). Furthermore, recent reports have claimed that in mature rats, 
not only is Na+-dependent phosphate transport insignificant, but also that 
this component is unlikely to be regulated, in contrast to the situation 
seen in weanling animals (Douard et al., 2010; Kirchner et al., 2008; 
Williams & DeLuca, 2007). 
 
Since in vitro phosphate uptake does not show saturation at phosphate 
concentrations of up to 10 mM, the Kt for the transport process is 
significantly higher than that reported for BBM vesicles (of 0.1 mM) and 
may be more representative of the Kt in vivo. The phenomenon of 
different Kt in vivo and in vitro has been reported for Na+-dependent 
glucose transport across the small intestine, where the reported Kt in vivo 
is approximately 20 mM, a value significantly higher than the Kt of 4 mM 
determined using everted sleeves, and of less than 0.5 mM using BBM 
vesicles and oocytes (Wright, 2001; Debnam et al., 1988; Wright, 2001).  
 
The disparity in the overall contribution of Na+-dependent transport 
observed in vivo and in vitro highlights the value and importance of using 
both approaches to study phosphate transport.  The use of a single 
method in most previous studies may explain the discrepancies in the 
literature concerning the mechanisms involved in phosphate transport.  
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Using everted sacs from mature rats (13-week old), Douard et al (2010) 
showed that phosphate absorption at 1.2 mM luminal phosphate is Na+-
independent. Since the everted sac technique can measure paracellular 
transport in addition to transepithelial transfer, Douard et al (2010) 
proposed that phosphate transport is solely mediated via the paracellular 
pathway, rather than the transcellular (NaPi-IIb) route. Present data from 
the in vivo in situ loop technique, which measures both transepithelial and 
paracellular phosphate transport, leads to similar conclusions to that of 
Douard et al (2010). Furthermore, the in vivo in situ loop technique was 
also sensitive enough to detect the low rates of Na+-dependent transport 
at luminal phosphate levels ≤ 2 mM.  
 
Data from work presented in this chapter suggest that the everted sleeve 
technique is a valid and useful measure of phosphate transport across 
the BBM of intact epithelium, since Na+-dependent transport is readily 
detectable. However, examining phosphate absorption in vivo may be 
more physiologically relevant and reveal regulatory changes in the 
dominant Na+-independent transport pathway.  In this context, it is 
notable that a facilitative pathway for intestinal glucose transport, now 
attributed to GLUT2, was overlooked in early in vitro studies, because of 
the rapid internalization of the transport protein away from the BBM 
during preparation of tissue for in vitro uptake studies (Kellett, 2001). 
 
Na+-independent phosphate absorption is mediated by either paracellular 
transport or an unidentified transcellular pathway.  The apparent 
contradictions between the in vivo and in vitro data concerning the 
contributions of Na+-dependent and Na+-independent transport may 
reflect differences in paracellular transport in these preparations. It is 
interesting to note that a facilitative component of intestinal glucose 
transport, now attributed to GLUT2, was overlooked in early in vitro 
studies due to rapid shuttling of this transport protein away from the BBM  
upon removal of the tissue from its blood supply (Kellett, 2001). It is 
important to characterise the pathway responsible for the higher Na+-
independent phosphate transport detected in vivo. 
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A potential role of type III transporters in intestinal phosphate handling 
has recently emerged. PiT1 mRNA has been detected in all regions of 
the rat small intestine, with highest expression levels in the ileum (Giral et 
al., 2009). However, the mRNA expression profile does not correspond to 
that seen for the translated protein: PiT1 protein levels are highest in the 
jejunum and absent in the ileum (Giral et al., 2009). PiT2 mRNA has 
been found at low levels throughout the rat small intestine (Giral et al., 
2009), but to date a profile for the protein in this species has not been 
established.  The Kt for PiT1 and PiT2 has been estimated to be ~25 µM 
in oocytes (Tatsumi et al., 1998), but the function of these proteins in 
phosphate absorption is unclear. Previous studies have shown PFA to be 
a specific inhibitor of NaPi-IIb-mediated transport, whilst only weakly 
inhibiting PiT-mediated transport when used at concentrations 50-fold 
higher than the level of phosphate (Bai et al., 2000; Ravera et al., 2007).  
Thus, at the higher (millimolar) phosphate concentrations used in the 
present study, 10 mM PFA would have selectively inhibited NaPi-IIb-
mediated transport, whereas at 0.1 mM phosphate 10 mM PFA is likely to 
have blocked both NaPi-IIb and PiT-mediated transport. 
 
Present study used PFA to differentiate between the contribution of type 
II and type III transporters to the Na+-dependent component of phosphate 
absorption. Increasing concentrations of PFA have been reported to 
progressively decrease renal Na+-dependent phosphate transport and the 
EC50 for PFA has been calculated to be ~3 mM (Picard et al., 2010).  The 
present study did not see a progressive decline in intestinal phosphate 
transport with PFA in vivo or in vitro, suggesting that NaPi-IIb is 
maximally inhibited. It is interesting that PFA inhibited all the Na+-
dependent transport measured in vivo, but not in vitro, which may reflect 
the relatively low contribution of Na+-dependent transport under in vivo 
conditions, or the possibility that PiT transporters contribute to phosphate 
transport across the BBM but not transepithelial transport. Non-specific 
effects of PFA have been documented at concentrations >10 mM (Picard 
et al., 2010; Ravera et al., 2007), making it unwise to use very high doses 
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of PFA in an attempt to totally block Na+-dependent transport. More 
specific PiT and NaPi-IIb transporter inhibitors are needed to confidently 
establish a role for PiT-mediated transport in intestinal phosphate 
transport and to distinguish between the relative contribution of NaPi-IIb 
and PiT proteins to Na+-dependent phosphate absorption. 
 
Small differences in the in vivo results between transepithelial absorption 
and mucosal retention data are partly due to unavoidable errors in the 
calculation of mucosal retention; e.g. errors in measurement of the length 
of intestinal section used for in vivo studies and measurement of wet 
mucosal tissue weight instead of dry tissue.  Additionally, some 32P 
activity in the scraped mucosa was probably due to bound 32P, which 
would not influence calculations of transepithelial phosphate transport. 
 
The involvement of the ileum in overall intestinal phosphate uptake is 
unclear. While some studies have reported the rat ileum to have little or 
no capacity to absorb phosphate (Marks et al., 2006; Peters & 
Binswanger, 1988), others reported that phosphate is absorbed equally 
by duodenum, jejunum and ileum, and to a lesser extent by colon 
(Cramer, 1961; Kayne et al., 1993). Present results show minimal ileal 
phosphate transport at 0.1 mM luminal phosphate.  In contrast, at high 
levels of phosphate there is readily detectable Na+-dependent phosphate 
transport both in vivo and in vitro, which is PFA-sensitive.  However, the 
transport rate is lower than that detected in the duodenum and jejunum at 
the same luminal phosphate concentrations. Since NaPi-IIb and PiT1 
proteins are not expressed at the ileal BBM in the rat (Giral et al., 2009; 
Marks et al., 2006), an additional, and as yet uncharacterised,  low affinity 
Na+-dependent transporter seems likely to be present in this region.  
Present data also provided evidence that the distal, but not proximal, 
colon can absorb phosphate from the lumen and transfer it into blood. 
Relative to the jejunum, the rate of phosphate absorption by the distal 
colon at 2 mM luminal phosphate is about 40% and, importantly, is 
mediated by a Na+-independent, PFA-insensitive pathway. Phosphate 
transport in the distal, but not the proximal, colon was previously detected 
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under in vitro conditions and attributed to a paracellular pathway (Hu et 
al., 1997; Lee et al., 1980).  
 
Gene expression of NaPi-IIb, PiT1 and PiT2 mRNA was detected in the 
distal colon by Capuano et al (2009). However, whether this is translated 
into protein expression is unknown. NaPi-IIb transporters function 
maximally at pH ≥7, whereas PiT transporters express higher level of 
Na+-dependent phosphate transport activity at pH <7.  The acidity of 
colonic contents is likely to favour PiT-mediated transport (Evans et al., 
1988; Cummings, 1981; Berner et al., 1976). However, Berner et al 
(1976) demonstrated that phosphate uptake by intestinal BBM vesicles at 
pH 6 does not involve cotransport with Na+, a finding that suggests a non-
PiT-mediated process. Thus, the mechanisms involved in the colonic 
transport process have yet to be elucidated. The significance of 
phosphate transport in the colon to overall phosphate homeostasis is 
unclear, since increasing solidity of colonic contents, particularly in the 
distal colon, would make phosphate less accessible for absorption. 
However, the uptake capacity of the colon for phosphate might be 
relevant to the clinical observation, and complication, of 
hyperphosphataemia following the use of high phosphate-containing 
enemas (Carl & Mitchell, 2007; Hunter et al., 1993; Hu et al., 1997).   
 
Hu et al (1997) directly compared intestinal permeability of phosphate 
and mannitol and proposed that absorption of phosphate occurred by the 
same paracellular pathway used by mannitol. However, mannitol is 
neutrally charged whereas phosphate is negatively charged; the two 
substrates cannot be considered as strictly equivalent in assessing their 
involvement in paracellular transport since transport through the tight 
junctions is both size and ionic charge selective. Mannitol was used to 
assess whether differences in its permeability were obvious between in 
vivo and in vitro techniques, especially the latter where one might expect 
greater passive permeability arising from tissue damage during its 
preparation for uptake studies. Mannitol was also used as an indicator of 
bound levels of radiolabelled substrate following uptake and tissue 
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washing procedures, and differences in variability in uptakes between the 
two techniques and between intestinal regions.  
 
As established previously (Krugliak et al., 1994), the jejunum, ileum and 
distal colon exhibited low mucosal permeability to mannitol in vivo and in 
vitro. This low mannitol permeability represents low levels of extracellular 
bound radiolabelled substrate, and demonstrates that phosphate uptake 
measured using both of these techniques is slightly overestimated. 
However, this is an expected limitation of any solute uptake techniques. 
Interestingly, data presented in this chapter indicate that transepithelial in 
vivo permeability to mannitol was greater in the distal colon compared 
with small intestine, asestablished previously (Krugliak et al., 1994). 
Combined with minimal mucosal mannitol retention, this data shows that 
transport of mannitol is via the paracellular, and not transcellular, 
pathway. Although jejunum and ileum are more ‘leaky’ epithelia, the high 
rate of water absorption (solvent drag) allows for high rate of mannitol 
permeability across the distal colon.). 
 
Paracellular transport of phosphate is the passive movement of the 
phosphate ion through tight junctions between adjacent epithelial cells, 
down its electrochemical gradient. After ingestion of a phosphate-
containing meal, the intestinal lumen is exposed to high concentrations of 
phosphate, thus it is possible that paracellular transport of phosphate is 
the predominate postprandial route. Paracellular transport of phosphate 
may occur via claudins. It may be that an anion selective claudin in 
surface epithelium mediates phosphate uptake. This is not surprising 
since cation-selective claudin-12 has been shown to transport Ca2+ 
(Fujita et al., 2008). Although over 20 different claudins have been 
identified, their species-specific expression, distribution and their roles 
have not yet been clearly defined. 
 
Interest in the Na+-independent component of phosphate transport is 
revived by the results presented in this chapter. Further experiments are 
needed to characterise this pathway in the proximal small intestine and 
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distal colon, especially under in vivo conditions. It also remains to be 
elucidated whether this transport route is regulated, as it is the case for 
Na+-dependent phosphate uptake. There are reports claiming that Na+-
independent phosphate transport in the small intestine is regulated (Yeh 
& Aloia, 1987; Debiec & Lorenc, 1985). In the colon, the presence of the 
vitamin D receptor (Lee et al., 1980) and the genomic upregulation of 
NaPi-IIb, PiT1 and PiT2 by dietary phosphate restriction (Capuano et al., 
2009) suggest that phosphate absorption in the colon may involve 
regulation by vitamin D and/or the level of phosphate in the diet. Further 
work is, however, needed to establish the importance of regulation of 
phosphate uptake in the colon to overall phosphate balance. 
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3.5. Conclusion 
 
In conclusion, the present study has shown phosphate concentrations 
along the intestine to be in the millimolar range, and the Na+-independent 
transport may be the dominant pathway in vivo. To date, study of the 
regulation of intestinal phosphate transport has used mainly in vitro 
techniques to assess changes in Na+-dependent phosphate transport; the 
pathway involved being attributed to NaPi-IIb. However, it is now clear 
that the contribution of Na+-dependent transport to overall transport is 
relatively small in vivo. Additional studies are needed to gain insight into 
the mechanisms and regulation of the Na+-independent component of 
phosphate absorption in the jejunum and colon, as well as the proteins 
responsible for Na+-dependent phosphate uptake that operate at normal 
luminal phosphate concentrations in the ileal lumen.  
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4.0. Genomic regulation of Na+-dependent 
phosphate cotransporters by low phosphate diet, 
age, chronic renal failure and matrix extracellular 
phosphoglycoprotein 
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4.1. Introduction 
 
Recent evidence suggests that in addition to the well characterised type II 
transporters, type III Na+-dependent phosphate transporters PiT1 and 
PiT2 may also play a critical role in the absorption of phosphate. PiT1 
and PiT2 transporters have a wide membrane expression, including the 
brush-border membrane (BBM) of the small intestine and kidney. 
 
Very little is known about the regulation of PiT transporters. In summary, 
the genomic expression of PiT1 and PiT2 is regulated by phosphate 
deprivation, potassium deficiency and metabolic acidosis (Villa-Bellosta 
et al., 2009b; Villa-Bellosta & Sorribas, 2010b; Collins et al., 2004; 
Breusegem et al., 2009). PiT1 and PiT2 protein expression is regulated 
by phosphate depletion, acute low phosphate diet, Fibroblast growth 
factor-23 (FGF-23), and by conditions that affect NaPi-IIa directly such as 
deletion of NaPi-IIa gene (Fernandes et al., 1999; Kavanaugh et al., 
1994; Nowik et al., 2008; Tomoe et al., 2010; Villa-Bellosta & Sorribas, 
2010b). These reports suggest a more significant role for PiT transporters 
in phosphate homeostasis, in contrast to the previous notion that PiT 
transporters play only a housekeeping role at the basolateral membrane 
(Bai et al., 2000; Collins et al., 2004). 
 
Rat and mouse are the two most common species used in the study of 
phosphate homeostasis. Recently, Giral et al (2009) showed that in rats 
PiT1 and PiT2 proteins are expressed at the renal BBM and that renal 
PiT2 protein is regulated by low phosphate diet. Conversely, they failed to 
find PiT2 mRNA expression in any regions along the small intestine. 
Although PiT1 protein was detected in the proximal small intestine, it was 
not regulated by dietary phosphate level. Region-specific expression of 
PiT transporters in the mouse small intestine is however unknown. To 
examine whether PiT transporters are differentially expressed in rat and 
mouse small intestine, and in different intestinal regions as reported for 
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NaPi-IIb expression (Marks et al., 2006), PiT1 and PiT2 mRNA 
expression was analysed in all three distinct areas of the small intestine.  
 
The regulation of PiT transporters by chronic low phosphate diet and age 
is not well characterised. The effect of one of the most common 
phosphate disorders, hyperphosphataemia, a consequence of chronic 
renal failure, on PiT transporter expression has also not been evaluated 
to date. The regulation of NaPi-IIa and NaPi-IIb mRNA expression by 
chronic renal failure in the small intestine and kidney is, however, 
established (Douard et al., 2010; Marks et al., 2007). There is also 
growing interest in the effect of the bone-derived phosphatonin matrix 
extracellular phosphoglycoprotein (MEPE), which has been shown to 
inhibit both intestinal and renal Na+-dependent phosphate transport 
(Marks et al., 2008; Shirley et al., 2010). 
 
The aims of the present study were to investigate whether increased 
BBM Na+-dependent phosphate transport, observed during the feeding of 
a low phosphate diet or during weaning, is mediated by changes in 
intestinal and renal PiT1 and PiT2 gene expression, and to establish the 
effects of severe chronic renal failure, using the 5/6 nephrectomy rat 
model. The effects of MEPE on NaPi-II and PiT transporters in the small 
intestine and kidney during chronic renal failure has also been examined. 
Since there are currently no suitable commercial antibodies for PiT1 and 
PiT2 proteins, changes in mRNA levels in respect of these proteins were 
analysed in rats using quantitative real-time polymerase chain reaction 
(PCR). 
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4.2. Materials and Methods  
 
4.2.1. Animals and diet 
 
4.2.1.1. Rats 
Male Sprague Dawley (SD) rats aged 3 weeks, 8 weeks and 16 weeks 
were obtained from Charles River Laboratories (UK) and used in 
accordance with the Animals (Scientific Procedures) Act 1986. Control 
rats were allowed ad libitum access to a standard rodent chow containing 
0.52% phosphate (Diet RM1, SDS Ltd, Witham, Essex, UK) and water.  
Some rats on a control diet were switched to a low phosphate diet 
containing 0.02% phosphate (Harlan Tekland, Indianapolis, USA) for 7 
days prior to experimentation. 
 
4.2.1.2. Mice 
Male C57BL/6 mice (25 g body weight) were obtained from the 
Comparative Biology Unit at the Royal Free campus of UCL and used in 
accordance with the Animals (Scientific Procedures) Act 1986. Control 
mice were allowed ad libitum access to a standard rodent chow 
containing 0.52% phosphate (Diet RM1, SDS Ltd, Witham, Essex, UK) 
and water. 
 
4.2.1.3. Chronic renal failure (5/6 nephrectomy) 
Surgically 5/6 nephrectomised SD rats, and sham-operated controls were 
supplied by Charles River Laboratories (MA, USA) and delivered to the 
laboratories of Acologix Inc (California, USA). Animals were fed a control 
diet (5L79, Purina Charles River) prior to and following 5/6 nephrectomy 
surgery. To induce severe hyperphosphataemia and 
hyperparathyroidism, secondary characteristics of chronic renal failure, 
animals were switched to a high phosphate (1.2%), but low calcium 
(0.4%) diet (Diet TD.07363, Harlan Teklad, Indianapolis, USA) post-
nephrectomy. MEPE treatment was also carried out at Acologix Inc. For 
this, sham and 5/6 nephrectomised animals were treated daily with an 
intravenous injection of HEPES-buffered saline (vehicle-treatment), or 
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HEPES-containing 3 mg/kg E.coli expressed MEPE (an optimal dose of 
the phosphatonin previously established by Acologix and by Marks et al 
(2009)) for 2 weeks. During this time, animals were switched to a control 
phosphate, but low calcium (0.4%) diet.  At the end of treatment, blood 
was collected from animals via a tail vein bleed. Acologix Inc measured 
parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D3 levels in 
plasma using a BioActive ELISA kit (Immunotopics), and plasma and 
urine phosphate levels using a Quantichrom phosphate assay kit 
(BioAssay Systems, Hayward, CA), according to the manufacturer’s 
instructions. Animals were killed by anaesthetic overdose and tissue was 
removed and snap-frozen with RNAlater solution (Ambion, Texas, USA) 
in liquid nitrogen and stored -70°C before shipment on dry ice to the UK. 
All experimentation carried out by Acologix were performed according to 
national and local ethical guidelines, 
 
4.2.2. RNA extraction from rat and mouse tissue 
Kidneys or intestinal mucosal scrapes from rats and mice (excluding 
those from 4.2.1.3) were snap-frozen with RNAlater solution (Ambion, 
Texas, USA) in liquid nitrogen and stored at -70°C until use. This was 
determined to be the best method for preserving RNA in stored tissue 
(Fig. 4.1). Tissue samples were ground to fine powder using liquid 
nitrogen, and pestle and mortar. RNA was then extracted from tissue 
using Trizol (Invitrogen, Paisley, UK), according to the manufacturer’s 
instructions. Extracted total RNA samples (1.5 µl) combined with loading 
buffer (Sigma, Dorset, UK), were run on 1.2% agarose gel containing 
0.1% ethidium bromide at 120 V to ensure that good quality RNA was 
extracted, evident by two bright ribosomal bands (28S and 18S, 2:1 
ratio), and from the reading from Nanodrop (Bio-Rad Laboratories Ltd, 
Hemel Hempstead, UK), where the 260/280 ratio was above 1.75. RNA 
concentration was also determined using the Nanodrop, and RNA was 
diluted to a concentration of 1 µg/µl. 
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4.2.3. mRNA quantification using real-time PCR 
RNA was reverse transcribed with 0.5 µg of oligo-dT 12-18 primer and a 
First Strand cDNA synthesis kit (Superscript II RNase H- reverse 
transcriptase; Life Technologies, Paisley, UK). NaPi-IIa and NaPi-IIb 
transporter mRNA expression levels were analysed using Real-Time 
PCR Chromo4™ Real-Time Detector (Bio-Rad Laboratories Ltd, Hemel 
Hempstead, UK), using QuantiTech SYBR® Green PCR kit (Qiagen, 
West Sussex, UK), following the manufacturer’s instructions for calibrator 
normalised protocols. Specific primers against rat and mouse were 
designed and the primer most suitable at detecting the gene of interest 
was chosen on the basis of lower cycle number for amplification and 
steepest fluorescence emission peak (Fig. 4.2). β-actin transcript was 
chosen as the housekeeping gene and run in parallel cycles. β-actin has 
been shown to have less variance in expression across a variety of 
treatment conditions and it is a commonly used as a control/standard in 
real-time PCR. Primers were tested for efficiency and checked for 
formation of primer dimers by running the PCR product in a 2% agarose 
gel with ethidium bromide for 30 min in an electrophoresis tank at 120 V. 
 
Primers were designed from PRIMER3 tool at: 
(http://www.ncbi.nlm.nih.gov/tools/primer-last/index.cgi?LINK_LOC=Blast 
Home), based on the published sequence of the specific gene of interest. 
Primer3 tool is useful for designing primers that are specific, in terms of 
the region of interest, minimum GC content and product size. The 
sequences of final primers chosen are listed in Table 4.1. 
 
All primers were run on the same cycling conditions as follows: 95°C for 
10 min followed by 45 cycles of 95°C for 15 s, 60°C for 20 s and 72°C for 
40 s with transition rates of 20°C s–1 and a single fluorescence acquisition 
at 81°C.  
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4.2.4. Calculation of expression fold change 
A calibrator (control) for NaPi-IIa, NaPi-IIc or NaPi-IIb and β-actin was run for 
every PCR cycle. The fold change in expression was calculated using the 
threshold cycle (Ct) value for the actin, and for the gene of interest (GOI) of 
each sample. The fold-change in GOI was equal to 2 (-∆∆Ct), where ∆∆Ct = [Ct 
(GOI) - Ct (actin)]sample – [Ct (GOI) - Ct (actin)]calibrator (Livak & Schmittgen, 2001). 
The difference in threshold cycle values for each reaction, the ∆Ct value (control 
and experimental), were dependent on the amplification efficiency, which was 
used to compensate for efficiency differences between samples and the 
calibrator.  
 
4.2.5. Statistical analysis 
Data are presented as means ± SEM. Unpaired t-test or a one-way ANOVA, as 
appropriate, was used and group differences were considered statistically 
significant if P <0.05; n represents the number of samples per group. Post hoc 
analysis was carried out within groups by using the Bonferroni correction. 
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4.3. Results 
 
4.3.1. Extraction of high integrity RNA 
RNA from animal tissues is prone to degradation. Intestinal tissue in 
particular is known to have the highest rate of RNA degradation (Lee et 
al., 2005). The initial choice of homogenising samples using an electrical 
homogeniser was not a sufficiently rapid and robust method, in 
comparison with grinding samples in liquid nitrogen using a pestle and 
mortar to prevent RNA degradation (Fig. 4.1A). On the basis of this 
finding, for all future experiments grinding with the liquid nitrogen method 
was used for extracting RNA. Tissues also need to be suitably stored if 
RNA extraction is needed at a later date. RNAlater solution allows 
tissues to be stored for months without sacrificing the integrity of RNA, 
since it stabilises the RNA. In contrast to strong RNA bands (28S and 
18S) seen after tissues were stored in RNAlater, Fig. 4.1B demonstrates 
RNA from intestinal tissue was fully degraded (represented by smear on 
gel) following storage for months without treatment with reagents to 
preserve RNA although the tissues were extracted for RNA by grinding 
with liquid nitrogen.  
 
4.3.2. Primer design for real-time PCR 
Following extraction of good quality RNA from intestinal and kidney 
samples, primers were designed from the published sequence of the 
Na+-dependent phosphate transporters NaPi-IIa, NaPi-IIb, NaPi-IIc, PiT1 
and PiT2 for rat and mouse. A number of potential primers, between 
200-300 base pairs, were tested for each gene of interest using SYBR 
green kit and a LightCycler Real-Time PCR instrument. The final choice 
of a primer for the gene of interest was made on the basis of the 
following: the steepest peak in fluorescence emission at the melting 
temperature of the PCR product (Fig. 4.2A), a lower cycle number, and a 
more linear response than the alternative primers tested for that gene 
(Fig. 4.2B).  
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Figure 4.1. Comparison of RNA extraction methods and storage 
conditions. A: extraction of a range of tissues using electrical 
homogeniser or liquid nitrogen (N2) grinding process. Samples were 
stored in RNAlater at -70°C. Good quality of RNA is represented by 
strong 28S and 18S ribosomal RNA bands. B: represents complete RNA 
degradation in duodenum and jejunum samples stored at -20°C without 
stabilising solution (RNAlater), following tissue removal from animal. 
A 
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Figure 4.2. Primers were tested for their use in real-time quantitative 
PCR, where A: the melting curve and B: the cycle number at which the 
cDNA begins to get amplified were measured for each set of primers 
tested for the reference gene. [1] Represents the final primer chosen for 
a particular gene.  
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Cycle number represents how many melting/annealment/extension 
cycles have occurred. The same cDNA sample was used for all primers 
tested and the lower the Ct (cycle number above threshold) at which the 
curve starts appearing, the more efficient are the primers.  
 
4.3.3. Comparison of phosphate transporter expression in rats and 
mice 
Once the conditions for quantifying mRNA were successfully optimised, 
known Na+-dependent phosphate transporters were quantified in three 
regions (duodenum, jejunum and ileum) of the small intestine of adult 
rats (Fig. 4.3) and mouse (Fig. 4.4). Although the jejunum plays the 
predominant role in Na+-dependent phosphate absorption across the 
small intestine (see Chapter 2 for further details), NaPi-IIb mRNA levels 
detected showed no significant differences between the duodenum and 
jejunum of rats (Fig. 4.3A), as previously noted (Marks et al., 2006). In 
the ileum, the region not involved in Na+-dependent phosphate 
absorption in the rat (see Chapter 2 for further details), NaPi-IIb mRNA 
expression was undetectable. In contrast, NaPi-IIb expression in the 
mouse ileum was significantly higher than that seen in the duodenum 
and jejunum (Fig. 4.4A), again as noted previously (Marks et al., 2006). 
This parallels previous NaPi-IIb protein expression and uptake data 
recorded in the mouse (Giral et al., 2009; Marks et al., 2006; Radanovic 
et al., 2005), which demonstrated this region to be largely responsible for 
overall intestinal phosphate absorption. Substantial levels of PiT1 mRNA 
(Figs. 4.3B and 4.4B) and PiT2 (Figs. 4.3C and 4.4C) were found in the 
duodenum and jejunum of rat and mouse. However, unlike NaPi-IIb, 
there was no region-specific expression pattern for PiT1 and PiT2 in 
either species.  
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Figure 4.3. Expression of A: NaPi-IIb, B: PiT1 and C: PiT2 mRNA in the 
mucosa of duodenum (duo), jejunum (jej) and ileum of adult rats fed a 
control diet, quantified using real-time PCR.  Fold change was calculated 
using the comparative ∆∆Ct method using actin as a house keeping 
gene. Results are means ± SEM. *P <0.05 and **P <0.01 compared with 
ileum using a one-way ANOVA with Bonferroni multiple comparisons 
post hoc test. n = 6. 
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Figure 4.4. Expression of A: NaPi-IIb, B: PiT1 and C: PiT2 mRNA in the 
mucosa of duodenum (duo), jejunum (jej) and ileum (ile) of adult mice 
fed a control diet, quantified using real-time PCR.  Results are means ± 
SEM. *P <0.05 compared with mouse ileum using a one-way ANOVA 
with Kruskal–Wallis post hoc test. n = 6. 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
NaPi-IIb
0
50
100
150
200
250
Duo Jej Ile
F
ol
d 
ch
an
ge
* *
PiT1
0
1
2
3
Duo Jej Ile
F
ol
d 
ch
an
ge
 173 
C 
PiT2
0
1
2
3
4
Duo Jej Ile
F
ol
d 
ch
an
ge
 174 
4.3.4. Response to chronic low phosphate diet  
The effect of chronic low phosphate diet on mRNA expression of 
intestinal and renal Na+-dependent phosphate transporters was 
investigated. Kidneys of animals that were chronically fed a low 
phosphate diet for 7 days showed higher levels of PiT2 and NaPi-IIa 
expression (upregulation by 3 and 6-fold, respectively, compared with 
animals fed a control diet) (Fig. 4.5A). This is in keeping with the 
previously established stimulatory effect of a chronic low phosphate diet 
on renal Na+-dependent phosphate transport and NaPi-IIa, and PiT2 
protein expression (Capuano et al., 2005; Giral et al., 2009; Madjdpour et 
al., 2004; Villa-Bellosta et al., 2009b). Therefore, the increase in renal 
Na+-dependent phosphate transport following a chronic low phosphate 
diet is partly mediated by genomic changes in the level of NaPi-IIa and 
PiT2 transporters. No changes were observed with respect to renal PiT1 
and NaPi-IIc mRNA expression.  
 
There were no changes in the genomic level of any of the Na+-
dependent phosphate transporters, NaPi-IIb, PiT1 or PiT2, expressed at 
the jejunal BBM in rats fed a low phosphate diet (Fig. 4.5B). Hence, a 
chronic low phosphate diet causes genomic upregulation of Na+-
dependent phosphate transporters expressed in the kidney only. Present 
data imply that the increased jejunal Na+-dependent phosphate transport 
observed with rats fed a low phosphate diet (see Chapter 2.3.3 for 
details) is not due to altered gene expression of NaPi-IIb, PiT1 or PiT2.  
 
4.3.5. Transporter responses to aging 
To evaluate whether intestinal and renal expression of PiT transporters 
are age-dependent at the genomic level, gene expression was analysed 
in 3-week and 8- or 16-week old rats. The level of NaPi-IIa mRNA was 
similar in both age groups (Fig. 4.6A). Renal NaPi-IIc and intestinal NaPi-
IIb expression is reported to decline with age (Silverstein et al., 1997; 
Segawa et al., 2002; Xu et al., 2001).  
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Figure 4.5. Changes in the mRNA expression of type II and type III 
transporters induced by a low phosphate diet. A: kidney cortex and B: 
jejunal mucosa was taken from rats maintained on a control or low 
phosphate diet for 7 days. Fold change was calculated using the 
comparative ∆∆Ct method using actin as a house keeping gene. Results 
are mean ± SEM. *P <0.05 and **P <0.01 compared with control diet, 
using unpaired t-test. n = 6.  
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Figure 4.6. Age-related changes in the mRNA expression of type II and 
type III transporters in the A: kidney cortex from young (3 weeks) and 
adult (8 weeks) rats, and B: duodenal and C: jejunal mucosa from young 
(3 weeks) and old (16 weeks) rats. Fold change was calculated using the 
comparative ∆∆Ct method using actin as a house keeping gene. Results 
are means ± SEM. *P <0.05, ***P <0.005 compared with younger 
animals, using unpaired t-test. n = 6. 
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Although NaPi-IIc mRNA expression appeared higher in 3-week old rats, 
this did not reach significance (P=0.23). Renal PiT1 and PiT2 mRNA 
levels were also similar in young and adult rats.  
 
This study shows the expected age-dependent decline in NaPi-IIb 
expression in both the duodenum (Fig. 4.6B) and jejunum (Fig. 4.6C). 
Interestingly, jejunal, but not duodenal, expression of PiT2 mRNA was 
regulated by age. PiT2 mRNA was 9-fold higher in young animals. These 
results parallel previous findings that Na+-dependent phosphate transport 
across the intestinal BBM is significantly greater in young rats (see 
Chapter 2.3.4 for further details). Intestinal PiT1 mRNA expression was 
similar in both age groups (P=0.09).   
 
4.3.6. Transporter responses to chronic renal failure  
To define the genomic effects of the 5/6 nephrectomy model of chronic 
renal failure on NaPi-II and PiT transporters, mRNA levels were 
quantified in the kidney and jejunum. For small intestine, only the jejunal 
region was analysed since it is responsible for the majority of Na+-
dependent phosphate transport in the rat (see Chapter 2.3.1). In the 
residual kidney of chronic renal failure rats, NaPi-IIa mRNA levels were 
significantly reduced (Fig. 4.7A). Interestingly, mRNA expression of PiT1 
(Fig. 4.7C) and PiT2 (Fig. 4.7D) were also markedly reduced compared 
with sham-operated animals. The mean value for NaPi-IIc mRNA 
expression (Fig. 4.7B) was reduced by chronic renal failure, but this was 
not statistically significant (P=0.09). In contrast to previous findings 
(Douard et al., 2010; Marks et al., 2007), NaPi-IIb levels were 
significantly reduced in the jejunum (P=0.05) compared with sham-
operated rats (Fig. 4.8A). Jejunal PiT1 (Fig. 4.8B) and PiT2 (Fig. 4.8C) 
mRNA levels were also downregulated significantly by chronic renal 
failure (P <0.05). Chronic renal failure reduced plasma 1,25-
dihyrdroxyvitamin D3 levels (Table 4.2) and increased plasma levels of 
PTH and phosphate, as established previously (Marks et al, 2007). 
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Figure 4.7. mRNA expression of renal A: NaPi-IIa, B: NaPi-IIc, C: PiT1 
and D: PiT2 in rats maintained on a control phosphate diet for 8 weeks 
and subjected to sham nephrectomy (Sham), 5/6 nephrectomy (CRF), or 
5/6 nephrectomy and treatment with 3 mg/kg/day MEPE for 2 weeks 
(MEPE). Fold change was calculated using the comparative ∆∆Ct 
method using actin as a house keeping gene. Results are mean ± SEM. 
*P <0.05 and **P <0.01, compared with sham nephrectomy. n = 3 for 
sham and n = 6 for CRF and treatment with MEPE, respectively. 
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Figure 4.8. Changes in the mRNA expression of jejunal A: NaPi-IIb, B: 
PiT1 and C: PiT2 in rats maintained on a control phosphate diet for 8 
weeks and subjected to sham nephrectomy (Sham), 5/6 nephrectomy 
(CRF), or 5/6 nephrectomy and treatment with 3 mg/kg/day MEPE for 2 
weeks (MEPE). Fold change was calculated using the comparative ∆∆Ct 
method using actin as a house keeping gene. Results are mean ± SEM. 
*P <0.05 and #P <0.05, compared with sham nephrectomy and 5/6 
nephrectomy, respectively. n = 3 for sham and n = 6 for CRF and 
treatment with MEPE, respectively. 
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4.3.7. MEPE treatment of chronic renal failure rats 
5/6 nephrectomised rats were injected daily with 3 mg/kg E.coli-derived 
MEPE. Following 2 weeks of MEPE treatment, animals displayed 
significantly lower plasma PTH levels and increased urinary excretion of 
phosphate compared with vehicle-treated chronic renal failure rats (Table 
4.2). Acute infusion of MEPE for 3 hours is known to decrease intestinal 
and renal phosphate absorption in healthy rats (Marks et al., 2008).  
 
In the present work, the effect of chronic MEPE treatment of chronic 
renal failure rats on the levels of NaPi-II and PiT mRNA expression was 
measured. MEPE treatment did not affect NaPi-IIa, PiT1 or PiT2 mRNA 
expression in the residual kidney of chronic renal failure rats (Fig. 4.7A). 
Gene expression of NaPi-IIc (Fig. 4.7B), PiT1 (Fig. 4.7C) and PiT2 (Fig. 
4.7D) appeared augmented at the end of the MEPE treatment period 
when compared with vehicle-treated chronic renal failure animals, 
although values did not reach statistical significance (P=0.15, 0.14 and 
0.17, respectively). When compared with vehicle-treated chronic renal 
failure animals, MEPE did reduce further jejunal expression of NaPi-IIb 
(Fig. 4.8A) and PiT2 (Fig. 4.8C). It is, therefore, possible that the effect of 
MEPE in reducing jejunal phosphate absorption (Marks et al., 2008) is 
mediated via regulation of NaPi-IIb and/or PiT2. MEPE treatment of 
chronic renal failure animals had reduced PiT1 mRNA levels in the 
jejunum (Fig. 4.8A), but this was not statistically significant. Thus, PiT 
transporters in the small intestine and kidney seem to be differentially 
affected by chronic renal failure and MEPE. 
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4.4. Discussion 
 
In contrast to NaPi-II transporters, which have been identified and 
studied in detail, the newly emerging type III transporters, the PiT 
transporters, were only recently revealed as high affinity BBM Na+-
dependent phosphate transporters. Although it is possible that PiT 
proteins may act as key transporters alongside type II transporters, in 
vivo evidence has not yet been shown to support this idea. The present 
study was designed to increase our understanding of the genomic 
expression and regulation of the type II and type III Na+-dependent 
phosphate transporters in kidney and small intestine. Na+-dependent 
phosphate transporters are differentially expressed in the small intestine 
and kidney, and there is thought to be functional heterogeneity between 
the type II and type III transporters (Marks et al., 2010; Villa-Bellosta et 
al., 2009b; Villa-Bellosta & Sorribas, 2010b; Virkki et al., 2007). A better 
understanding of the specific properties of renal and intestinal PiT 
transporters would be important in therapeutic intervention to treat 
hyperphosphataemia and help prevent vascular calcification in chronic 
renal failure patients.  
 
Renal and intestinal phosphate absorption has been shown to be 
modulated by dietary phosphate intake, age, 1,25-dihydroxyvitamin D3, 
PTH and phosphatonins such as MEPE. In the present study, the relative 
abundance of mRNA expression for PiT transporters in the small 
intestine and kidney was measured under conditions of chronic low 
phosphate diet, aging, and chronic renal failure, and compared with 
NaPi-II mRNA levels to study adaptation at the genomic level. In rats, 
renal PiT2 mRNA expression was augmented by chronic low phosphate 
diet. Results of the present study also provide compelling evidence that 
intestinal, but not renal, PiT2 gene expression is higher in young 
animals. PiT1 mRNA expression in both kidney and small intestine was 
not altered by chronic low phosphate diet or aging, highlighting the 
differential regulation of PiT1 and PiT2. Animals with chronic renal failure 
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displayed reduced intestinal and renal PiT1 and PiT2 mRNA expression. 
Furthermore, the data show that chronic treatment with the phosphaturic 
protein MEPE to chronic renal failure rats downregulates NaPi-IIb and 
PiT2 mRNA in the jejunum, but does not affect NaPi-IIa and PiT2 mRNA 
expression in the kidney. This is the first report of the effect of chronic 
renal failure on expression of PiT transporters and the effect of chronic 
treatment with MEPE on expression of both PiT and NaPi-II transporters. 
 
Rat and mice exhibit significant differences in intestinal phosphate 
handling (Marks et al., 2006; Radanovic et al., 2005). In agreement with 
previous work, data in the present study show that NaPi-IIb mRNA 
transcript is highly expressed in the mouse ileum but undetectable in the 
rat ileum. Similar levels of NaPi-IIb are present in the rat duodenum and 
jejunum. PiT1 and PiT2 are equally expressed and at significant levels in 
all three regions of rat and mouse small intestine. This contradicts a 
recent report which demonstrated minimal PiT2 mRNA expression along 
the entire length of the rat small intestine (Giral et al., 2009). Giral et al 
(2009) also found that PiT1 mRNA was highly expressed in the ileum, 
but PiT1 protein was undetectable in the ileum. The present study shows 
no segmental or species differences in the genomic expression of PiT1 
and PiT2 transporters in rat and mouse small intestine. 
 
The rat ileum has very little ability to absorb phosphate and further 
evidence for this comes from previous studies showing negligible 
expression of NaPi-IIb and PiT1 at the ileal BBM (Giral et al., 2009; 
Marks et al., 2006). In contrast to the rat, all regions of the mouse small 
intestine have the capacity to absorb phosphate (Marks et al., 2006; 
Radanovic et al., 2005). So the fact that significant levels of PiT1 and 
PiT2 mRNA are detectable in the mouse small intestine could mean that 
PiT1 and PiT2 mediate Na+-dependent phosphate absorption, 
particularly in the duodenum and jejunum, where there is minimal 
expression of both NaPi-IIb mRNA and protein (Marks et al., 2006; 
Radanovic et al., 2005).  It has been suggested that the rat ileum is a site 
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of paracellular phosphate secretion (Peters & Binswanger, 1988), but 
this statement has yet to be confirmed. 
 
The role of PiT transporters in phosphate homeostasis is only just 
emerging and their role under conditions that stimulate phosphate 
absorption, such as feeding a low phosphate diet, has yet to be defined. 
Restriction of dietary phosphate intake is used in patients with chronic 
renal failure to lower plasma phosphate levels. What is known so far is 
that PiT2 is a highly regulated protein (Breusegem et al., 2009; Giral et 
al., 2009; Villa-Bellosta et al., 2009b; Villa-Bellosta & Sorribas, 2010b). 
Villa-Bellosta et al (2009b) demonstrated that switching from a low to 
high phosphate diet inhibited PiT2-mediated transport to a greater 
degree than NaPi-IIa- and NaPi-IIc-mediated transport. Therefore, 
although both NaPi-IIb and PiT proteins transport the same substrate, 
they are differentially regulated. This is also evident from the finding that 
rat PiT2 is intermediate between NaPi-IIa and NaPi-IIc in the time taken 
for the half-maximal renal response to dietary phosphate loading (Villa-
Bellosta et al., 2009b). Present results show that animals fed a chronic 
low phosphate diet had not only a significantly increased mRNA 
expression of renal NaPi-IIa, but also increased PiT2. NaPi-IIc and PiT1 
mRNA levels were however unaffected. This parallels recent work that 
found increased protein expression of NaPi-IIa and PiT2 in phosphate-
deprived rats (Giral et al., 2009; Villa-Bellosta et al., 2009b). Therefore, 
increased renal Na+-dependent phosphate transport seen following a 
chronic low phosphate diet is mediated by genomic changes in NaPi-IIa, 
and probably PiT2. In adult rats, the relative contribution of non-NaPi-II-
mediated transport (phosphonoformic acid (PFA)-insensitive) in kidney 
has been estimated to be between 25-50%, depending on the dietary 
conditions, and PiT2 is thought to be a strong candidate for this 
component (Villa-Bellosta & Sorribas, 2010b; Picard et al., 2010). In 
double knockout mice, where both NaPi-IIa and NaPi-IIc genes were 
deleted, substantial Na+-dependent phosphate reabsorption remained 
(Segawa et al., 2009a); PiT transporters are thought to be responsible 
for this component. In mouse however, renal expression of PiT1 and 
 188 
PiT2 mRNA is not regulated by a low phosphate diet (Hoag et al., 1999; 
Tenenhouse et al., 1998).  
 
The mechanism by which low phosphate diet upregulates intestinal 
phosphate absorption does not involve changes to NaPi-IIb or PiT1 
mRNA expression (Capuano et al., 2005; Giral et al., 2009; Hattenhauer 
et al., 1999; Katai et al., 1999). The response is, therefore, thought to 
involve post-translational mechanisms, where NaPi-IIb protein 
expression at the intestinal BBM is controlled according to dietary 
phosphate intake (Capuano et al., 2005; Hattenhauer et al., 1999; Katai 
et al., 1999; Giral et al., 2009). In the present study, NaPi-IIb and PiT1 
mRNA levels were unchanged in rats fed a low phosphate diet. For the 
first time, the present study indicates that intestinal PiT2 mRNA 
expression is not regulated by a low phosphate diet.  
 
Taken together with the uptake data presented in Chapter 2, the 
increased intestinal Na+-dependent and Na+-independent phosphate 
transport seen following a chronic low phosphate diet was not due to 
changes in mRNA expression of NaPi-IIb, PiT1 or PiT2. At the protein 
level, Giral et al (2009) showed that although significant levels of PiT1 
proteins were detectable in duodenum and jejunum, their expression was 
not altered by a low phosphate or a high phosphate diet. Intestinal PiT2 
protein expression under conditions of a low phosphate diet has not yet 
been examined. Thus, although intestinal PiT2 mRNA expression is 
unchanged by a low phosphate diet, PiT2 protein level may be regulated. 
Therefore, it is critical that future studies examine intestinal PiT2 protein 
expression following the feeding of a low phosphate diet. 
 
Phosphate absorption is regulated according to body demand for 
phosphate during development. Na+-dependent phosphate uptake by 
intestinal and renal BBM vesicles decreases with age (Hoag et al., 1999; 
Silverstein et al., 1997; Xu et al., 2002a).  This is complemented at the 
genomic level, evident from the proportional age-dependent decline in 
intestinal NaPi-IIb and renal NaPi-IIc expression (Kirchner et al., 2008; 
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Segawa et al., 2002; Silverstein et al., 1997; Xu et al., 2002a). In 
contrast, expression of NaPi-IIa protein increases with age and the 
highest levels are found in adult kidney (Arar et al., 1999; Chau et al., 
2003; Sorribas et al., 1996). In the present study, expression of PiT 
transporters was analysed in young and adult rats to assess their role in 
phosphate absorption during growth. NaPi-IIa mRNA expression was 
similar in both young animals and adults, but surprisingly NaPi-IIc mRNA 
levels were also similar. It is generally accepted that NaPi-IIc expression 
is age-dependent. However, there are only two reports confirming this 
(Segawa et al., 2002; Silverstein et al., 1997). Before NaPi-IIc was 
cloned, Silverstein et al (1997) demonstrated that a specific mRNA in rat 
kidney, partially homologous to the NaPi-IIa isoform, mediated higher 
renal Na+-dependent phosphate transport in younger rats than in adults. 
Later, Segawa et al (2002) focused on rats at three developmental 
stages: sucklings (not separated from their mother, and milk is their only 
source of food), weaning animals (separated from their mother and 
subjected to some solid food), and adults. They found NaPi-IIc protein 
and mRNA expression was lowest in sucklings and highest in weaning 
animals, whilst in adults NaPi-IIc was lower. Data obtained in the present 
study did not show the age-dependent decline in NaPi-IIc mRNA 
expression. This is likely to be because sucklings were used in the 
present study instead of weaning animals, which have similar levels of 
NaPi-IIc expression to adult rats (Segawa et al., 2002). Current 
knowledge of NaPi-IIc protein, which is historically thought to play a 
minor role in kidney phosphate reabsorption, is being challenged by 
newly emerging roles for NaPi-IIc in adults, especially under 
pathophysiological conditions associated with phosphate wasting 
disorders (Bergwitz et al., 2006; Jaureguiberry et al., 2008; Segawa et 
al., 2009a & 2009b). 
 
PiT1 and PiT2 are proposed to play an insignificant role in renal 
phosphate reabsorption in mice. A study by Hoag et al (1999) showed 
that PiT1 and PiT2 are not age-dependent in wild type mice, although 
their genomic expression was age-dependent in NaPi-IIa knockout mice.. 
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The results of this present study show that, similar to the mouse, rat 
renal PiT1 and PiT2 gene expression is not age-dependent.  
 
Present data show that gene expression of NaPi-IIb is elevated in the 
duodenum and jejunum of young rats, corresponding to the increased 
Na+-dependent phosphate uptake seen in the duodenum and jejunum 
(see Chapter 2). Similar to the kidney, intestinal PiT1 mRNA expression 
was also not regulated by age. In contrast, PiT2 mRNA expression in the 
jejunum, but not the duodenum, declined with age. Therefore, the small 
intestine of young rats adapts to increased phosphate need during 
growth by expressing augmented levels of PiT2 in the jejunum, the 
intestinal region where the majority of the phosphate is absorbed (see 
Chapter 2), in addition to higher NaPi-IIb mRNA levels in both the 
duodenum and jejunum. These data provide evidence for the first time of 
region-specific adaptation of PiT transporters. It is tempting to propose 
that, combined with the uptake data from rats of the three different ages 
(see Chapter 2), the elevated phosphate transport activity in young 
animals is mediated by higher expression of both NaPi-IIb and PiT2.  
 
Information is lacking as to whether changes in mRNA data are matched 
at the protein level. Results of the present study are at the genomic level, 
which means they may not mirror the abundance of transporter protein. It 
is clear that neither renal nor intestinal PiT1 mRNA is regulated by a low 
phosphate diet and age, the two most important physiological regulators 
of phosphate absorption in mammals. 
 
In chronic renal failure, hyperphosphataemia increases vascular and soft 
tissue calcification. There is compelling evidence that PiT1 has a direct 
role in promoting calcification in vascular smooth muscle cells (Li et al., 
2006; Villa-Bellosta et al., 2009a). However, little is known concerning 
the expression of PiT transporters in the small intestine and kidney in 
chronic renal failure. Studies have reported a reduction of renal 
expression of NaPi-IIa in chronic renal failure rats (Bacic et al., 2006; 
Marks et al., 2006; Traebert et al., 2000). In keeping with these reports, 
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present data show that declining renal function is associated with 
downregulation of NaPi-IIa mRNA. In agreement with earlier reports 
(Imanishi et al., 1996; Nagano et al., 2006), chronic renal failure animals 
used in the present work showed secondary hyperparathyroidism with 
elevated plasma PTH levels. PTH is a major regulator of renal phosphate 
handling and causes both acute and chronic reductions in renal tubular 
phosphate reabsorption by promoting the internalisation, and subsequent 
lysosomal degradation of NaPi-IIa from the BBM (Bacic et al., 2006; 
Murer et al., 2000; Traebert et al., 2000). In contrast, PTH has no direct 
effect on intestinal phosphate transport. The chronic renal failure-induced 
reduction in NaPi-IIa mRNA expression may be mediated by the 
increased circulating PTH levels. Although PTH levels are elevated in 
chronic renal failure, the involvement of PTH in renal responses to 
chronic renal failure is uncertain, due to possible tissue resistance to the 
hormone (Rodriguez et al., 1991; Massry et al., 1973). 
 
Segawa et al (2007) provided compelling evidence that PTH is also a 
major regulator of NaPi-IIc.  In their study, NaPi-IIc protein levels were 
augmented in thyroparathyroidectomised rats, and acute administration 
of PTH caused a decrease in NaPi-IIc proteins, an effect that involved 
retrieval of NaPi-IIc protein from the BBM. Furthermore, Picard et al 
(2010) showed that PTH completely inhibited PFA-sensitive Na+-
dependent phosphate transport in the kidney (Picard et al., 2010). The 
PFA-sensitive uptake component in the kidney represents both NaPi-IIa- 
and NaPi-IIc-mediated transport. Although results presented in this 
chapter show that the mean value for renal NaPi-IIc mRNA expression is 
reduced by chronic renal failure, it was not statistically significant 
(P=0.09). However, the trend implies that chronic renal failure affects 
NaPi-IIc expression at the genomic level. 
 
Hyp is a mouse mutation characterised by phosphate wasting, due to a 
defect in Na+-dependent phosphate transport at the renal BBM. In the 
Hyp mouse, the serum phosphate level is lower than normal and NaPi-
IIa mRNA is reduced by some 50% (Roy et al., 1997; Tenenhouse et al., 
 192 
1998). Interestingly, the study of Tenenhouse et al (1998) showed that 
renal mRNA expression of PiT1 but not PiT2 is higher in the Hyp mouse, 
suggesting that PiT1 plays a compensatory role for NaPi-IIa under 
phosphate wasting conditions in mouse. Therefore, the data of 
Tenenhouse et al (1998) suggests that the adaptive changes in PiT1 
mRNA levels contribute to the effects of the Hyp mutation on the renal 
handling of phosphate. What happens to Na+-dependent phosphate 
transport across the small intestine under these conditions is however 
unknown. Therefore, it was of interest to compare the regulation of PiT1 
and PiT2 during hyperphosphataemia. Results presented in this chapter 
provide evidence, for the first time, that in chronic renal failure rats levels 
of both PiT1 and PiT2 mRNA are reduced in the kidney. Picard et al 
(2010) recently demonstrated that in the kidney of control rats, PTH not 
only reduced PFA-sensitive NaPi-IIa- and NaPi-IIc-mediated transport, 
but also PFA-resistant Na+-dependent phosphate uptake, suggesting 
that PiT transporters are responsible for this PFA-resistant component, 
and that they are inhibited by PTH (Picard et al., 2010).  Similarly, PTH 
inhibited PiT1-mediated Na+-dependent phosphate uptake in human 
embryonic kidney cells in vitro (Fernandes et al., 1999). The reduced 
levels of renal PiT1 and PiT2 mRNA observed in the present study, 
therefore, may be mediated by the inhibitory action of PTH. 
 
The intestinal handling of phosphate and the genomic and protein 
expression of NaPi-IIb are reported to be unaffected in chronic renal 
failure rats (Douard et al., 2010; Marks et al., 2007). Data presented in 
the present study however show that NaPi-IIb mRNA expression is 
reduced in chronic renal failure rats. The apparent discrepancy may be 
explained by the fact that the present study used chronic renal failure 
model that displayed both hyperphosphataemia and secondary 
hyperparathyroidsim, which was induced by feeding chronic renal failure 
animals with a high phosphate/low calcium diet to accentuate the 
features normally seen in chronic renal failure animals that have not 
been given any dietary treatment. Thus, the severity of 
hyperphosphataemia may have differential effects on the intestinal 
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expression of Na+-dependent phosphate transporters. Evidently, in 
patients with end-stage renal disease (severe chronic renal failure 
requiring haemodialysis), jejunal phosphate absorption is significantly 
reduced (Davis et al., 1983). A similar phenomenon has also been 
reported for NaPi-IIa, where NaPi-IIa protein and mRNA expression are 
reduced only in severe chronic renal failure animals (Laouari et al., 
1997). Their study demonstrated that vitamin D3 deficiency of chronic 
renal failure reduced active, but not passive, phosphate absorption by 
50%, an effect likely to have been mediated by reduced expression of 
Na+-dependent phosphate transporters. 
 
Data presented in this chapter provide evidence that intestinal 
expression of PiT1 and PiT2 mRNA is reduced in chronic renal failure 
rats. The mechanism through which this downregulation is achieved is 
not clear at the present time. As discussed previously, intestinal and 
renal handling of phosphate is regulated by different mechanisms and 
PTH is not thought to play a direct role in the regulation of intestinal 
phosphate absorption (Borle  et al., 1963; Murer et al., 2001; Nemere & 
Larsson, 2002).  Decreased secretion of 1,25-dihyrdroxyvitamin D3 may 
be responsible for causing the reduced intestinal PiT1 and PiT2 and/or 
NaPi-IIb mRNA expression, since plasma 1,25-dihydroxyvitamin D3 
levels were reduced in the chronic renal failure animals used in the 
present work. Although it is clear that NaPi-IIb expression is increased by 
1,25-dihyrdroxyvitamin D3, there is only one published report of 1,25-
dihyrdroxyvitamin D3 regulation of PiT transporters: Katai et al (1999) 
demonstrated a greater rate of PiT2-mediated transport and increased 
expression of PiT2 mRNA in enterocytes from rats treated with 1,25-
dihyrdroxyvitamin D3. 
 
The phosphaturic protein MEPE inhibits both intestinal and renal Na+-
dependent phosphate transport in healthy animals (David et al., 2009; 
Marks et al., 2008; Rowe et al., 2004). Acute inhibition of renal 
phosphate reabsorption by MEPE is mediated by decreased NaPi-IIa 
protein expression at the BBM (David et al., 2009; Marks et al., 2008). 
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However, whether MEPE has a similar effect on phosphate transporter 
expression in chronic renal failure is unknown. The present work, 
therefore, focused on whether chronic MEPE treatment can further 
downregulate the expression of intestinal and renal phosphate 
transporters in chronic renal failure. To study this, the genomic 
expression of renal and jejunal NaPi-II and PiT transporters were 
analysed. Since there are currently no suitable antibodies available for 
detection of NaPi-IIb and PiT transporters in rats, expression of these 
proteins could not be assessed. Data show that renal expression of 
NaPi-IIa, NaPi-IIc, PiT1 and PiT2 mRNA is not significantly affected by 
chronic treatment with MEPE in chronic renal failure rats. Although mean 
values for expression of these transporters were increased by MEPE, the 
changes did not reach significance. 
  
In the small intestine, acute infusion of MEPE is known to decrease 
jejunal, but not duodenal, phosphate absorption in a dose-dependent 
manner (Marks et al., 2008). Although the study of Marks et al (2008) did 
not involve the analysis of expression levels of Na+-dependent 
phosphate transporters at the intestinal BBM, it is unlikely that the acute 
3-hour infusion caused a change at the genomic level. Data presented in 
this chapter show that chronic treatment with MEPE reduced NaPi-IIb 
and PiT2 mRNA expression in the jejunum of chronic renal failure 
animals. The mechanism of this action is unknown and may be direct or 
indirect. Intestinal PiT1 mRNA levels were not altered by MEPE. Taken 
together, these findings show that jejunal PiT2 is as highly regulated as 
NaPi-IIb, since both transporters are regulated at the genomic level by 
aging, chronic renal failure, and MEPE.  
 
Low dietary intake of phosphate and the use of oral phosphate binders 
are currently used to control hyperphosphataemia in man. However, 
these approaches have several disadvantages that make them not ideal 
for reducing plasma levels of phosphate. An alternative method would be 
to directly target renal and intestinal PiT transporters, in addition to NaPi-
IIa and NaPi-IIb transporters. The small intestine is arguably a better 
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target for agents designed to control hypephosphataemia, since chronic 
renal failure progressively reduces renal function. Thus, MEPE is a 
promising candidate for the suppression of intestinal phosphate uptake 
to reduce plasma levels of phosphate. Modulation of PiT expression and 
PiT-mediated transport in small intestine might also be used for 
prevention and treatment of hyperphosphataemia. 
 
4.5. Conclusion 
 
There are no clear regional differences between the rat and mouse 
regarding the intestinal expression of PiT1 and PiT2. These proteins are 
equally expressed at the genomic level in all three regions of the small 
intestine. Changes in intestinal Na+-dependent phosphate transport 
mediated by a chronic low phosphate diet does not require de novo RNA 
synthesis of NaPi-IIb, PiT1 and PiT2. For the kidney, adaptation to a 
chronic low phosphate diet is mediated by changes to both NaPi-IIa and 
PiT2 expression. Young rats express higher levels of both NaPi-IIb and 
PiT2 mRNA in the small intestine in contrast to the kidney, which shows 
no obvious age-dependent adaptation of NaPi-IIa, NaPi-IIc, PiT1 and 
PiT2 mRNA levels. Chronic renal failure reduces PiT1 and PiT2 mRNA 
expression in both rat small intestine and kidney. This effect might be 
mediated by decreased 1,25-dihyrdroxyvitamin D3 and/or increased 
plasma PTH levels. However, the mechanism of 1,25-dihyrdroxyvitamin 
D3 and PTH on PiT expression remains to be elucidated. MEPE 
successfully downregulates intestinal expression of NaPi-IIb and PiT2 
mRNA in chronic renal failure, but does not significantly affect expression 
of renal phosphate transporters, although there was a trend towards 
stimulation. PiT transporters have been strongly implicated in various 
conditions of altered phosphate balance; therefore, it is important to 
characterise further the role of PiT transporters in both normal and 
disease conditions. This study extends our previously limited knowledge 
of the regulation of PiT transporters and may help to define the ways in 
which these proteins are regulated. 
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5.0. The effect of duodenal phosphate instillation 
on intestinal phosphate uptake and expression of 
renal phosphate transporters 
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5.1. Introduction 
 
The small intestine and kidney are highly specialised organs that have 
the capacity to communicate with each other to co-ordinate regulation of 
certain plasma constituents. An example of such regulation is seen after 
oral sodium loading. Sodium homeostasis involves an enteric-renal 
communication axis; the intestine produces guanylin and uroguanylin 
that are important for natriuresis and these peptides influence intestinal 
and renal epithelial cells to increase excretion of sodium and water 
(Currie et al., 1992; Hamra et al., 1993; Kita et al., 1999; Sindic  & 
Schlatter, 2007). An enteric-renal axis has also been reported for calcium 
and potassium (Conigrave & Brown, 2006; Lee et al., 2007).  Calcium-
sensing receptors are widely expressed in epithelial cells of the 
gastrointestinal tract and kidney, and the receptor plays a key role in 
calcium homeostasis (Chattopadhyay et al., 1998; Conigrave & Brown, 
2006; Hebert et al., 2004; Lee et al., 2007).  
 
Berndt et al (2007) demonstrated that instillation of a high concentration 
of sodium-phosphate (1.3 M) into the proximal small intestine increased 
renal phosphate excretion; an acute effect achieved within 20 min. When 
an equimolar concentration of sodium chloride was instilled into the 
duodenum no effect on phosphate excretion was observed, and 
instillation of 1.3 M phosphate into the stomach was also without effect 
on phosphate excretion, indicating a specific effect of phosphate in the 
upper small intestine. Furthermore, the response was not due to 
changes in serum levels of phosphate, PTH, Fibroblast growth factor-23 
(FGF-23) or secreted frizzled-related protein-4 (sFRP-4), or changes in 
glomerular filtration rate or the involvement of a neural reflex.  
Additionally, Berndt et al (2007) showed that duodenal infusion of an 
extract prepared from the duodenal mucosa had a phosphaturic effect. 
Thus, the duodenum is proposed to sense phosphate and secrete a 
phosphaturic humoral factor that is able to communicate rapidly with the 
kidney to regulate renal phosphate reabsorption. This factor is so far 
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unidentified and whether it affects phosphate absorption locally, in other 
regions of the small intestine, is also undetermined.  
 
PTH is a major regulator of renal phosphate reabsorption and it is 
capable of changing renal phosphate transport within minutes. Martin et 
al (2005) showed that the introduction of phosphate (60 µmol) into the 
upper intestinal tract rapidly (within 10 minutes) increased plasma levels 
of phosphate and PTH, which throws some doubt on the mechanism 
causing the increased phosphate excretion in the experiments of Berndt 
et al (2007). Martin et al (2005) also showed that duodenal infusion of 
phosphonoformic acid (PFA - NaPi-IIb inhibitor) increased PTH levels 
rapidly (within 5 minutes), but this effect was independent of changes in 
plasma phosphate levels.  
 
Recently, matrix extracellular phosphoglycoprotein (MEPE) mRNA was 
found to be highly expressed in the duodenum, almost 17-fold higher 
than in the jejunum and ileum (Marks et al., 2010). The phosphatonin 
MEPE, found also in the kidney (Ogbureke & Fisher, 2005), inhibits 
phosphate absorption in both the small intestine and the kidney, and its 
actions in the small intestine are independent of changes in levels of 
1,25-dihydroxyvitamin D3, PTH and FGF-23 (David et al., 2009; Marks et 
al., 2008; Rowe et al., 2000), as observed for the duodenal phosphaturic 
factor proposed by Berndt et al (2007). Thus, MEPE is a potential 
candidate for the ‘intestinal phosphatonin’. However, the pathway 
through which MEPE inhibits phosphate absorption has not yet been 
characterised. The inhibitory effect of MEPE on intestinal phosphate 
absorption is confined to the jejunum and does not affect the duodenum. 
It is therefore of interest to examine whether the putative intestinal 
phosphatonin affects phosphate uptake in the jejunum following 
exposure of the intestinal mucosa to high phosphate concentrations. 
 
The 1.3 M phosphate concentration used by Berndt et al (2007) for 
instillation experiments is a non-physiological choice of phosphate 
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concentration, and the study needs to be repeated using phosphate 
levels normally seen after ingestion of a phosphate-containing meal. 
Furthermore, although the study by Berndt et al (2007) showed an 
increase in fractional excretion of phosphate, renal expression of 
phosphate transporters NaPi-IIa and NaPi-IIc was not determined.  Such 
information would be a key indicator of changes in renal Na+-dependent 
phosphate transport.  
 
Due to declining kidney function in chronic renal failure, the kidney 
cannot be targeted for treatment of hyperphosphataemia. The small 
intestine on the other hand is suitable, since intestinal phosphate 
absorption is not significantly altered in chronic renal failure (Douard et 
al., 2010; Marks et al., 2007). It is, therefore, important to investigate 
whether a proposed intestinal mucosal factor affects intestinal phosphate 
transport since the factor might be a potential candidate for the control of 
serum phosphate levels in hyperphosphataemia. 
  
The aim of the present study was to establish whether acute duodenal 
exposure to high millimolar (physiological) and molar (non-physiological) 
concentrations of phosphate causes local adaptation of phosphate 
absorption in the upper small intestine, and whether the claimed effect 
on renal phosphate excretion, by Berndt et al (2007), is mediated 
through changes in expression of NaPi-IIa or NaPi-IIc proteins. This was 
investigated by instilling phosphate into in vivo duodenal loops for 30 
minutes, and subsequently measuring phosphate uptake using the 
everted sleeve technique. The expression of phosphate transporters in 
BBM prepared from kidneys taken from these animals was also 
quantified. 
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5.2. Materials and Methods  
 
5.2.1. Animals 
Male Sprague Dawley (SD) rats aged 8 weeks were obtained from 
Charles River Laboratories (UK) and used in accordance with the 
Animals (Scientific Procedures) Act 1986. Control rats were allowed ad 
libitum access to a standard rodent chow containing 0.52% phosphate 
(Diet RM1, SDS Ltd, Witham, Essex, UK), and to water. 
During anaesthesia, Animals were checked for pedal withdrawl to a 
pinch and eye-blink reflex before starting surgery. Additional anaesthetic 
was given if animals showed any of these two reflex responses. 
 
5.2.2. Phosphate instillation into the duodenum 
 
5.2.2.1. 15 mM phosphate  
The procedures and buffers used were identical to those given by Berndt 
et al (2007) except that the instilled solution in the duodenum was 
prevented from entering the jejunal lumen by setting a ligature at the 
duodenal-jejunal junction. This allowed investigation of the local effect of 
duodenal instillation of phosphate on jejunal phosphate transport. Rats 
were anaesthetised with an intraperitoneal injection of 45 mg/kg 
pentobarbitone sodium and their body temperature was maintained at 
37°C throughout the instillation period using a thermostatically controlled 
heating blanket. The duodenum was cannulated with a small incision ~1 
cm from the pylorus. A needle was inserted and tied in place by a 
ligature. About 5 cm distal to the needle, a ligature was placed to create 
a closed duodenal loop. 1 ml of 15 mM NaH2PO4, dissolved in distilled 
water (pH 5), was then infused via the duodenal needle over a period of 
15 sec.  For control experiments, 1 ml of 15 mM NaCl was similarly 
instilled. An instillation period of 30 min was used.  
 
5.2.2.2. 1.3 M phosphate 
This was carried out as described above, except 1 ml of 1.3 M NaH2PO4 
(test buffer), or 1.3 M NaCl (control buffer) dissolved in distilled water (pH 
 201 
5) was used. Berndt et al (2007) do not mention the solution in which 
sodium chloride and sodium phosphate were dissolved; the present 
study opted to use distilled water because of the high solution osmolarity. 
 
5.2.3. Phosphate uptake by everted intestinal sleeves 
Phosphate uptake by duodenum (the region used for instillation) and 
jejunum (2-3 cm from the ligament of Treitz) was measured after 30 min 
exposure of the duodenum to the instillation solutions. The everted 
sleeve technique was used and the procedure was as described in 
section 2.2.2.1. The incubation buffer contained 0.1 mM 32P. 
 
5.2.4. Preparation of kidney BBM  
Kidney BBM were prepared using a double Mg+ chelation procedure at 
4°C, as described previously by Biber et al (1981). Both kidneys were 
excised and transferred to a beaker containing ice cold 154 mM NaCl. 
Each kidney was placed on an ice-cold glass surface and the fat and 
capsule was removed and the kidney was sliced into 2 mm sections.  
The outer layer of cortex was removed and the remainder of the kidney 
was discarded. The weight of the cortex (representing proximal tubules) 
was recorded and in some cases kidney sections were pooled. A starting 
cortex weight of about 1 g was homogenised using an Ultra Turrax 
homogeniser for 2 min at setting 5 in 30 ml R1 buffer (pH 7.4) containing, 
in mM: 300 mannitol, 12 Tris-HCl, 5 EGTA and protease inhibitors 
(Sigma, UK). Deionised water (42 ml) and MgCl2 was added to the 
homogenate to a final Mg concentration of 12 mM, and stirred 
continuously for 15 min. This mixture was centrifuged at 3,000 g for 15 
min and the supernatant further centrifuged at 27,000 g for 30 min. The 
resulting pellet was resuspended in 20 ml R2 buffer (pH 7.4) containing, 
in mM: 150 mannitol, 6 Tris-HCl, 2.5 EGTA and protease inhibitors, using 
a hand-held Teflon homogeniser.  This mixture was stirred with 12 mM 
MgCl2 for 15 min and centrifuged twice as described above. The 
resulting pellet was resuspended in 20 ml R3 buffer (pH 7.4) containing, 
in mM: 300 mannitol, 12 Tris-HCl, 2.5 EGTA and protease inhibitors, 
using the hand-held homogeniser, and centrifuged at 27,000 g for 30 
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min. The final pellet was resuspended in ~500 µl R3 buffer, using a 21-
gauge needle fitted to a syringe, to a final protein concentration of ~5-9 
mg/ml. Aliquots of BBM suspension were immediately frozen in liquid 
nitrogen and stored at -20°C. 
 
5.2.5. Determination of protein concentration and vesicle purity 
Protein concentration was determined using the Bradford assay, as 
described in section 2.2.4.3. 
 
BBM purity was assessed using alkaline phosphatase assay, as 
described in section 2.2.4.4. BBM showed enrichment of 6.12 ± 0.43 fold 
(n=24) with respect to the starting homogenate. 
 
5.2.6. Western Blotting 
The NaPi-IIa and NaPi-IIc antibodies listed in Table 5.1 were used to 
quantify changes in levels of these proteins at the BBM, as described in 
section 2.2.6.1. β-Actin was used as a loading control. 
 
5.2.7. Statistical analysis.  
Data are presented as means ± SEM. The unpaired t-test was used and 
group differences were considered statistically significant if P <0.05; n, 
represents the number of samples per group.  
 20
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5.3. Results 
 
5.3.1. Effect of 15 mM phosphate instillation on intestinal phosphate 
uptake 
A 15 mM phosphate concentration was chosen to represent that normally 
present in the intestinal lumen following ingestion of a high phosphate-
containing diet. Following ingestion of a normal diet, the average ‘free’ 
(unbound) concentration of phosphate noted in the lumen of stomach and 
duodenum of rats is ~15 and 7 mM, respectively (see Chapter 2, Table 
2.1). In contrast to the protocol of Berndt et al (2007), the test solution 
instilled into the duodenum was prevented from entering the jejunum. 
 
The jejunum displayed a higher rate of phosphate uptake than the 
duodenum (Figs. 5.1), as observed in Chapter 2.  Rats instilled with 15 
mM phosphate expressed similar levels of phosphate transport in the 
duodenum (Fig. 5.1A) and jejunum (Fig. 5.1B), as those instilled with 
control solution of equimolar concentration of saline.  
 
5.3.2. Effect of 15 mM phosphate instillation on expression of Na+-
dependent phosphate cotransporters at the renal BBM 
To determine whether the decreased renal phosphate reabsorption 
reported by  Berndt et al (2007) is mediated through altered expression of 
Na+-dependent phosphate transporters at the renal BBM, NaPi-IIa and 
NaPi-IIc proteins were quantified using western blotting. Results revealed 
no statistically significant difference in the expression of NaPi-IIa (P=0.36) 
or NaPi-IIc (P=0.15) between the two groups (Fig 5.2), although there 
was a trend for decrease in NaPi-IIa expression with 15 mM phosphate 
instillation. It was not possible to obtain urinary phosphate excretion data, 
since preliminary data showed that stress of the surgery caused 
instability in the glomerular filtration rate. 
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Figure 5.1. Phosphate transport measured in vitro using A: duodenum 
and B: jejunum, following instillation of 1ml 15 mM saline (NaCl) or 15 
mM phosphate (KH2PO4) into the duodenum. Uptake was measured for 2 
min using buffer containing 0.1 mM 32P. Data are means ± SEM. n = 6.  
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Figure 5.2. Quantification of NaPi-IIa and NaPi-IIc proteins in renal BBM 
using western blotting. BBM was prepared from animals instilled with 1 ml 
of 15 mM saline (clear bars) or 15 mM phosphate (shaded bars) into the 
duodenum for 30 min. β-actin was used as a loading control to calculate 
expression of NaPi-IIa and NaPi-IIc proteins. Results are expressed as 
means ± SEM. n = 6. 
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5.3.3. Effect of 1.3 M phosphate instillation on intestinal phosphate 
uptake 
To mimic the effects seen by Berndt et al (2007), 1.3 M phosphate was 
instilled into the duodenum for 30 minutes. An equimolar concentration of 
saline was used as a control. As observed with 15 mM instillation, jejunal 
phosphate transport was unaffected by instillation of 1.3 M phosphate 
into the duodenum (Fig 5.3B).  
 
Interestingly, phosphate transport in the duodenum (Fig. 5.3A) was 
upregulated by 59% following instillation of 1.3 M phosphate, when 
compared with instillation of 1.3 M saline. A similar transport response 
was reported in BBM vesicles from duodenum, but not the jejunum, 
following acute feeding of a high phosphate diet (for 4 hours) to rats 
(Giral et al., 2009). Interestingly, duodenal, but not jejunal, phosphate 
transport activity was over 4-fold lower with 1.3 M phosphate instillation 
compared with 15 mM phosphate instillation (Fig. 5.1A vs Fig. 5.3A). This 
might be due to the much higher osmolarity of the 1.3 M phosphate 
solution.   
 
5.3.4. Effect of 1.3 M phosphate instillation on expression of Na+-
dependent phosphate cotransporters at the renal BBM  
As observed with instillation experiments using 15 mM phosphate, 1.3 M 
phosphate instillation did not cause a significant change in the BBM 
expression of NaPi-IIa or NaPi-IIc proteins when compared with control 
saline instillation (Fig. 5.4). This means that the increased urinary 
phosphate excretion observed by Berndt et al (2007) following instillation 
of 1.3 M sodium-phosphate into the duodenum is not due to reduced 
expression of transporter protein at the renal BBM.   
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Figure 5.3. Phosphate transport measured in vitro using A: duodenum 
and B: jejunum, following instillation of 1ml of 1.3 M saline (NaCl) or 1.3 
M phosphate (KH2PO4) into the duodenum. Uptake was measured for 2 
min using buffer containing 0.1 mM 32P. Data are means ± SEM. n = 6. 
***P <0.005 compared with 1.3 M saline instillation. 
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Figure 5.4. Quantification of NaPi-IIa and NaPi-IIc proteins in renal BBM 
using western blotting. BBM was prepared from animals instilled with 1 ml 
of 1.3 M saline (clear bars) or 1.3 M phosphate (shaded bars) into the 
duodenum for 30 min. β-actin was used as a loading control to calculate 
expression of NaPi-IIa and NaPi-IIc proteins. Results are expressed as 
means ± SEM. n = 6. 
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5.4. Discussion  
 
Despite our understanding of the mechanisms involved in phosphate 
homeostasis, little is known about the primary events involved in the 
intestinal detection of changes in dietary phosphate load and the 
subsequent downstream cascade of regulatory events. Past evidence 
demonstrates that the acute effect of dietary phosphate is independent of 
known regulators such as vitamin D3, PTH and phosphatonins (Berndt & 
Kumar, 2007; Berndt et al., 2005; Brautbar et al., 1979; Capuano et al., 
2005; Segawa et al., 2004; Trohler et al., 1976). Furthermore, control of 
phosphate absorption by the major regulators generally occurs over a 
period of hours or days, rather than minutes (Bacic et al., 2006; Murer et 
al., 2000; Sommer et al., 2007). Berndt et al (2007) recently 
demonstrated that instillation of phosphate into the duodenum caused an 
acute increase in the fractional excretion of phosphate within 20 minutes.  
Replication of their experiments in the present study proved to be difficult, 
since their original publication stated that the instillate contained 1.3 mM 
phosphate, and a subsequent erratum amended the phosphate 
concentration to 1.3 M (Berndt et al., 2007). The reason behind the use of 
a supra-physiological concentration of phosphate (which is also 
hypertonic) was not justified. 
An ‘intestinal phosphatonin’ was proposed to be responsible for the rapid 
reduction in renal phosphate reabsorption, since levels of PTH, the main 
hormone involved in phosphate balance, and FGF-23, were unaltered. 
Nishida et al (2006) also observed in man an increased fractional 
excretion of phosphate that was independent of changes in FGF-23 
levels within an hour of ingestion of a high phosphate diet (Nishida et al., 
2006). The present study examined the local effect on intestinal 
phosphate absorption induced by duodenal instillation of physiological 
(15 mM) and non-physiological concentrations (1.3 M) of phosphate, 
using the everted sleeve technique. Findings in the present study 
demonstrated that the instillation of 15 mM phosphate into the duodenum 
did not affect either phosphate uptake by the duodenum and jejunum or 
NaPi-IIa and NaPi-IIc protein expression at the renal BBM. The only 
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significant effect observed was an increase in phosphate uptake in the 
duodenum, but not jejunum, following instillation of 1.3 M phosphate. 
Duodenal instillation of 1.3 M phosphate did not cause corresponding 
changes in expression of NaPi-IIa and NaPi-IIc proteins at the renal BBM.  
 
Several reports suggest that phosphate regulation involves a bone-kidney 
axis, since phosphatonins such as FGF-23 and MEPE are bone-derived 
and act on the kidney to regulate renal phosphate reabsorption (Quarles, 
2003; Rowe et al., 2004; Shirley et al., 2010). This, in conjunction with a 
gut-renal cross talk proposed by Berndt et al (2007), may help maintain 
plasma phosphate concentrations within a narrow range. The phosphate-
sensing effect, in gut-renal cross talk, is specific to the proximal small 
intestine, since the same response was not elicited by the stomach 
(Berndt et al., 2007). Certain regions of the gastrointestinal tract are able 
to sense different nutrients (Buchan, 1999; Flemstrom & Sjoblom, 2005; 
Furness et al., 1999); therefore, the idea that phosphate is also sensed 
by the small intestine has been proposed by several workers. However, 
the potential phosphate-sensing receptor and the mechanisms involved 
are so far uncharacterised. 
 
An increased urinary phosphate excretion might be the result of a parallel 
change in plasma phosphate concentration (Fiske, 1921).  However, the 
renal response to raised plasma phosphate concentration depends on 
maximum tubular reabsorption (Tm) of phosphate as a result of NaPi-IIa 
transporters at the renal brush-border membrane. The observations of 
Berndt et al (2007) could be explained by a reduction in Tm leading to 
excess phosphate being excreted in the urine. PTH has been shown to 
lower Tm. The proposed phosphaturic factor might therefore have 
reduced Tm under the experimental conditions used by Berndt et al 
(2007). 
 
MEPE is a possible candidate for an ‘intestinal phosphatonin’, since it is 
expressed in the proximal small intestine and induces phosphaturia 
(Shirley et al., 2010; Marks et al., 2008 & 2010). NaPi-IIb, the primary 
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intestinal Na+-dependent phosphate transporter that has been 
characterised, is another candidate for a phosphate sensor, since an 
acute intestinal phosphate load increases serum phosphate levels in wild 
type, but not NaPi-IIb-null, mice (Sabbagh et al., 2009). 
 
Several reports have claimed that phosphaturic factors may be released 
from other organs, such as the liver. Phosphaturia and 
hypophosphataemia are frequently observed following liver injury and 
hepatectomy, an effect independent of changes in the major phosphate 
regulators FGF-23, FGF-7, sFRP-4, and PTH (George & Shiu, 1992; 
Pomposelli et al., 2001; Smyrniotis et al., 2003; Salem & Tray, 2005; 
Dawson et al., 1987; Nafidi et al., 2007). However, the phosphatonin 
MEPE, and ASARM (Acidic, Serine- and Aspartic acid-Rich Motif) 
peptides might be involved in this response, since the liver contains an 
abundant source of the protease cathepsin B that can convert MEPE into 
ASARM (Nafidi et al., 2009). This may be relevant to the communication 
axis between the small intestine and kidney in phosphate handling.  
 
The observation of Berndt et al (2007) raises the question of whether the 
proposed duodenal factor causes a local effect in the small intestine. The 
present study used the everted sleeve method to investigate phosphate 
uptake in the duodenum and jejunum, the two main regions involved in 
phosphate transport, following instillation of phosphate into the 
duodenum for 30 minutes. A concentration of 15 mM phosphate was 
initally used, since this represents the ‘free’ (unbound) phosphate 
concentration in the upper gastrointestinal tract (see Chapter 3, Table 
3.1). Data shows that duodenal and jejunal phosphate uptake was 
unaltered by duodenal exposure to 15 mM phosphate. This is not 
surprising, considering that dietary adaptation to phosphate levels in the 
small intestine involving Na+-dependent phosphate cotransporters is a 
slow process compared to the kidney (Radanovic et al., 2005). 
 
Additionally, solution containing 1.3 M phosphate was also instilled into 
the duodenum to assess whether this supra-physiological level of 
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phosphate would have a local effect on phosphate transport. Although 
the jejunum transported similar levels of phosphate when exposed to 1.3 
M phosphate or equimolar concentration of saline, the duodenum 
interestingly exhibited an increase of 1.6 fold in phosphate transport with 
1.3 M phosphate instillation. Acute regulation of phosphate uptake in 
duodenal, but not jejunal, BBM vesicles was reported previously following 
an acute feeding of a high phosphate diet (Giral et al., 2009). The study 
of Giral et al (2009) demonstrated that the increased duodenal Na+-
dependent phosphate uptake was associated with decreased NaPi-IIb 
protein expression in the duodenum.  Renal expression of NaPi-IIa 
protein was also reduced. Although the present study noted a similar 
acute increase in duodenal but not jejunal phosphate uptake, studies of 
NaPi-IIb protein expression were not possible, since there are no reliable 
commercial antibodies for NaPi-IIb protein detection in rats (see Chapter 
2, section 2.4), and access to the antibody used by Giral et al (2009) was 
not possible.  
 
The study of Berndt et al (2007) showed that renal regulation imposed by 
duodenal instillation of a solution containing a high level of phosphate 
occurs independently of changes in PTH, FGF-23, sFRP-4 and plasma 
phosphate levels. The phosphaturic factors PTH, FGF-23 and sFRP-4 
decrease renal phosphate reabsorption by causing the retrieval of renal 
NaPi-IIa transporters from the BBM (see Chapter 1 for further details). 
The phosphaturic factor released from the duodenum is, therefore, also 
likely to reduce renal phosphate reabsorption via the same cellular 
mechanism. Berndt et al (2007), however, did not quantify changes in 
renal NaPi-II proteins, despite the availability of antibodies for NaPi-IIa 
and NaPi-IIc. Thus, the present study examined changes in NaPi-IIa and 
NaPi-IIc proteins at the renal BBM following duodenal instillation of 15 
mM or 1.3 M phosphate. The results showed no change in NaPi-IIa and 
NaPi-IIc expression following instillation of either concentration of 
phosphate.  
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The fact that the present study could not detect a significant decrease in 
NaPi-IIa protein expression may be due to the experimental protocol. A 
duodenal instillation period of 30 minutes was chosen, whereas Giral et al 
(2009) observed a decrease in NaPi-IIa protein 4 hours after the animals 
were switched from a low phosphate diet (of 7 days duration). Thus, 
switching from one extreme diet to another is more likely to induce 
adaptation compared with conditions used in the present study. 
Therefore, the findings of increased renal phosphate excretion reported 
by Berndt et al (2007) are unlikely to be due to reduced levels of NaPi-IIa 
or NaPi-IIc proteins at the BBM.  
 
Interestingly, inhibition of renal phosphate reabsorption by PTH occurs 
via two distinct pathways one involving the retrieval of NaPi-IIa from the 
BBM, and the other involving no change in the membrane abundance of 
NaPi-IIa protein (see section 1.9.2.2 for further details). The latter 
pathway involves the ERK signal transduction pathway (Lederer et al., 
2000). For example, potassium deficiency decreases renal Na+-
dependent phosphate transport but increases abundance of NaPi-IIa at 
the BBM (Inoue et al., 2004). This post-translational reduction of Na+-
dependent phosphate transport in potassium deficiency is facilitated by 
increased partitioning of NaPi-IIa into cholesterol-, sphingomyelin-, and 
glycosphingolipid-enriched BBM microdomains. Other studies have 
further supported the effect of alterations in membrane lipid composition 
on NaPi-IIa-mediated transport at the BBM (Breusegem et al., 2005; Levi 
et al., 1995; Zajicek et al., 2001). The study of Bielesz et al (2006) 
demonstrated that diurnal increases in renal phosphate excretion were 
linked only moderately to a decrease in renal Na+-dependent phosphate 
transport, and that the abundance of NaPi-IIa was not altered. They 
proposed that diurnal changes in urinary phosphate excretion are 
dependent on changes in serum phosphate concentration and tubular 
reabsorptive threshold, and not NaPi-IIa expression at the BBM. 
Therefore it remains possible that duodenal instillation of 15 mM and/or 
1.3 M phosphate could have inhibited renal BBM phosphate transport 
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without affecting the BBM abundance of NaPi-IIa within the 30 minute 
time period used.  
 
Although regulation of proximal tubular phosphate reabsorption is largely 
attributed to changes in the abundance of NaPi-IIa at the BBM, other 
transporters are also likely to be involved in phosphate uptake. Evidence 
is emerging that type III (PiT) transporters may be involved in phosphate 
transport. PiT1 and PiT2 are Na+-dependent phosphate transporters 
expressed at the intestinal and renal BBM, respectively (Giral et al., 2009; 
Villa-Bellosta et al., 2009b). Data presented in Chapter 4 established the 
genomic upregulation of renal PiT2 by phosphate diet, a conclusion also 
made by Giral et al (2009) who demonstrated upregulation of renal PiT2 
protein following dietary restriction of phosphate. The present study also 
revealed that significant levels of PiT2 mRNA is found in the rat small 
intestine (see Chapter 4) and an in vitro study showed intestinal PiT2 
regulation by 1,25-dihydroxyvitamin D3 (Katai et al., 1999). It was not 
possible to detect PiT1 and PiT2 proteins in the present study due to lack 
of suitable antibodies; access to the antibodies used by Giral et al (2009) 
was not possible.  
 
A long-standing hypothesis concerning phosphate homeostasis is that 
phosphate-sensing may be an integral mechanism in certain organs to 
communicate changes in local phosphate levels to other organs. Some 
reports have hypothesised that PiT2 transporters may act as a 
‘phosphate sensor’ (Rodrigues & Heard, 1999; Salaun et al., 2004), 
although there is a lack of experimental evidence for this suggestion. 
PiT1, the Na+-dependent phosphate transporter present in the 
parathyroid glands, was proposed to act as a ‘phosphate sensor’ in this 
tissue, since changes in Na+-dependent phosphate transport in 
parathyroid cells correlated with extracellular phosphate concentrations 
(Miyamoto et al., 1999; Tatsumi et al., 1998). Phosphate-sensing was 
also described by Martin et al (2005) who demonstrated that duodenal 
exposure to phosphate or PFA increased PTH levels acutely within 
minutes, an effect that was independent of changes in serum phosphate 
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concentration. In agreement, Bevilacqua et al (2010) reported acute 
increases in PTH levels in response to high phosphate concentration in 
the jejunal lumen, and, therefore, proposed that a signal from the 
gastrointestinal tract to the parathyroids was responsible for this effect.   
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5.5. Conclusion 
 
The study by Berndt et al (2007) postulated the release of a humoral 
factor(s) by the duodenum following sensing of increased phosphate 
levels in the intestinal lumen. This results in a rapid increase in renal 
phosphate excretion, whilst maintaining normal plasma phosphate 
concentration. The present study showed that instillation of physiological 
levels (15 mM) of phosphate into the duodenal lumen did not affect 
phosphate transport in either the duodenum or jejunum measured in vitro. 
Duodenal instillation of a supra-physiological (1.3 M) concentration of 
phosphate was also without effect on jejunal phosphate transport, but 
increased duodenal phosphate uptake. However, instillation of these 
concentrations of phosphate into the duodenum did not alter renal BBM 
expression of NaPi-IIa and NaPi-IIc. The proposed gut-renal axis and the 
‘intestinal phosphatonin’ requires further investigation, since elucidation 
of the phosphate-sensing mechanism may lead to development of 
therapy that could be used to control elevated plasma phosphate 
concentrations in renal failure. 
   
218 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.0. General discussion and suggestions for future 
experiments 
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6.1. Short background 
 
The small intestine has not previously been considered to be a major 
organ for maintenance of body phosphate, since postprandial increases 
in serum phosphate are rapidly handled by the kidney; thus past studies 
have focused on characterising the mechanism and control of phosphate 
transport in the kidney. Recent work, however, has shown that an enteric-
renal axis can exert acute regulation of phosphate balance by releasing a 
phosphaturic factor into the circulation (Berndt et al., 2007; Martin et al., 
2005). This suggests that the small intestine plays a more significant role 
in phosphate homeostasis than previously acknowledged. Phosphate 
absorption across the intestinal epithelium is mediated by transcellular 
and paracellular pathways. The former pathway is mediated by high 
affinity Na+-dependent phosphate transporters NaPi-IIb and, potentially, 
PiT1 and PiT2, all three being expressed at the intestinal brush-border 
membrane (BBM) (Giral et al., 2009; Marks et al., 2010; Sabbagh et al., 
2009). In comparison, little is known about the paracellular pathway for 
phosphate transport. 
 
Studies involving animal knockout models, together with the preparation 
of purified BBM vesicles, revealed NaPi-IIb to be the main Na+-dependent 
phosphate transporter for intestinal phosphate absorption (Giral et al., 
2009; Loghman-Adham et al., 1987 & 1993; Sabbagh et al., 2009; Xu et 
al., 2002a). Furthermore, the majority of past studies in rats concluded 
that phosphate is absorbed predominantly across the proximal small 
intestine (Giral et al., 2009; Marks et al., 2006). In vivo studies however 
have suggested that the paracellular pathway is the predominant route 
for phosphate absorption (Aloia & Yeh, 1985; McHardy, 1956; Williams & 
DeLuca, 2007). The discrepancies between the contributions of Na+-
dependent (transcellular) and Na+-independent pathways for total 
phosphate absorption are partly due to the wide variety of experimental 
techniques used for assessing uptake, as well as widely differing 
phosphate concentrations present in uptake buffers. The latter reflects 
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ignorance of normal postprandial phosphate levels present in the 
intestinal lumen. 
 
6.2. Aims of experiments 
 
An important objective of the present study was to validate suitable in 
vivo and in vitro techniques for the accurate robust measurement of 
phosphate uptake. The in vitro everted sleeve and in vivo loop technique, 
which measures respectively the appearance of luminal 32P in mucosa of 
specific regions of intestine and the appearance of 32P in the plasma, 
were used; uptake was measured in control, low phosphate diet and in 
rats of different ages. Both techniques have been previously adapted for 
use in solute uptake studies in several species (Balakrishnan et al., 2008, 
Marks et al., 2006 & 2007; Shultz et al., 1982; Starck et al., 2000; Stein & 
Williams, 2003). Far fewer studies have performed phosphate uptake 
studies in man due to ethical reasons.  The triple lumen intestinal 
perfusion technique has been used to measure in vivo phosphate 
absorption in small intestine (Walton & Gray, 1979; Davis et al., 1983).  
With the use of the validated in vivo and in vitro methods in rats, the 
contribution of the Na+-dependent and -independent components of total 
phosphate absorption at normal luminal phosphate concentrations were 
determined.  In order to cary out these experiments under physiological 
conditions, a further aim of the present work was to determine the 
phosphate levels present in the intestinal lumen of rats following ingestion 
of a normal diet.  
 
The ileum and colon are not thought to play a major role in phosphate 
absorption in rats (Cramer, 1961; Marks et al., 2006). However, a few 
studies found the ileum and colon to be capable of absorbing phosphate 
(Capuano et al., 2009; Cramer, 1961; Hu et al., 1997; Kayne et al., 1993). 
Thus, absorption of phosphate in the ileum and proximal and distal colon 
was investigated in vivo and in vitro at normal luminal phosphate 
concentrations. 
 
   
221 
The competitive inhibitor phosphonoformic acid (PFA) was used in order 
to distinguish between NaPi-IIb-mediated and non-NaPi-IIb-mediated 
transport to characterise a new pathway that may be involved in 
phosphate absorption, as proposed by several authors (Aloia & Yeh, 
1985; Berner et al., 1976; Douard et al., 2010; Lee et al., 1986b; Williams 
& DeLuca, 2007). 
 
In contrast to NaPi-II transporters, there is very little information on the 
newly emerging PiT family of Na+-dependent phosphate transporters, 
therefore their genomic expression was investigated in those conditions 
known to affect phosphate absorption, i.e. low phosphate diet, age and 
hyperphosphataemia. 
 
The effect of the proposed ‘intestinal phosphaturic’ factor on intestinal 
phosphate uptake, following duodenal instillation of millimolar and molar 
phosphate concentrations, was investigated in addition to the effect of 
this procedure on changes in expression of NaPi-II proteins at the renal 
BBM. 
 
6.3. Measure of intestinal phosphate transport using in vitro and in 
vivo techniques 
 
Using the everted sleeve technique, the study demonstrated that the 
feeding of a low phosphate diet for 7 days increased Na+-dependent and 
Na+-independent transport in the duodenum and jejunum; the increase 
seen in the Na+-independent component was much smaller compared 
with that observed for the Na+-dependent component. The enhanced 
Na+-dependent transport was attributed to an increased expression of 
NaPi-IIb protein, as reported previously (Giral et al., 2009; Hattenhauer et 
al., 1999). However, the identity of the transporter responsible for the 
increased rate of Na+-independent transport in the duodenum and 
jejunum following a low phosphate diet is not known and requires further 
investigation. 
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Studies carried out in vitro showed that the rate of Na+-dependent 
transport was greater in the duodenum and jejunum of young animals 
compared with adults. Na+-dependent phosphate transport did not 
decline further once animals reached adulthood. Ageing also did not 
affect Na+-dependent phosphate transport in the ileum or the Na+-
independent transport in all regions of small intestine. The present study 
successfully used the in situ loop technique to distinguish between Na+-
dependent and Na+-independent transport in three regions of small 
intestine. Past studies have failed to observe Na+-dependent transport in 
vivo (Douard et al., 2010; McHardy, 1956; Williams & DeLuca, 2007). 
Furthermore, no previous study has investigated the changes in intestinal 
phosphate absorption, Na+-dependent and Na+–independent, caused by 
a low phosphate diet and ageing in vivo, and this technique may be 
employed for this purpose in future studies. 
 
Under all conditions used, a higher rate of phosphate transport was 
observed in the jejunum compared with duodenum, as established 
previously (Loghman-Adham et al., 1987). Additionally, Marks et al (2006 
& 2008) reported that regulation of intestinal phosphate absorption in the 
rat is largely confined to jejunum. Thus, future studies should focus on 
the jejunum when investigating the control of intestinal phosphate 
absorption.  
 
In addition to low phosphate diet, increases in the level of 1,25-
dihydroxyvitamin D3 (which may be caused by low phosphate diet per se)  
is another important regulator of intestinal phosphate transport 
(Hattenhauer et al., 1999; Katai et al., 1999; Lee et al., 1986b; Marks et 
al., 2006). In man, 1,25-dihydroxyvitamin D3 therapy does not increase 
jejunal phosphate absorption in normal subjects (Gray TK et al., 1977; 
Davis et al., 1983). Similarly, Williams & Deluca (2007) reported that in 
rats when molar concentrations of phosphate are used in in vivo uptake 
buffers, the stimulatory effect of 1,25-dihroxyvitamin D3 on intestinal 
phosphate absorption is eliminated and transport at these high phosphate 
concentrations is completely Na+-independent. Interestingly, the majority 
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of the early studies used 0.1 mM phosphate in uptake buffers whereas 
more recent studies have used low millimolar phosphate concentrations 
to measure uptake.  The present study, using 0.1 mM phosphate in 
uptake buffer, showed upregulation of Na+-dependent transport in the 
proximal small intestine of young animals and adults fed a low phosphate 
diet.  However, whether this would be the case at higher phosphate 
concentrations need to be investigated. Furthermore, 0.1 mM phosphate 
used for in vitro uptake studies could have acted as a rate-limiting step 
and masked a potentially bigger effect of low phosphate and age on the 
Na+-independent component than that observed in the present study. 
 
6.4. Regional variations in Na+-dependent and Na+-independent 
phosphate transport along the rat small intestine and colon 
 
Analysis of intestinal luminal contents revealed, surprisingly, that 
phosphate concentrations are in the low millimolar range following 
ingestion of a normal phosphate diet. Uptake data presented in Chapter 3 
showed that at these concentrations, transport in the jejunum was 
predominantly Na+-independent and this component was not inhibited by 
the NaPi-IIb inhibitor PFA. The identity of this pathway, whether a Na+-
independent transporter or passive diffusion, is not yet known. Phosphate 
transport in the duodenum was Na+-independent regardless of the 
phosphate concentrations used for in vivo and in vitro uptake studies. 
Thus, although NaPi-IIb is expressed in the duodenum, it is unlikely to 
play a significant role in phosphate absorption in this region under normal 
dietary conditions. This further highlights the differential regional 
regulation of intestinal phosphate absorption. Although PFA is an ideal 
inhibitor of NaPi-IIb-mediated transport, it is also a weak inhibitor of PiT-
mediated transport (Collins et al., 2004; Ravera et al., 2007; Virkki et al., 
2007). A suitable inhibitor is needed to determine the relative 
contributions of NaPi-II-mediated and PiT-mediated transport in the 
different regions of small intestine, and in the kidney.  
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Jejunal phosphate transport showed considerably more Na+-dependency 
in vitro than in vivo. Rapid shuttling of a facilitative phosphate transporter 
to the BBM may explain the observed Na+-independency in vivo. A 
similar situation has been observed for glucose transport. The GLUT2 
glucose transporter can be detected at the intestinal BBM during luminal 
exposure to high glucose concentrations (Kellett, 2001a). The existence 
of GLUT2 transporter at the BBM was overlooked due to rapid membrane 
turnover of the transporter in response to glucose level in the luminal fluid 
(Helliwell et al., 2000a & 2000b). Similarly, phosphate-sensing and 
uptake by NaPi-IIb may cause BBM expression of an alternative 
phosphate transport system following increased luminal phosphate 
levels. This theory could be explored by using techniques that were used 
for identifying shuttling of GLUT2 (Helliwell et al., 2000a & 2000b; Kellett, 
2001). However, the factor responsible for the linear increase in in vitro 
jejunal, but not duodenal, Na+-dependent phosphate transport at higher 
luminal phosphate concentrations is not known, since NaPi-IIb has a Kt of 
~0.1 mM (Hilfiker et al., 1998; Loghman-Adham et al., 1987). It is 
possible that there are additional molecular types of phosphate 
transporters at the intestinal BBM that mediate phosphate uptake.   
 
Debiec & Lorenc (1985) showed an increase in, Na+-independent 
phosphate uptake by duodenal and jejunal BBM vesicles when lactose 
was added to the pre-incubation medium. The mechanism behind this 
lactose-mediated increase in uptake is not known. Dietary lactose is also 
reported to stimulate calcium absorption across the small intestine 
(Bushnell & DeLuca, 1981; Lengemann & Comar, 1961; Sato et al., 
1983). It is important to establish the route of passive permeability of 
phosphate. The human intestinal Caco-2 cell line is a potentially useful 
model to study the passive permeability of solutes and the contribution of 
paracellular transport, since the model has been successfully used to 
establish intestinal passive permeability of iron and copper (Ferruzza et 
al., 1999 & 2002).  
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Claudins are tight junction integral membrane proteins that act as the 
primary determinants of permeability of the tight junction (Kiuchi-Saishin 
et al., 2002; Teshima & Meddings, 2008). Claudins are, therefore, a 
potential target for modifying the absorption of solutes or drugs that are 
passively transported through the tight junctions (Kondoh et al., 2005). 
Claudins could be modulated at normal phosphate concentrations to 
determine their effects on phosphate absorption. Claudin-4 is 
preferentially expressed at the apices of intestinal villi and is associated 
with loosening of intercellular junctions, allowing access to the 
paracellular space; therefore, a substrate such as the C-terminal 
fragment of Clostridium perfringens enterotoxin (C-CPE), which directly 
interacts with claudin-4 in the jejunum (Kondoh et al., 2005; Tamagawa et 
al., 2003), could be used to determine if altered intestinal permeability, 
without damage to the intestinal mucosa, influences Na+-independent 
phosphate absorption in vivo. 
 
Marks et al (2008) have reported that the phosphatonin matrix 
extracellular phosphoglycoprotein (MEPE), a potential treatment for 
hyperphosphataemia, dose-dependently inhibited jejunal phosphate 
absorption measured in vivo. The MEPE data were obtained using 0.1 
mM phosphate in the uptake buffer. It would be interesting to see if the 
inhibitory effect of MEPE occurs at physiological (low millimolar) 
phosphate concentrations and whether MEPE affects Na+-independent 
phosphate uptake.  Furthermore, detailed studies are needed to evaluate 
the effect of established regulators of phosphate uptake, i.e. 
glucocorticoids, growth hormone, thyroid hormone and phosphatonins 
such as FGF-23, on passive diffusion of phosphate across the small 
intestine. 
 
At odds with previous reports, findings described in Chapter 3 
demonstrated significant Na+-dependent phosphate transport in the ileum 
and distal colon in vivo and in vitro, at phosphate levels normally found in 
the intestinal lumen. The transport pathway responsible for the Na+-
dependent, PFA-sensitive transport in the ileum is different from that 
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responsible for Na+-independent PFA-insensitive transport in the distal 
colon. NaPi-IIb and PiT transporters are unlikely to be responsible for 
ileal phosphate transport, since levels of these proteins are not 
detectable in the ileum (Giral et al., 2009), and phosphate transport was 
minimal in the present study when measured using 0.1 mM phosphate in 
uptake buffer. In this context, a so far unidentified Na+-dependent 
transporter, with a low affinity (high Kt), is likely to be present at the ileal 
BBM to facilitate phosphate transport at millimolar phosphate 
concentrations. Further studies are needed for its characterisation.  
 
Although the present study used mannitol to estimate passive intestinal 
permeability, it cannot be used as a probe for intestinal permeability 
specifically for phosphate due to charge and molecular size differences 
between mannitol (neutral molecule) and phosphate (an anion). 
Therefore, results presented in Chapter 3 cannot be used to establish 
whether colonic phosphate transport is mediated through a passive 
pathway, as proposed by Hu et al (1997) or via a Na+-independent 
phosphate transporter. Capuano et al (2009) reported genomic 
expression of NaPi-IIb and PiT transporters in the distal colon, and their 
regulation by a chronic low phosphate diet, but it is not known whether 
translation to the transporter protein occurs. However, this is unlikely, 
based on the PFA-insensitive Na+-independent colonic phosphate uptake 
data presented in Chapter 3. Further studies are needed for clarification. 
Interestingly, the present study detected significant transepithelial 
absorption of mannitol in the distal colon. The route is unknown at the 
present time and autoradiography (using tritiated mannitol) could be used 
to assess whether mannitol moves paracellularly or transcellularly across 
this epithelium. The involvement of claudins and the overall role of the 
paracellular pathway in mediating Na+-independent phosphate uptake 
need to be characterised in detail.  Changes in the electrical potential 
difference induced by the replacement of sodium with choline needs to be 
clearly studied in order to investigate whether a change in the potential 
difference was responsible for the apparent Na+-independency seen in 
the experiments presented in this thesis, and if so to what extent. 
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The finding that the distal colon is capable of absorbing phosphate has 
implications for the clinical use of phosphate-containing enemas, which 
contain molar concentrations of phosphate and carries the risk of causing 
symptomatic hyperphosphataemia (Carl & Mitchell, 2007; Hu et al., 1997; 
Hunter et al., 1993;). Furthermore, the effectiveness of current treatments 
of hyperphosphataemia with oral phosphate binders is questionable, 
since the high levels of anions (chiefly short-chain fatty acids) in the 
colonic lumen might displace bound phosphate from these agents, thus 
making phosphate available for absorption by the distal colon. This could 
negate any upstream benefit of phosphate binders on reducing 
phosphate absorption. 
 
6.5. Genomic regulation of Na+-dependent phosphate transporters 
by low phosphate diet, age, chronic renal failure, and MEPE 
 
PiT transporters were previously thought to serve housekeeping roles by 
absorbing phosphate from interstitial fluid for normal cellular functions 
(Tatsumi et al., 1998; Collins et al., 2004). However, recent evidence 
suggests that they have specific roles in intestinal and renal handling of 
phosphate (Giral et al., 2009; Villa-Bellosta et al., 2009b; Villa-Bellosta & 
Sorribas, 2010b).  Genomic expression of NaPi-IIb in the small intestine 
is region-specific and differs between rat and mouse; in contrast, the data 
presented in Chapter 4 shows that gene expression of PiT1 and PiT2 are 
similar in the duodenum, jejunum and ileum of rat and mouse small 
intestine. However, this information needs to be supplemented with the 
protein expression of PiT1 and PiT2. 
 
Data presented in Chapter 4 also show that intestinal, but not renal, 
expression of PiT2 in rats is age-dependent. PiT2 mRNA was 
significantly higher in the jejunum, but not duodenum, of young animals 
compared with adults. PiT2 was also upregulated in the kidneys of adult 
rats fed a chronic low phosphate diet. In contrast, PiT1 mRNA expression 
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in the small intestine and kidney was not regulated by age or low 
phosphate diet. This regulation of PiT2 highlights the differential 
regulation of phosphate transporters expressed at the BBM of small 
intestine and kidney. The study of Villa-Bellosta & Sorribas (2010b) 
reported that mRNA levels of PiT1 and PiT2 are low in rats. However, 
they have also provided immunohistochemical evidence of significant 
expression of PiT2 protein at the renal BBM and its upregulation by low 
phosphate diet (Villa-Bellosta et al., 2009b; Villa-Bellosta & Sorribas, 
2010b).  Immunohistochemical evidence of PiT1 protein expression and 
its regulation by low phosphate diet and age at the renal and intestinal 
BBM is needed. Whether PiT2 protein is expressed at the intestinal BBM 
is also not known. 
 
The experiments described in Chapter 4 also provide evidence that 
intestinal NaPi-IIb, and intestinal and renal PiT1 and PiT2 mRNA are 
downregulated by a more severe model of chronic renal failure. This is 
surprising, since other reports claim that intestinal phosphate uptake and 
genomic expression of NaPi-IIb are unaffected by chronic renal failure 
(Douard et al., 2010; Marks et al., 2007). A factor to consider for this 
difference is the severity of chronic renal failure on phosphate 
homeostasis. Comparison of the present study to that reported by Douard 
et al (2010) and Marks et al (2007) suggests that intestinal Na+-
dependent phosphate transporters are differentially regulated with 
progression of chronic renal failure. This changes the current view about 
intestinal phosphate uptake during chronic renal failure and has 
implications in the targeting of the process of intestinal phosphate uptake 
for therapeutic interventions during chronic renal failure. 
 
In patients with chronic renal failure on haemodialysis, jejunal phosphate 
absorption in vivo was reduced compared with normal subjects and 
phosphate was absorbed by both passive and active pathways (Davis et 
al., 1983). The study of Davis et al (1983) also demonstrated that 
phosphate absorption in chronic renal failure patients saturated at a 
luminal phosphate concentration above 2 mM. In chronic renal failure 
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patients the level of phosphate in the jejunal lumen was found to vary 
between 1 and 12 mM. Whether BBM Na+-dependent and Na+-
independent transport is altered in chronic renal failure rats is not clearly 
established, especially considering that data presented in Chapter 4 
show that Na+-independent transport is the predominant pathway under 
normal (millimolar) luminal phosphate levels.  
 
The present study found reduced renal expression of NaPi-IIa mRNA in 
chronic renal failure rats, as established previously (Brooks et al., 1997; 
Marks et al., 2007). Interestingly, mRNA levels of renal PiT1 and PiT2 
were also downregulated. The mechanisms behind the reduction in the 
genomic levels of these phosphate transporters in chronic renal failure 
are not yet known. It remains to be established whether renal PiT1 and 
PiT2 transporters are regulated by major regulators of phosphate balance 
such as parathyroid hormone (PTH). PTH inhibits Na+-dependent 
phosphate transport in the kidney by inducing the internalisation of NaPi-
IIa. Picard et al (2010) recently showed that PTH inhibits PFA-resistant 
Na+-dependent phosphate transport, suggesting an action of the 
hormone on PiT transporters.  Thus, augmented PTH levels, as seen in 
chronic renal failure animals, may be responsible for reducing renal 
expression of NaPi-IIa, PiT1 and PiT2 mRNA in chronic renal failure rats. 
Due to a lack of suitable antibodies, it was not possible to analyse protein 
levels of PiT1 and PiT2 in renal BBM of chronic renal failure rats. 
Furthermore, the cellular signals leading to the internalisation of NaPi-IIb, 
NaPi-IIc, PiT1 and PiT2 are unknown.  
 
The recently described genomic intestine expression of the phosphatonin 
MEPE (Marks et al., 2010) is relevant to the data presented in Chapter 4. 
Thus, chronic renal failure animals chronically treated with MEPE were 
analysed for expression of Na+-dependent phosphate transporters. The 
fact that MEPE is expressed in both kidney and small intestine, and it 
inhibits phosphate absorption in both tissues (Marks et al., 2008 & 2010; 
Rowe et al., 2000 & Rowe et al., 2004) makes it a promising target for 
controlling hyperphosphataemia, especially, since data presented in 
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Chapter 4 show that intestinal NaPi-IIb and PiT2 mRNA were 
downregulated by MEPE in chronic renal failure rats. The reason why 
MEPE influences intestinal, but not renal, expression of Na+-dependent 
phosphate transporters is not known. The effect of chronic renal failure 
on expression of PiT transporters in the small intestine and kidney before 
and after treatment with MEPE requires further study, particularly whether 
changes at the genomic levels are translated to the protein level. This 
could be carried out using BBM if suitable antibodies for NaPi-IIb and 
PiT1 and PiT2 become available.  
 
There is no reliable assay for measurement of MEPE levels in blood.  
Knowledge of this is important to understand the link between normal and 
abnormal regulation of phosphate handling in small intestine and kidney. 
Although the cellular process by which MEPE exerts its inhibitory effect in 
the jejunum is unknown, the action of MEPE on phosphate transport 
occurs within 3 hours in rats and is independent of the main regulators of 
phosphate balance, PTH, 1,25-dihyroxyvitamin D3 and FGF-23. Thus, the 
inhibitory effect of MEPE on intestinal phosphate transport may be direct 
or indirect and this needs to be investigated in future studies. Renal PiT2, 
along with renal NaPi-II transporters, is reported to be involved in the 
phosphaturic effect of FGF-23, another phosphatonin. Further 
experiments are also needed to characterise the regulation of intestinal 
and renal expression of NaPi-II and PiT transporters by other 
phosphatonins such as FGF-23, FGF-7 and sFRP-4. 
 
Intestinal phosphate absorption is thought to be primarily mediated by the 
Na+-dependent transporter NaPi-IIb, which is pH sensitive and exhibits 
higher transport activities at alkaline pH (Hilfiker et al., 1998). In intestinal 
BBM vesicles, phosphate uptake was reduced at pH 7.4, but not at pH 6 
under Na+-free conditions (Berner et al., 1976). This raises the possibility 
that PiT transporters might be involved, since they function more 
effectively at acidic pH. If this is so, then it would be important to know 
whether PiT transporters strictly require Na+ for phosphate uptake. 
Although the present study and past reports show regulation of PiT 
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transporters at the genomic and protein level, there is no evidence that 
they are involved in phosphate absorption across the small intestine or 
kidney under normal conditions. However, evidence is emerging that PiT 
transporters are important in cellular processes in other tissues, such as 
vascular calcification and liver growth (Beck et al., 2010; Villa-Bellosta et 
al., 2007 & 2009a). The fact that PiT transporters were found to be 
affected by chronic renal failure in the present study, and by 
hypophosphataemia (in mice) (Tenenhouse et al., 1998), indicates that 
they may play a role in the pathophysiology of phosphate absorption. 
 
6.6. The effect of duodenal phosphate instillation on intestinal 
phosphate uptake and expression of renal phosphate transporters 
 
The importance of the small intestine in phosphate balance has led to 
suggestions of an ‘intestinal phosphaturic’ factor (Berndt et al., 2007; 
Martin et al., 2005). However, the identity of this enteric mucosal factor 
and the mechanisms involved in mediating the renal effect are unclear. 
Data presented in Chapter 5 show that instillation of molar (1.3 M), but 
not millimolar (15 mM), phosphate concentrations into the duodenum for 
30 minutes increased duodenal phosphate transport. A similar acute 
effect was observed in duodenal BBM vesicles by Giral et al (2010), 
which was attributed to increased expression of NaPi-IIb protein at the 
duodenal BBM. The reason why the jejunum, which also expresses NaPi-
IIb at similar levels to the duodenum (Giral et al., 2009; Marks et al., 
2006), does not show this adaptation is not known. 
 
Present data provide no evidence that changes in expression of NaPi-IIa 
and NaPi-IIc at the renal BBM following administration of 1.3 M 
phosphate into the duodenum were responsible for the increased urinary 
excretion of phosphate, as observed by Berndt et al (2007).  However, 
Berndt et al (2007) used a supra-physiological concentration of 1.3 M 
phosphate for their experiments. Therefore, the significance of their 
finding is unlikely to apply at normal luminal phosphate concentrations in 
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man or experimental animals.  Importantly, the present study establishes 
that duodenal exposure to such a high phosphate concentration does 
locally affect phosphate transport in the duodenum, but not in adjacent, 
unexposed regions of intestine.  
 
Although duodenal phosphate instillation was without effect on 
expression of renal NaP-II transporters, PiT transporters may have been 
regulated during this procedure. However, expression of PiT1 and PiT2 
proteins were not analysed owing to a lack of suitable antibodies. It is 
possible that changes in expression of NaPi-II proteins at the renal BBM 
might occur following a longer duodenal exposure to phosphate. Thus, it 
would be useful to repeat the present study, but using a longer duodenal 
phosphate instillation period. Also, the study of Berndt et al (2007), and 
the present study did not address whether exposure of the jejunum to 
phosphate is capable of inducing changes in urinary phosphate excretion.  
 
The transport pathway responsible for the efflux of phosphate across the 
basolateral membrane in both small intestine and kidney epithelia has not 
been characterised. This is an important issue to resolve, since this 
pathway might also be targeted to decrease plasma phosphate levels in 
hyperphosphataemia.  
 
A recent clinical report by Lynch et al (2011) caused controversy over the 
current understanding and application of therapy for hyperphosphataemia 
in chronic renal failure patients by demonstrating that restriction of 
phosphate in the diet was not associated with better survival rate among 
haemodialysis patients. They showed that increasing levels of phosphate 
restriction may cause greater mortality. The significance of this report and 
the future effect on patient treatment is not known. However, it is certain 
that this report is likely to play a role in the direction of future research on 
the control of intestinal and renal phosphate handling.  
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Figure 6.1 summarises our current understanding of the regulation of 
intestinal and renal phosphate absorption by the major factors considered 
in the present study: low phosphate diet, age and chronic renal failure. 
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6.7. Conclusion 
 
Experiments described in this thesis have shown that millimolar 
phosphate concentrations are present in the intestinal lumen and 
phosphate absorption across all three regions of the rat small intestine 
and the distal colon occurs by mechanisms involving both Na+-dependent 
and Na+-independent pathways. In addition to NaPi-II, PiT transporters 
expressed in the small intestine and kidney are also regulated at the 
genomic level by chronic renal failure, low phosphate diet and age. Thus, 
PiT transporters may play an important role in the regulation of 
phosphate transport in these tissues. The proposed ‘phosphaturic factor’ 
that may be released from rat duodenum following exposure to high 
luminal phosphate concentrations does not affect jejunal phosphate 
transport nor the expression of NaPi-II proteins at the renal BBM. 
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